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Actinobacteria have a protein O-glycosylation system that resembles eukaryotic protein O-
mannosylation. Both M. tuberculosis and S. coelicolor have growth retarded phenotypes when a 
membrane bound protein O-mannosyl transferase (Pmt), which transfers mannose from polyprenol 
phosphate mannose to a target protein, is absent. Moreover, S. coelicolor pmt – mutants are resistant to 
infection by ϕC31 phage and have increased susceptibility to vancomycin and several β-lactams. S. 
coelicolor strains that lack polyprenol phosphate mannose synthase (Ppm1), which transfers mannose 
from GDP-mannose to polyprenol phosphate, are even more susceptible to antibiotics and a ppm1 – 
mutant in M. tuberculosis is lethal. Pmt and Ppm1 are therefore possible new targets for the isolation of 
novel antimicrobials to be used against M. tuberculosis. The aim of this PhD thesis was to gain a deeper 
understanding of the structure and function of both S. coelicolor enzymes. 
 
For Ppm1, ten mutant alleles (the majority being individual alanine substitutions) were tested and eight 
were essential for S. coelicolor DT3017, a ppm1 – strain, complementation, with four of the corresponding 
residues positioned close to the predicted catalytic DXD motif. Attempts were made to purify and develop 
an enzyme assay for Ppm1 but we were overtaken by the activities from another laboratory (Manuela 
Tosin, Warwick) with whom we then collaborated. Enzyme activity data of detergent solubilised Ppm1 
from the Tosin laboratory was in general agreement with my work on the in vivo phenotypes. Roles for 
these critical residues have consequently been proposed with a great degree of confidence, with the 
majority likely being catalytic and/or involved in substrate binding.  
Sequence alignments and structural bioinformatics were used with S. coelicolor Ppm1 and Pmt to identify 
targets for site-directed mutagenesis. Mutant alleles were introduced into ppm1 – (DT3017) or pmt – 
(DT2008/DT1025) S. coelicolor strains using conjugative integrative plasmids and scored for their ability 
to complement phage sensitivity and antibiotic hyper-susceptible phenotypes. Twenty-three highly 
conserved Pmt residues were each changed to alanine and six mutant alleles failed to complement the 
pmt- strains, indicating essentiality. Modelling the six corresponding residues indicated that five are 
positioned close to the predicted catalytic DE motif. Western blotting showed that none of the non-
complementing pmt – alleles expressed protein that could be localised to the membrane fractions and 
could not be detected in whole cell lysates. Conservative and semi-conservative substitutions were made 
to each of these six residues and with only a few exceptions, the alleles failed to complement DT1025 pmt 
–, indicating that strict conservation was necessary to preserve function. Moreover western blots 
continued to indicate that the non-complementing mutated Pmt proteins still failed to localise to the 
membrane. Evidently there is a relationship between the activity of Pmt and its localisation such that only 
functional Pmt could localise correctly to the membrane.  Crucially, five of the six critical residues have 
not previously been proposed to have functional significance in the Pmt family and therefore could be 
important for the M. tuberculosis homologue. Whilst some of the mutations were predicted to impair 
catalytic activity, others may have affected localisation or substrate binding.  
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Antibiotics revolutionised modern medicine following their widespread use in the middle of the 
20th century. Previously untreatable infections including tuberculosis, syphilis, pneumonia and 
cholera could now be tackled in the clinic. Since the introduction of antibiotics, they have saved 
millions of lives, it is estimated that at least 200 million lives across the globe have been saved 
by penicillin alone (Macfarlane 1984). Alexander Fleming is credited with the discovery of 
penicillin and in 1945 during his Nobel Lecture, he warned that 'man may easily under dose 
himself and by exposing his microbes to non-lethal quantities of the drug make them resistant', 
essentially predicting the evolutionary arms race between man and microbes before it had 
really begun (Fleming 1945). Antibiotics kill or inhibit the growth of bacteria by exploiting 
specific targets, the most common being cell wall biosynthesis, DNA replication, transcription 
and translation (Figure 1.1). Unfortunately, the over-prescription of antibiotics by clinicians, 
combined with patients failing to finish their prescribed course, has helped create an 
evolutionary selection pressure that has greatly favoured the survival of bacteria that have 
acquired resistance determinants (usually genes carried on a plasmid). Worryingly, a recent 
report estimated that antibiotic resistance would be responsible for around 300 million 
premature deaths by 2050, with a loss of up to $100 trillion to the global economy (O’ Neil 
2014).   
This increasingly dire situation is exacerbated by the lack of a robust antibiotic discovery 
pipeline. The pharmaceutical industry has reduced their focus on the discovery, development 
and testing of antimicrobials, instead favouring the development of medicines to treat cancer, in 
addition to respiratory, cardiovascular and neurodegenerative diseases. Consequently, despite 
modest improvements made to antibiotic prescribing practises and patient compliance, 
infections have emerged that are now almost untreatable. In extreme cases this has left 
clinicians with no reliable alternatives to treat patients infected with multi drug resistant 
bacteria. The growing resistance to the so-called antibiotics of last resort such as vancomycin is 






























Figure 1.1: Diagram showing the targets of clinically relevant antibiotic classes and 
individual antibiotics   
 
Image by Kendrick Johnson: Creative Commons Attribution-Share Alike 3.0 Unported license 
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1.2 Streptomyces  
1.2.1 An introduction to Streptomyces 
The majority of antibiotics used in medicine, veterinary practise and agriculture originate from 
bacteria of the Streptomyces genus. Remarkably, genome analysis of Streptomyces species reveal 
that only a fraction of the synthetic capacity of this genus has been tested for antibiotic activity 
(Charlop-Powers et al., 2015). Streptomyces are a genus of high GC Gram-positive bacteria that 
belong to the Actinobacteria phylum, well known for a distinct “earthy odour” that results from 
the production of the volatile metabolite geosmin (Kieser et al., 2000).  
At the start of the Streptomyces lifecycle, semi-dormant spores capable of surviving in the soil 
for long periods germinate, with the emergence of distinct germ tubes. Streptomycetes then 
grow vegetatively as a network of branching hyphal filaments to form a mat of mycelium. The 
hyphae “dig” into the substrate to acquire nutrients and upon nutrient depletion, differentiation 
is triggered in which aerial hyphae emerge from the mycelium. Partition walls are more 
frequently formed and on the distal parts of the aerial hyphae, chains of spores are generated 
(Figure 1.2).  
In the middle of the 20th century, Waksman and other pioneers of Streptomyces research could 
not decide whether they belonged to the prokaryotic or eukaryotic kingdoms. Streptomyces and 
other members of the actinomycete family were noted to have a cell wall structure and 
composition that was closer to bacteria than fungi, however their behaviours and appearance 
were very fungus-like. Consequently, a new taxonomic group was created whereby they were 
categorised as an intermediate life form that bridged the gap between fungi and bacteria. The 
development of Streptomyces genetics, pioneered by Hopwood at the John Innes Centre, ensured 
that Streptomyces and a whole host of other similar soil dwelling organisms would eventually be 
categorised as actinobacteria (Kieser et al., 2000). The similarities between fungi and bacteria 
proved to be largely superficial.  
Physiological studies have been conducted in the model organism S. coelicolor and studied on 
solid agar medium. S. coelicolor (and the majority of other streptomycetes) fail to undergo a full 
developmental cycle in liquid culture.  Developmental asynchrony and heterogeneity were 
major recurring problems affecting surface grown cultures, these were recently circumvented 
through the development of the newer model organism S. venezuelae, which sporulates in liquid 
culture and is therefore able to undergo a full development cycle (Schlimpert et al., 2016).  
Streptomyces is the largest genus of the actinobacteria and to date, over 600 members of this 
genus have been identified. S. coelicolor was the first member of the Streptomyces genus to have 
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its genome fully sequenced.  The genome is composed of a single ~8,670 kbp linear 
chromosome with 7,825 predicted genes (Bentley et al, 2002). Remarkably, S. coelicolor was the 
first bacterium found to have a fully sequenced genome that harboured more genes than that of 
the eukaryotic model organism Saccharomyces cerevisiae, with 6203 genes (Bentley et al., 
2002).  Indeed all Streptomyces chromosomes are large, with sizes typically ranging from 6,000-
12,000 kbp. These chromosome sizes and configurations are however not representative of the 
entire family of actinobacteria. For example, the S. coelicolor genome is notably larger and 
configured differently to that of the first sequenced mycobacterial genome (M. tuberculosis), 
which has a single ~4,410 kbp circular chromosome (Cole et al., 1998). It is also noteworthy 
that unlike the majority of bacterial genomes which exist as circular chromosomes, 
Actinobacteria have a relatively high number of genera with linear genomes including 
Actinoplanes, Micromonospora, Nocardia and of course Streptomyces (Ventura et al., 2007).  
In S. coelicolor over 20 gene clusters have been implicated in secondary metabolite biosynthesis 
and consequently, there is a lot of interest in the relationship between antibiotic production and 
physiology (Bibb 1996). These S. coelicolor studies have been made easier by the production of 
two pigmented antibiotics, the blue/red pigmented (depending on pH) polyketide actinorhodin 
(ACT) and the red pigmented tripyrrole prodiginines (REDs)(Liu et al., 2013). The wide range of 
pigments, antibiotics and fungicides produced by Streptomyces sp. allow them to inhibit the 
growth of competing organisms. They are also well adapted to survive in nutrient scarce 
environments through the possession of multiple catabolic enzymes that facilitate the 
metabolism of abundant carbon sources such as cellulose, chitin, xylan and cellulose.  Other 
notable Streptomyces genomes that have been sequenced include S. ambofaciens, which has 
remarkable genetic diversity (Choulet et al., 2006), S. avermitillis, the producer of avermectin 
(Omura et al., 2001) and S. scabies, the causative agent of potato scab disease (Loria et al., 2006). 
Streptomyces sp. are relatively benign, despite belonging to the Actinobacteria phylum that 
includes well known pathogens in the Mycobacteria family. Instances of pathogenicity have 
however been noted; examples include human mycetoma which is caused by Streptomyces 
somaliensis (Trujillo et al., 2003) and potato scab disease caused by Streptomyces scabies (Loria 

















Figure 1.2: Summary of the Streptomyces lifecycle. 
 
Taken from Angert et al., 2005 
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1.2.2 An introduction to the Streptomyces infecting phage: ΦC31 
Phages are viruses that infect and replicate in bacterial hosts. They are the most abundant 
biological agents on this planet, with the highest density in shallow sea water (Chen et al., 
2006). Their genetic diversity is largely unparalleled by any other life form.  Upon infection of 
the bacterial host, temperate phages can embark on either lytic or lysogenic lifecycles (Figure 
1.3). Prior to infection, the phage particle must first recognise and then bind to a host cell 
receptor, before injecting its DNA into the host. Lytic phage infection of a lawn of susceptible 
bacteria will lead to clear plaques on solid agar plates. Temperate phage can form lysogens, this 
happens where the viral DNA (genome) becomes stably integrated into the host genome. When 
this happens, the host bacterial cell carrying the integrated phage genome (prophage) is termed 
a lysogen. Induction of the lytic pathway through stress factors can subsequently result in the 
rapid assembly of infective phage particles and lysis of the host cell releasing phage particles 
that are now free to find and infect further hosts. The processes of integration and excision are 
highly regulated to ensure switching between the lytic and lysogenic pathways is efficient and 
yields favourable outcomes for the phage.  
Streptomyces phage are of particular interest as they can provide useful tools such as integrases 
and phage vectors that have applications in genetic engineering (Smith 2006). Streptomyces sp. 
are susceptible to infection by multiple phages, with the temperate phage ΦC31 being the most 
extensively studied, in part, due to its ability to plaque and lysogenise roughly two thirds of 
Streptomyces sp. (Lomovskaya et al., 1980; Kobler et al., 1991; Smith et al., 1999). Clear plaque 
mutants of ΦC31 were isolated that can only develop through the lytic cycle and were found to 
have undergone point mutation or deletions in the repressor gene c, which is required for both 
the establishment and maintenance of the lysogenic state. ΦC31cΔ25 is one of several common 
ΦC31 clear plaque mutants (Lomovskaya et al., 1972). Electron microscopy analysis showed 
that ΦC31 is a typical tailed phage, roughly 150 nm in length. It is composed of an icosahedral 
capsid (57 x 54 nm) and a non-contractile tail (123 x 10 nm) with a basal plate and tail fibres 
(Lomovskaya et al., 1980).  
ϕC31 was the first Streptomyces phage genome to be completely sequenced (Smith et al., 1999). 
The double stranded DNA genome of ΦC31 is 41,495 bp in length and encodes 52 genes. The 
genes for phage assembly and DNA metabolism are clustered in accordance with their function 
in the genome.  Late genes of ΦC31 principally include those encoding capsid head and tail 
assembly while early genes are mainly involved in regulation, DNA metabolism or 
recombination. This recombination region includes the integrase gene and the attP site, both of 
which have been exploited in vectors to facilitate the manipulation of Streptomyces sp (Kuhstoss 
et al., 1991). 
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The integrase belongs to the serine recombinase family and catalyses site specific 
recombination between attP and attB attachment sites on the phage and bacterial genomes 
respectively. Phages use Recombination Directionality Factors (RDFs) to control the 
directionality of integrase. RDFs were historically difficult to study since for the serine integrase 
family, there is a general lack of sequence conservation. For ΦC31, the early protein gp3 was 
eventually identified as the RDF (Fogg et al., 2018). Finally, in the virions there are cohesive 
ends derived from the cos sites these are required for both circularisation and DNA packaging of 
the capsid via cos site recognition. 
Bacteria have evolved multiple mechanisms of resistance to phage infection. S. coelicolor has a 
variety of restriction-modification systems (González‐Cerón et al., 2009) and an unusual system 
called phage growth limitation or Pgl conferred by multiple genes (pglW, pglX, pglY and pglZ) 
(Chinenova et al., 1982; Bedford et al., 1995; Sumby et al., 2003). Pgl+ strains support a phage 
burst upon initial infection but subsequent cycles are strongly attenuated. However mutations 
in any of the four pgl genes is sufficient to confer sensitivity to ΦC31.  
A second mechanism of resistance to phage infection comes via blocking host recognition 
usually through phage adsorption. This mechanism depends on the interaction between the 
host’s phage receptors and some component of the phage tail, usually the tail fibres. If the host 
receptor is changed or removed the stable interaction is removed and infection is severely 
compromised. The ΦC31 receptor in sensitive Streptomyces sp. remains unknown, although 
there has been progress on identification of a protein glycosylation pathway that is required for 







































Figure 1.3: Summary of the phage lysogenic and lytic life cycles. 
 
Taken from Seipke et al., 2012 
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1.3 Glycosyltransferase structure and function  
The glycosyltransferases are a diverse group of enzymes that transfer a sugar moiety from an 
activated donor substrate such as a nucleotide activated sugar to an acceptor substrate. 
Acceptor substrates include DNA, protein and lipid, in addition to sugar moieties of 
glycoproteins and glycolipids. (Lommel and Strahl, 2009). The names of many glycosyl 
transferases account for both the stereochemistry of the donor sugar and the created glycosidic 
linkage that connects the sugar with the acceptor substrate post catalysis (Figure 1.4). If the 
stereochemistry is changed from α to β or vice versa, the enzymes is characterised as an 
inverting glycosyl transferase, if the configuration remains unchanged, it is called a retaining 
glycosyl transferase. 
Glycosyl transferases, exhibit a narrower range of folds, relative to the glycosyl hydrolases. The 
Carbohydrate Active Enzyme database (CAZy) classifies the glycosyltransferases into three 
distinct superfamilies GT-A, GT-B and GT-C, each with a distinct structural topology (Lombard et 
al., 2014; Lommel and Strahl, 2009) (Figure 1.5). While the sequence diversity within the 
superfamilies can be considerable, the structural topologies and the chemical reaction 
mechanisms show little diversification.  
Atomic resolution structures deposited in the Protein Data Bank show that the GT-A fold 
comprises an α/β/α sandwich, whereby the β-sheet core has typically seven strands. In 
addition, the binding sites for the sugar nucleotide and acceptor substrate are in close proximity 
(within the same subdomain). Catalytic motifs are a hallmark of this family and while the DxD 
(where ‘x’ is any amino acid) motif is widespread, other variants including TDD, EDD and DxH have 
also been identified (Lommel and Strahl, 2009). GT-B domains consist of two Rossmann-like 
domains containing multiple parallel β-strands linked to α-helices. A linker region connects both N 
and C-terminal domains. One domain is involved in acceptor binding and the other in the donor 
nucleotide di-phosphate sugar binding, consequently, the active site resides in an interdomain 
cleft. In contrast to GT-A enzymes that are generally metal-ion dependent, the GT-B enzymes are 
generally metal-ion independent and consequently, lack the conserved motifs associated with 
divalent metal binding in the GT-A and GT-C enzymes. It is noteworthy that the GT-A and GT-B core 
structures can combine with other domains, such as regions that can anchor the protein to the 
membrane. Finally, the GT-C superfamily contains glycosyl transferases that have 8–13 predicted 
transmembrane (TM) helices, in addition to the first extracellular or luminal loop containing a DEx 
motif, other variants include DxD ExD, DxE, Dx. In many cases, multiple hydrophobic amino acids 
















Figure 1.4: Stereochemistry of glycosyltransferase catalysed reactions.  
Glycosyltransferases catalyse glycosyl group transfer with either inversion or retention of the 
anomeric stereochemistry with respect to the donor sugar. 
 




























Figure 1.5: Topology of GT-A, GT-B and GT-C enzymes. (A) Lipopolysaccharyl-alpha-1,4-
galactosyltransferase C (LgtC) from Neisseria meningitides (B) TDP-epi-Vancosaminyltransferase 








1.4 Eukaryotic protein O-mannosylation  
1.4.1 Principles of protein O-mannosylation in the eukaryotes  
In S. cerevisiae, 20 % of cell dry weight is made up of cell wall, of which half is made up 
mannosylated proteins (Strahl-Bolsinger et al., 1999). Indeed, many of the fundamental features 
of protein O-mannosylation were first elucidated in yeast and later expanded, principally to 
humans and flies (Lommel and Strahl 2009). The O-linked sugar chains are unbranched and 
typically made up of four to five mannose sugars added to the serine or threonine side chain 
hydroxyl by a glycosidic linkage. These O-linked sugar chains are also notably shorter than N-
linked sugar chains. Protein O-mannosylation is initiated in the endoplasmic reticulum in 
eukaryotes, with the initial steps between fungi, humans and animals being conserved 
(Haselbeck and Tanner 1983, Jurado et al., 1999; Harty et al., 2001; Ichimiya et al., 2004; Manya 
et al., 2004). Diversification is notable at the subsequent stage in the Golgi apparatus, where 
mannose chains are extended by the addition of mannose and/or other sugars such as N acetyl 
glucosamine, sialic acid and galactose (Romero et al., 1999; Takahashi et al., 2001). Protein O-
mannosylation requires two glycosyl transferase catalysed steps: first the synthesis of the 
mannosyl donor and second, the transfer of mannose from the donor onto the acceptor 
polypeptide chains.  
1.4.2 Mannosyl donor synthesis in the eukaryotes  
The mannosyl donor in eukaryotes is dolichol phosphate β-D-mannose (Dol-P-Man). The donor 
is synthesised on the cytoplasmic face of the ER membrane and the mannose transfer to Dol-P is 
catalysed by GDP-α-D-Man:Dol-P β-D-mannosyltransferase (Lommel and Strahl 2009). Dpm1 
was identified by Haselbech (1989) with catalytic activity later demonstrated following E. coli 
heterologous expression (Orlean et al., 1988). The same mannose donor is also used in N-
glycosylation (whereby mannose is transferred to the amide of an asparagine side chain) and is 
required for LLO extension in the ER and GPI anchor biosynthesis (Kornfeld 1985; Stevens et al., 
1995) Knockout mutants of dpm1 in the lower eukaryote S. cerevisiae are lethal (Orlean 1990), 
an unsurprising phenotype given the requirement of Dol-P-Man as a donor for yeast mannan 
synthesis. Similarly, in the higher eukaryote Schizosaccharomyces pombe disruption of the dpm1 
gene has also been shown to be lethal (Colussi et al., 1997). In humans glycosylation defects 
related to human dpm1 disruption have been linked to breast cancer, as well as congenital 





1.4.3 Protein O-mannosylation in the eukaryotes 
Following Dol-P-Man synthesis by Dpm1, Dol-P-Man is flipped to the other side of the ER 
membrane by a currently unknown mechanism, though a flippase is believed to be involved 
(Lommel and Strahl 2009). A second glycosyl transferase Dol-P-Man:Protein O-
mannosyltransferase (Pmt) then catalyses the transfer of mannose from Dol-P-Man to serine or 
threonine residues on the target protein. Considering the location of mannosylation, it was 
suggested that protein O-mannosylation was coupled to translocation into the ER (Shematek et 
al., 1980). Since then, Pmt mediated protein O-mannosylation has been reported on misfolded 
proteins following their translocation to the ER. The modification served to both reduce the 
dependency on chaperones for protein folding, while increasing protein solubility through the 
addition of hydrophilic sugar moieties (Nakatsukasa et al., 2004).  Consequently, Pmt mediated 
protein O-mannosylation is not exclusively coupled to translocation into the ER, as previously 
thought.  
In S. cerevisiae, there are at least six members of the PMT family (Pmt1p-Pmt6p) (Strahl-
Bolsinger et al., 1991; Strahl-Bolsinger et al., 1993; Gentzsch et al., 1996). In S. cerevisiae, PMTs 
are known to form dimeric complexes; a complex readily observed is Pmt1p-Pmt2p (Lommel et 
al., 2009). Functional studies showed the N-terminus of Pmt1p interacts with Pmt2p and that 
the central ER lumen facing loop 5 of Pmt1p is essential for the enzyme’s mannosyl transferase 
activity (Girrbach et al., 2000). The human equivalent to PMTs are the POMT family, Pomt1-
Pomt2 complexes have been well studied and are essential for mannosyl transferase activity 
(Akasaka-Manya et al., 2006; Lommel and Strahl 2009). Complex formation therefore appears to 
be critical for PMT O-linked mannosylation activity in both yeast and humans. 
Protein O-mannosylation and the impact of mannosylation defects have been more extensively 
probed in the eukaryotic kingdom.  In Candida albicans, knockout mutations in Pmt isoforms 
affected growth, morphogenesis and antifungal resistance (Prill et al., 2005) Protein O-
mannosylation has a critical role in maintaining a stable cell wall in fungi, and it has been shown 
that knockout of Pmt family members in S. cerevisiae, S. pombe, A. fumigatus and C. neoformans 
is lethal (Gentzsch and Tanner 1996; Willer et al., 2005; Olson et al., 2007; Mouyna et al., 2010) 
Interestingly, in S. cerevisiae, ER stress can drive the expression of Pmt genes and the associated 
O-mannosylation helps to solubilise misfolded proteins in the ER. Solubilisation of misfolded 
proteins facilitates their degradation, preventing a potentially cytotoxic build-up of aggregates 
(Travers et al., 2000; Nakatsukasa et al., 2004; Hirayama et al., 2008).  
 
The best studied O-mannosylated protein in higher eukaryotes is α dystroglycan, an essential 
component of skeletal muscle. RNAi knockdown of POMT1 or POMT2 in D. melanogaster 
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reduced viability, notably, causing severe muscle development defects (Ichimiya et al., 2004). 
Mutations in these genes during larval development yielded comparable phenotypes (Haines et 
al., 2007). In mice embryos, Pomt1 disruption is fatal (Willer et al., 2004). In humans, mutations 
in either POMT1 or POMT2 contribute to Muscle-eye–brain disease (MEB) and Walker–Warburg 
syndrome (WWS). Both are autosomal recessively-inherited disorders characterised by 
muscular dystrophy and impaired neuronal migration. The visual impairment seen in both 
conditions is attributed to structural abnormalities and eye muscle paralysis in WWS and MBB 
respectively (Taniguchi et al., 2003; Van Reeuwijk et al., 2005; Van Reeuwijk et al., 2006; 
Godfrey et al., 2007).  
 
While Pmt will add the first mannose to the protein in the ER membrane, extension of the 
growing chain is carried out by additional glycosyl transferases in the Golgi apparatus. In S. 
cerevisiae KTR and MNN-1 family mannosyl transferases further extend the glycan, creating 
α(1,2) and α(1,3) linkages (Lussier et al., 1999). In C. albicans addition of the second mannose to 
the growing chain is catalysed by the mannosyl transferase, MNT1. The absence of this enzyme 
reduced the ability of the yeast cells to adhere to each other. These null mutants also showed 
greatly attenuated virulence in both mouse and guinea pig models of systemic candidosis 
















1.5 Prokaryotic protein O-mannosylation  
1.5.1 Principles of protein O-mannosylation in the prokaryotes  
Before the mid-1970s protein glycosylation (and post translational modifications more 
generally) were thought to occur exclusively in the eukaryotic kingdom. This hypothesis was 
disproved upon the discovery of the first glycosylated prokaryotic glycoprotein in 
Halobacterium salinarium (Mescher et al., 1976). It is now understood that prokaryotes can also 
decorate proteins with a variety of N- and O- linked glycans. Prokaryotic protein O-
mannosylation is particularly well studied in Mycobacteria spp. with Corynebacterium spp. and 
Streptomyces spp. also attracting attention.  
1.5.2 Mannosyl donor synthesis in the prokaryotes 
The protein O-mannosylation pathway in prokaryotes is very similar to that seen in eukaryotes 
however there are several key differences. One notable difference is that the mannosyl donor is 
polyprenol phosphate, a functional analogue of dolichol phosphate (Strahl-Bolsinger et al., 
1999; Xing et al., 2000; Cowlishaw et al., 2002; Gurcha et al., 2002; Gibson et al., 2003). A 
polyprenol phosphate mannose synthase (homologous to the eukaryotic dolichol phosphate 
mannose synthases) transfers the mannose to the lipid phosphate. Prokaryotes however lack 
membrane bound organelles and consequently, mannosylation is initiated at the cytoplasmic 
membrane instead of the ER.  
In Corynebacterium glutamicum, polyprenol phosphate mannose synthase possesses two 
domain architecture with separate catalytic and membrane domains (Gibson et al., 2003). 
Inactivation of the catalytic domain led to a lipoglycan-less phenotype and a modest reduction 
in growth rate (Gibson et al., 2003). The two domain architecture is also present in M. 
tuberculosis, but not in M. smegmatis and M. leprae, which instead produce two separate 
proteins (one catalytic and one membrane) encoded by adjacent genes (ppm1 and ppm2) 
(Gurcha et al., 2002). The M. smegmatis Ppm1 homologue of the M. tuberculosis catalytic domain 
has previously been shown to be essential for survival (Gurcha et al., 2002). The introduction of 
a functional copy of the gene encoding M. tuberculosis PpmD2, the catalytic equivalent, was later 
shown to be sufficient to rescue the phenotype of M. smegmatis Ppm1 mutants (Rana et al., 
2012). Finally, in M. smegmatis, the membrane protein Ppm2 was shown to be an integral 
membrane protein that greatly enhanced the catalytic activity of Ppm1 (Baulard et al., 2003). 
These studies indicate that the two domain architecture of C. glutamicum and M. tuberculosis 




1.5.3 Protein O-mannosylation in Mycobacterium species 
As previously mentioned, protein O-mannosylation was first thought to be confined to the 
eukaryotes. The first understanding that mannosylation also took place in actinobacteria came 
with the isolation of culture filtrate proteins that were capable of binding the lectin 
concanavalin (Con A) (Espitia et al., 1989). Direct evidence for glycosylated residues on a 
mycobacterial protein was shown a few years later, whereby a purified culture filtrate protein 
was shown to have mannobiose or mannotriose sugars linked to threonine residues, the glycans 
were composed of α1,2 linkages (Dobos et al., 1995). α1,3 linkages were subsequently identified 
in a secreted glycoprotein from Mycobacterium bovis (Michell et al., 2003). Analysis of 
Mycobacterium tuberculosis culture filtrate showed glycosylation occurring on both threonine 
and serine residues (Smith et al., 2014).  
The PMT homologue of M. tuberculosis was shown to catalyse the first step in the mannosylation 
of unfolded proteins translocated by the SEC pathway (VanderVen et al., 2005). Inactivation of 
M. tuberculosis Pmt greatly impaired growth and reduced pathogenicity in 
immunocompromised mice (Liu et al., 2013). Comparable mutants in M. smegmatis lacked the 
growth-retarded phenotype, however mutant hypersensitivity to SDS treatment indicates the 
loss of Pmt likely results in changes to overall cell wall composition.  
A Ppm-dependent α1,2 mannosyl transferase (PimE) was subsequently identified in M. 
smegmatis and implicated in elongation of the glycan chain, the identification of α1,2- linked 
mannobiose and mannotriose glycans indicates a similar mechanism of glycan extension also 
exists in other mycobacteria (Morita et al., 2006). 
It is thought that protein O-mannosylation has a role in pathogenicity. Mannosylation of 
secreted proteins has specifically been shown to stimulate T lymphocyte responses (Horn et al., 
1999). Altered mannosylation patterns of the glycoprotein Apa in M. smegmatis had a limited 
ability to stimulate an in vitro T lymphocyte response, Apa that completely lacked 
mannosylation completely failed to stimulate a response (Horn et al., 1999). This is supported 
by further studies showing that mannosylation is required for interactions with host immune 
system C-type lectins, again indicting the glycosylation status of Apa is important for immune 
system recognition (Ragas et al., 2007). In M. tuberculosis and M. leprae similar studies have 
been conducted. A secreted protein SodC is recognised by antibodies (Sartain et al., 2009). 
Furthermore, M. leprae SodC binds in a carbohydrate dependent manner to r-langerin on 
antigen presenting dendritic cells of the immune system (Kim et al., 2015).  These studies in 




1.5.4 Protein O-mannosylation in Streptomyces  
Streptomyces protein O-mannosylation was first reported following Cowlishaw and Smith’s 
investigation that aimed to probe the molecular basis of ΦC31 infection of Streptomyces 
coelicolor. UV-induced and spontaneous mutants were identified that were resistant to the lytic 
phage ΦC31 cΔ25. While transfection of phage DNA into protoplasts of the resistant mutants 
that were regenerated in the presence of sensitive hosts was sufficient to cause a lytic burst, the 
phage could not form plaques on these mutants. The implication was that ΦC31 infection was 
blocked at the receptor binding stage. It was eventually deduced through genetic analysis and 
subsequent complementation studies that four of thirteen phage resistant mutants were 
deficient in Pmt. (Cowlishaw and Smith 2001). It was then thought that since PMT was a 
mannosyl transferase, another gene encoding an enzyme in the same pathway might 
complement the remaining nine mutants. A gene encoding a homologue of S. cerevisiae Dpm1 
and mycobacterial Ppm1 was identified. The product was therefore predicted to be S. coelicolor 
Ppm1. Introduction of the SCO1423 allele did complement three additional strains that had not 
been complemented by SCO3145 (Cowlishaw and Smith 2002). The link with glycosylation was 
further shown with the identification of glycosylated proteins via western blot analysis of the 
ppm1 +, pmt + parent strain (J1929) using ConA as a probe.  The proteins were not detected in 
the pmt – strain DT1025 (Cowlishaw and Smith 2002).     
The first characterised glycoprotein from S. coelicolor is PstS, a lipoprotein that is part of a high 
affinity phosphate uptake system. This protein was shown to be mannosylated with a trihexose 
in the J1929 parent strain, but not the pmt null mutant strain DT1025 (Wehmeier et al., 2009). 
Two serine rich synthetic peptides, designed using the PstS sequence as a template, were shown 
to be glycosylated by membranes derived from J1929, these peptide studies indicated that O-
mannosylation occurs only on specific serine or threonine residues, rather than being a random 
process. Further studies showed that Ppm1 was able to transfer mannose from a nucleotide 
activated sugar (GDP-mannose) onto the polyprenol phosphate in purified S. coelicolor 
membrane fractions. The lipid linked carrier polyprenol phosphate was therefore confirmed for 
the first time to be required for O-linked glycosylation, with the sugar itself being a mannose. 
Since it was already understood that mycobacteria Ppm1 had a two-domain architecture (with 
either 1) one domain anchored to the membrane or 2) separate catalytic and membrane 
embedded proteins that formed a complex. One of these mechanisms was presumably involved 
in localisation of S. coelicolor Ppm1 to the membrane. The absence of continuous hydrophobic 
stretches that could constitute a transmembrane helix in the S. coelicolor Ppm1 primary 
structure meant that S. coelicolor Ppm1 presumably interacted with another protein that would 
ensure localisation to the membrane.  The membrane protein Lnt1 (encoded by the SCO1014 
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gene) was identified as a homologue of the membrane associated domain of M. tuberculosis was 
identified in S. coelicolor. Lnt1 was suspected to be an interacting partner, however further 
investigation revealed that Lnt1 and Ppm1 did not interact (Anttonen 2010; Cordova Davalos et 
al., 2014). Lnt1 mutants were sensitive to infection by ΦC31 and were also shown to glycosylate 
the M. tuberculosis glycoprotein Apa (Cordova Davalos et al., 2014). There remains no evidence 
that Lnt1 is required for glycosylation in S. coelicolor.  
In addition to being resistant to phage infections, the ppm1 and pmt - strains identified by 
Cowlishaw and Smith (2001) had a growth-retarded phenotype. It was also noted that the ppm1 
– strains exhibited greatly increased susceptibility to multiple cell wall targeting antibiotics 
including vancomycin, daptomycin and multiple β-lactams (Howlett et al., 2018a). The 
phenotype was less extreme in the pmt – strains, nevertheless notable increases in sensitivity 
were shown for vancomycin and the carbapenems imipenem and meropenem. Induction of the 
vancomycin resistance cluster failed to alleviate the high vancomycin sensitivity of the ppm1 
and pmt – mutants. The implication of these studies was that Pmt mediated glycosylation is 
required for the function of periplasmic and membrane enzymes required for cell wall 
biosynthesis. Furthermore, RNAseq analysis conducted by Howlett et al (2018a) showed S. 
coelicolor ppm1 – mutants had increased expression of fatty acid biosynthesis genes and a 
greater proportion of unsaturated fatty acids. Additional Raman spectroscopy analysis showed 
changes in membrane lipids in the ppm1 deficient strain.  
Enzymes in the GDP-mannose synthesis pathway were later probed, namely 
phosphomannomutase (ManB – encoded by SCO3028) which converts mannose-6-phosphate to 
mannose-1 phosphate, and the GDP mannose pyrophosphorylases (ManC – encoded by 
SCO1388, SCO3039 and SCO4238) that use GTP and mannose-1-phosphate as substrates to 
synthesise GDP mannose.  SCO3039 and SCO4238 were investigated further and their 
importance for growth was indicated by the failure to generate a strain in which SCO3039 and 
SCO4238 were completely knocked out (Howlett et al., 2018b). S. coelicolor strains with knocked 
down ManC activity or with a mutation in SCO3028 rendering ManB inactive acquire 
phenotypes that closely resemble those of the ppm1 – mutants (C31 resistant and susceptible 
to cell wall inhibitor antibiotics).  Interestingly, the manB - strains had an extremely small 
colony phenotype. These findings indicate that ManB and ManC are an essential part of the 
protein O-mannosylation pathway in S. coelicolor. Furthermore, GDP-mannose itself may lie at 
branch point in metabolism, whereby it could be subject to further modification to supply 
alternative nucleotide activated sugar donors.  
The most recent published work on protein O-mannosylation in S. coelicolor describes a 
combination of biochemical and mass spectrometry approaches, resulting in the 
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characterisation of the S. coelicolor membrane glycoproteome for the first time (Keenan et al., 
2019). In this study, 37 novel S. coelicolor glycoproteins were identified, in addition to a more 
detailed understanding of PstS glycosylation sites. The glycoproteins identified have diverse 
roles including solute binding, ABC transporters, and cell wall biosynthesis. This is of particular 
interest considering the previously identified increased susceptibility of pmt – strains to cell wall 
targeting antibiotics. Two cell wall active glycoproteins identified in this study ((a putative D-
Ala-D-Ala carboxypeptidase (SCO4847) and an L,D-transpeptidase (SCO4934)) were mutated 
and the resulting strains were found to be hypersensitive to cell wall targeting antibiotics. These 
findings indicate a crucial role for glycoproteins in the maintenance of cell wall stability in S. 
coelicolor. 
1.5.5 The current model for protein O-mannosylation in S. coelicolor 
Based on all the currently available literature, a model for S. coelicolor protein O-mannosylation 
can be proposed (Figure 1.6). GDP mannose biosynthesis is carried out by the phosphomannose 
isomerase, the phosphomannomutase Man B. and the GDP-Mannose pyrophosphorylases ManC. 
With the nucleotide activated sugar GDP-mannose synthesised, Ppm1 catalyses the transfer of 
mannose to polyprenol phosphate on the cytoplasmic face of the membrane. Presumably, Ppm1 
is anchored to the membrane by an interacting membrane protein or an anchor of some kind, 
however the means by which Ppm1 is localised to the membrane remains unknown. The 
mannosylatated polyprenol is then flipped onto the periplasmic face of the membrane, a 
flippase is thought to be responsible however the mechanism also remains unknown. Finally 
Pmt catalyses the first step in protein O-mannosylation by adding the first mannose from 
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The antibiotic hyper susceptibility phenotypes obtained in mannosylation deficient strains of S. 
coelicolor are of great interest, since homologues of Ppm1 and Pmt are found in pathogenic 
bacteria. Inhibitors of these enzymes could potentially be used in combination with our existing 
arsenal of antibiotics. Given the depleted antibiotic pipeline, and the ever-increasing emergence 
of resistance, resensitising pathogenic bacteria to our current arsenal of antibiotics could be a 
significant turning point in this evolutionary arms race. The long term goal of Ppm1 and Pmt 
inhibitor development, is contingent on first gaining a more intimate understanding of enzyme 
function through mutational analysis. 
The aim of this project was therefore to develop and test a library of S. coelicolor Ppm1 and Pmt 
mutants in order to better understand the roles of residues critical for in vivo activity 
Specifically the objectives were: 
1. Express and purify pure, stable and homogenous polyprenol phosphate mannose 
synthase for structure and function studies. 
2. Produce a library of ppm1 mutant alleles and test their ability to complement a ppm1- 
strain using antibiotic/phage susceptibility assays, in addition to colony phenotype 
analysis. 
3. Develop a model to define roles for any residues critical for Ppm1 activity using in vivo 
mutant characterisation, structural bioinformatics approaches and existing literature.    
4. Produce a library of pmt mutant alleles and test their ability to complement a pmt – 
strain using antibiotic/phage susceptibility assays, in addition to colony phenotype 
analysis. 
5. Develop a model to define roles for any residues critical for Pmt activity using in vivo 
















All chemicals were purchased from Sigma-Aldrich, Fisher Scientific, Thermo Fisher, Melford or 
VWR International unless otherwise stated. Difco nutrient broth (DNB) and Difco nutrient agar 
(DNA) (Beckton Dickinson and Company), both used for the growth of S. coelicolor were 
purchased from Appleton Woods Ltd. Soya flour, also used for S. coelicolor growth was 
purchased from Holland & Barratt. All restriction enzymes, DNA polymerases and 
deoxynucleotides were purchased from New England Biolabs. PCR primers were purchased 
from Integrated DNA Technologies. DNA sequencing was carried out by Eurofins Genomics.  
 
2.1.2 Media and buffers 
Difco nutrient broth (DNB) (Kieser et al., 2000): 8 g of DNB powder was made up to 1000 ml 
with ddH20 and autoclaved (115 °C, 15 min).  
Difco nutrient agar (DNA) (Kieser et al., 2000): 4.6 g of solid DNA was made up to 250 ml 
with ddH20 and autoclaved (115 °C, 15 min). 
Soft nutrient agar (SNA) (Kieser et al., 2000): 8 g of DNB powder was made up to 1000 ml 
with ddH20 and autoclaved (115 °C, 15 min). 
Mannitol soya flour agar (MSA) (Kieser et al., 2000): 4 g of mannitol, 4 g soya flour and 4 g 
agar was made up to 250 ml with ddH2O and autoclaved twice (115 °C, 15 min). 
2x YT medium (Sandbrook et al., 1989): 16 g Bacto Tryptone, 10 g Bacto Yeast Extract and 5 
g NaCl was made up to 1000 ml with ddH20 and autoclaved (115 °C, 15 min). 
Luria Burtani (LB) broth and agar (Sandbrook et al., 1989): 10 g tryptone, 10 g NaCl and 5 g 
yeast extract were dissolved in ddH20 and made up to 1000 ml. For LB agar, 1.5 g of agar per 







Snapgene Viewer software (version 3.2) was used for plasmid map construction and analysis of 
sequencing data. BLAST was used to carry out gene and protein sequence homology searches 
https://blast.ncbi.nlm.nih.gov/Blast.cgi. Clustal omega was used to perform multiple sequence 
alignments https://www.ebi.ac.uk/Tools/msa/clustalo/. Agarose gels were analysed using 
Quantity one (version 4.6.2; Basic) software. Transmembrane helices were predicted using the 
TMHMM Server v. 2.0 algorithm http://www.cbs.dtu.dk/services/TMHMM/. Phyre2 was used 
to generate homology models http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index . 
CCP4-MG was used to visualise protein structures (McNicholas et al., 2011). ChemDraw was 

























2.1.4  Primers and plasmids 
Primers for PCR were supplied by IDT. Sequences are shown below: 
 
 
Primer Sequence Use 
Ippm1F 5’-ACAGGAGGCCCCATATGAACGACGGCGACGGGAC Amplify integration ppm1 
Ippm1R 5’-TCACTCGAGATCTCATATGTCAGGCCTTGGCGT Amplify integration ppm1 
Nppm1F 5’-ATGCTAGTCGCGGTTGATCG Amplify native ppm1 
Nppm1R 5’-TCGTTAGTCGGAGGCCAAACG Amplify native ppm1 
IpmtF 5’-ACAGGAGGCCCCATATGCACAGCGCGGTTCCC Amplify integration pmt 
IpmtR 5’TCACTCGAGATCTCATATGCTAGACCCACGTGTCGA
GCCAC 
Amplify integration pmt 
IpmtNSF 5’ACAGGAGGCCCCATATGTGGAGCCACCCGCAGTTCG
AGAAGCACAGCGCGGTTCCC 
Amplify integration pmt + 
N-terminal StrepII tag  
IpmtCSR 5’TCACTCGAGATCTCATATGCTACTTCTCGAACTGCG
GGTGGCTCCAGACCCACGTGT 
Amplify integration pmt + 
C-terminal StrepII tag  
R82AF   5’-GATGATCGCCTGGTCGGCGTGGGGCGGGC pmt mutagenesis 
R82AR 5’-GACCAGGCGATCATCCGGTCGGTGAGCGG pmt mutagenesis 
D113AF   5’-GATATTCGCGGAGACGTACTACGCCAAGGACGCG pmt mutagenesis 
D113AR 5’-CGTCTCCGCGAATATCACCGCCTTCGGGC pmt mutagenesis 
E114AF   5’-ATTCGACGCCACGTACTACGCCAAGGACGCGT pmt mutagenesis 
E114AR 5’-GTACGTGGCGTCGAATATCACCGCCTTCGGGC pmt mutagenesis 
V158AF 5’-GTACGTCGCGCACCCGCCGGTCGGCAAG pmt mutagenesis 
V158AR 5’-GGGTGCGCGACGTACGCCGCGTCGGT pmt mutagenesis 
H159AF 5’-CGTCGTCGCCCCGCCGGTCGGCAAGTAC pmt mutagenesis 
H159AR 5’-CCGGCGGGGCGACGACGTACGCCG pmt mutagenesis 
P160AF 5’-GTCCACGCCCCGGTCGGCAAGTACATCATCGG pmt mutagenesis 
P160AR 5’-CCGACCGGGGCGTGGACGACGTACGCCG pmt mutagenesis 
P161AF 5’-CCACCCGGCCGTCGGCAAGTACATCATCGGC pmt mutagenesis 
P161AR 5’-CTTGCCGACGGCCGGGTGGACGACGTAC pmt mutagenesis 
K164AF 5’-GGTCGGCGCGTACATCATCGGCCTCGGC pmt mutagenesis 
K164AR 5’-TGATGTACGCGCCGACCGGCGGGTGGAC pmt mutagenesis 
R182AF 5’-CGGCTGGGCCTTCATGACGGCGCTGCTCG pmt mutagenesis 
R182AR   5’-ATGAAGGCCCAGCCGAACGGGTCGAAGCC pmt mutagenesis 
R201AF 5’-GATCGGCGCCCGCCTGTTCCGCTCCACGTTC pmt mutagenesis 
R201AR 5’-AGGCGGGCGCCGATCCGGCACAGCAGC pmt mutagenesis 
R228AF 5’-GATGAGCGCCACCGCGCTGCTGGACAGC pmt mutagenesis 
R228AR 5’-GCGGTGGCGCTCATCACGAAGTGCAGGCC pmt mutagenesis 
L231AF 5’-CACCGCGGCGCTGGACAGCGTGCTGATGTTC pmt mutagenesis 
L231AR 5’-TCCAGCGCCGCGGTGCGGCTCATCACG pmt mutagenesis 
L232AF 5’-CGCGCTGGCGGACAGCGTGCTGATGTTCTTC pmt mutagenesis 
L232AR 5’-CTGTCCGCCAGCGCGGTGCGGCTCATCACG pmt mutagenesis 
D220AF 5’-GGCGCTGGCGGGCCTGCACTTCGTGATGAGC pmt mutagenesis 
D220AR 5’-AGGCCCGCCAGCGCCATCAGGGCGC pmt mutagenesis 
D233AF 5’-GCTGCTGGCGAGCGTGCTGATGTTCTTCGTGC pmt mutagenesis 
Table 2.1: List of PCR primer sequences 
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D233AR 5’-ACGCTCGCCAGCAGCGCGGTGCGGCTCATC pmt mutagenesis 
K332AF 5’-GGCCACCGCGTGGAACGGCCTCTACATCATGG pmt mutagenesis 
K332AR 5’-TTCCACGCGGTGGCCGCCGCCAGGCCCA pmt mutagenesis 
R338AF 5’-CGTACTCGCCCACGACCTGGGCTGGGCCTTCC pmt mutagenesis 
R338AR 5’-TCGTGGGCGAGTACGGCGCGGTAGGGGC pmt mutagenesis 
P393AF 5’-GCTCTTCGCGGACTGGTGGCGCAGCCTGTG pmt mutagenesis 
P393AR 5’-CCAGTCCGCGAAGAGCCACGACCAGGAGCTG pmt mutagenesis 
W400AF 5’-GCAGCCTGGCCCACTACGAGACCCAGGTCCTCG  pmt mutagenesis 
W400AR 5’-GTAGTGGCCCAGGCTGCGCCACCAGTCGG pmt mutagenesis 
H410AF 5’-CGAATTCGCCACCCACCTGACCTCGCCGCA pmt mutagenesis 
H410AR 5’-TGGGTGGCGAATTCGAGGACCTGGGTCTCG pmt mutagenesis 
S421AF 5’-CTACCAGGCCAACCCCTGGAGCTGGATCG pmt mutagenesis 
S421AR 5’AGGGGTTGCCCTGGTAGGTGTGCGGCGAGGTCAGG pmt mutagenesis 
W426AF 5’-CTGGAGCGCGATCGTCCTGGGCCGCCCGGTCTC pmt mutagenesis 
W426AR 5’-ACGATCGCGCTCCAGGGGTTCGACTGGTAGG pmt mutagenesis 
R510AF 5’-CCAGGAGGCCACGATCTTCCTCTTCTACGCCG pmt mutagenesis 
R510AR 5’-ATCGTGGCCTCCTGGTACATGAACCAGGGCAG pmt mutagenesis 
F564AF    5’-GTGGAACGCCATCTACTTCTGGCCCCTGTACACGG pmt mutagenesis 
F564AR 5’-GTAGATGGCGTTCCACGCGATGAGGAGCACCAGG pmt mutagenesis 
R82KF CGACCACTTGATCATCCGGTCGGTGAGCGG pmt mutagenesis 
R82KR ACCGGATGATCAAGTGGTCGGCGTGGGGC pmt mutagenesis 
R82HF ATGATCCACTGGTCGGCGTGGGGC pmt mutagenesis 
R82HR GACCAGTGGATCATCCGGTCGGTGAG pmt mutagenesis 
D113PF GATATTCCCCGAGACGTACTACGCCAAGGACGCG pmt mutagenesis 
D113PR CGTCTCGGGGAATATCACCGCCTTCGGGC pmt mutagenesis 
D113LF GATATTCCTCGAGACGTACTACGCCAAGGACGCG pmt mutagenesis 
D113LR CGTCTCGAGGAATATCACCGCCTTCGGGC pmt mutagenesis 
D113YF GATATTCTACGAGACGTACTACGCCAAGGACGCG pmt mutagenesis 
D113YR CGTCTCGTAGAATATCACCGCCTTCGGGC pmt mutagenesis 
D113SF GATATTCAGCGAGACGTACTACGCCAAGGACGCG pmt mutagenesis 
D113SR CGTCTCGCTGAATATCACCGCCTTCGGGC pmt mutagenesis 
D113RF GATATTCCGCGAGACGTACTACGCCAAGGACGCG pmt mutagenesis 
D113RR CGTCTCGCGGAATATCACCGCCTTCGGGC pmt mutagenesis 
D113NF GATATTCAACGAGACGTACTACGCCAAGGACGCG pmt mutagenesis 
D113NR CGTCTCGTTGAATATCACCGCCTTCGGGC pmt mutagenesis 
D113EF GATATTCGAGGAGACGTACTACGCCAAGGACGCG pmt mutagenesis 
D113ER GTACGTCTCCTCGAATATCACCGCCTTCGGGC pmt mutagenesis 
H159KF GTCGTCAAGCCGCCGGTCGGCAAGTAC pmt mutagenesis 
H159KR CCGGCGGCTTGACGACGTACGCCGCGTC pmt mutagenesis 
H159NF TCGTCAACCCGCCGGTCGGCAAG pmt mutagenesis 
H159NR GGCGGGTTGACGACGTACGCCG pmt mutagenesis 
D233NF GCTGCTGAATAGCGTGCTGATGTTCTTCGTGC pmt mutagenesis 
D233NR ACGCTATTCAGCAGCGCGGTGCGGCTCATC pmt mutagenesis 
D233EF CTGCTGGAGAGCGTGCTGATGTTCTTCGTGC pmt mutagenesis 
D233ER ACGCTCTCCAGCAGCGCGGTGCG pmt mutagenesis 
K332HF CCACCCACTGGAACGGCCTCTACATCATGG pmt mutagenesis 
K332HR TTCCAGTGGGTGGCCGCCGCCAGGCCC pmt mutagenesis 
K332RF CCACCCGGTGGAACGGCCTCTACATCATGG pmt mutagenesis 
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K332RR TTCCACCGGGTGGCCGCCGCCAGGCCCA pmt mutagenesis 
R510HF ACCAGGAGCACACGATCTTCCTCTTCTACGCCGTC pmt mutagenesis 
R510HR AGATCGTGTGCTCCTGGTACATGAACCAGGG pmt mutagenesis 
R510KF ACCAGGAGAAGACGATCTTCCTCTTCTACGCCGTC pmt mutagenesis 

































Plasmid Details Reference 
pIJ10257 Integrating vector conferring 
hygromycin resistance with constitutive 
ermEp* promoter  
Gregory et al., 2003 
pNHC1 ScPpm1 (WT) in pIJ10257 This work 
pNHC2 ScPpm1 (D57A) in pIJ10257 This work 
pNHC3 ScPpm1 (R82A) in pIJ10257 This work 
pNHC4 ScPpm1 (D111A) in pIJ10257 This work 
pNHC5 ScPpm1 (D113A) in pIJ10257 This work 
pNHC6 ScPpm1 (H116D) in pIJ10257 This work 
pNHC7 ScPpm1 (R138A) in pIJ10257 This work 
pNHC8 ScPpm1 (G143V) in pIJ10257 This work 
pNHC9 ScPpm1 (S163L) in pIJ10257 This work 
pNHC10 ScPpm1 (R226A) in pIJ10257 This work 
pNHC18 ScPmt (WT) in pIJ10257 This work 
pNHC19 ScPmt (R82) in pIJ10257 This work 
pNHC20 ScPmt (D113A) in pIJ10257 This work 
pNHC21 ScPmt (E114A) in pIJ10257 This work 
pNHC22 ScPmt (V158A) in pIJ10257 This work 
pNHC23 ScPmt (H159A) in pIJ10257 This work 
pNHC24 ScPmt (P161A) in pIJ10257 This work 
pNHC25 ScPmt (K164A) in pIJ10257 This work 
pNHC26 ScPmt (R182A) in pIJ10257 This work 
pNHC27 ScPmt (R201A) in pIJ10257 This work 
pNHC28 ScPmt (R228A) in pIJ10257 This work 
pNHC29 ScPmt (L231A) in pIJ10257 This work 
pNHC30 ScPmt (L232A) in pIJ10257 This work 
pNHC31 ScPmt (D233A) in pIJ10257 This work 
pNHC32 ScPmt (K332A) in pIJ10257 This work 
pNHC33 ScPmt (R335A) in pIJ10257 This work 
pNHC34 ScPmt (P393A) in pIJ10257 This work 
pNHC35 ScPmt (W400A) in pIJ10257 This work 
pNHC36 ScPmt (H410A) in pIJ10257 This work 
pNHC37 ScPmt (S421A) in pIJ10257 This work 
pNHC38 ScPmt (W426A) in pIJ10257 This work 
pHHC39 ScPmt (P503A) in pIJ10257 This work 
pNHC40 ScPmt (R510A) in pIJ10257 This work 
pNHC41 ScPmt (F564A) in pIJ10257 This work 
pNHC42 ScPmt (N-StrepII  R82A) in pIJ10257 This work 
pNHC43 ScPmt (C-StrepII  + R82A) in pIJ10257 This work 
pNHC44 ScPmt (N-StrepII +  D113A) in pIJ10257 This work 
pNHC45 ScPmt (C-StrepII  + D113A) in pIJ10257 This work 
pNHC46 ScPmt (N-StrepII  + H159A) in pIJ10257 This work 
pNHC47 ScPmt (C-StrepII  + H159A) in pIJ10257 This work 
pNHC48 ScPmt (N-StrepII  + D233A) in pIJ10257 This work 
Table 2.2: List of constructs 
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pNHC49 ScPmt (C-StrepII  + D233A) in pIJ10257 This work 
pNHC50 ScPmt (N-StrepII  + K302A) in pIJ10257 This work 
pNHC51 ScPmt (C-StrepII  + K302A) in pIJ10257 This work 
pNHC52 ScPmt (N-StrepII  + R510A) in pIJ10257 This work 
pNHC53 ScPmt (C-StrepII  + R510A) in pIJ10257 This work 
pNHC54 ScPmt (N-StrepII  + P160A) in pIJ10257 This work 
pNHC55 ScPmt (C-StrepII  + P160A) in pIJ10257 This work 
pNHC56 ScPmt (N-StrepII  + K164A) in pIJ10257 This work 
pNHC57 ScPmt (C-StrepII  + K164A) in pIJ10257 This work 
pNHC58 ScPmt (N-StrepII  + R228A) in pIJ10257 This work 
pNHC59 ScPmt (C-StrepII  + R228A) in pIJ10257 This work 
pNHC60 ScPmt (N-StrepII  + L231A) in pIJ10257 This work 
pNHC61 ScPmt (C-StrepII  + L231A) in pIJ10257 This work 
pNHC62 ScPmt (N-StrepII  + R335A) in pIJ10257 This work 
pNHC63 ScPmt (C-StrepII  + R335A) in pIJ10257 This work 
pNHC64 ScPmt (N-StrepII  + S421A) in pIJ10257 This work 
pNHC65 ScPmt (C-StrepII  + S421A) in pIJ10257 This work 
pNHC72 ScPmt (C-StrepII + R82K) in pIJ10257 This work 
pNHC73 ScPmt (C-StrepII + R82H) in pIJ10257 This work 
pNHC74 ScPmt (C-StrepII + D113P) in pIJ10257 This work 
pNHC75 ScPmt (C-StrepII + D113L) in pIJ10257 This work 
pNHC76 ScPmt (C-StrepII  + D113Y) in pIJ10257 This work 
pNHC77 ScPmt (C-StrepII  + D113S) in pIJ10257 This work 
pNHC78 ScPmt (C-StrepII  + D113R) in pIJ10257 This work 
pNHC79 ScPmt (C-StrepII  + D113N) in pIJ10257 This work 
pNHC80 ScPmt (C-StrepII  + D113E) in pIJ10257 This work 
pNHC81 ScPmt (C-StrepII + H159K) in pIJ10257 This work 
pNHC82 ScPmt (C-StrepII + H159N) in pIJ10257 This work 
pNHC83 ScPmt (C-StrepII + D233N) in pIJ10257 This work 
pNHC84 ScPmt (C-StrepII + D233E) in pIJ10257 This work 
pNHC85 ScPmt (C-StrepII + K332H) in pIJ10257 This work 
pNHC86 ScPmt (C-StrepII + K332R) in pIJ10257 This work 
pNHC87 ScPmt (C-StrepII + R510H) in pIJ10257 This work 












S. coelicolor DT3017, DT1020, DT1029, DT1025, DT2008 (all derived from a J1929 parent 
strain) and J1929 were used as acceptor hosts for plasmid conjugation, these strains were 
obtained previously (Bedford et al., 1995; Cowlishaw and Smith 2002). E. coli ET12567 
(pUZ8002), a methylation deficient strain, was used as a donor host for plasmid conjugation 
with Streptomyces acceptor strains. E. coli DH5α was used for pIJ10257 plasmid propagation 
and cloning to yield recombinant plasmids containing either a pmt or ppm1 allele cloned into 




Streptomyces strain Genotype Reference 
J1929 pglY mutant Bedford et al., 1995 
DT1025 pmt W389STOP mutant Cowlishaw and Smith 2002 
DT2008 Not known Cowlishaw and Smith 2002 
DT1020 ppm1 H116D mutant Cowlishaw and Smith 2002 
DT1029 ppm1 S163L mutant Cowlishaw and Smith 2002 
DT3017 ppm1 E218V mutant  Cowlishaw and Smith 2002 
E coli strain Genotype Reference 
ET12567(pUZ8002) dam- dcm- hsdS, RP4 transfer 
genes 
MacNeil 1988 
DH5α F- endA1 glnV44 thi-1 recA1 
relA1 gyrA96 deoR nupG 
ϕ80dlacZ ΔM15 l Δ(lacZYA-
argF)U196, hsdR17(rk-mk+), λ- 
Green et al., 2012 
 
 
Bl21 (DE3) fhuA2 [lon] ompT gal (λ DE3) 









Table 2.3: List of bacterial strains 
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2.2 Molecular procedures 
2.2.1 Growth of E. coli 
E. coli strains were cultivated on LB agar at 37 °C overnight. E. coli strains were cultured for 12 – 
16 H at 37 °C (180 rpm). The LB broth growth medium was supplemented with antibiotics as 
required. To ensure plasmids were maintained in E. coli, glycerol stocks were prepared by 
storing the strains in (20 % v/v) glycerol at -80 °C 
2.2.2 Preparation of chemically competent cells 
A 5 ml 18 H overnight E. coli culture was grown and 500 µl added to 50 ml of LB. The culture 
was incubated at 37 °C with shaking until mid-log phase was reached (OD600nm = 0.4). The cells 
were centrifuged (10 min, 4000 x g, 4 °C). The supernatant was discarded and the pellet 
resuspended in 15 ml TFB1 and incubated on ice for 90 min. Cells were harvested by 
centrifugation (10 min, 4000 x g, 4 °C) and the pellet resuspended in 2 ml TFB2. 250 µl aliquots 
of competent cells were snap frozen in liquid nitrogen. This method is based on that described 
in Sandbrook et al., (1989). 
TFB 1: 100 mM RbCl , 50 mM MnCl2. 30 mM KAc, 10 mM CaCl2, 15 % glycerol (pH 5.8 with HCl) 
TFB2: 10 mM MOPS, 10 mM RbCl, 75 mM CaCl2, 15 % glycerol (pH 8.0 with NaOH) 
 
2.2.3 Transformation of E. coli 
100 ng DNA was added to 30 μl of competent E. coli DH5α and kept on ice for 30 min. The cells 
were heat shocked at 42 °C for 45 s and cooled on ice for 5 min. The cells were resuspended in 
250 μl Luria-Bertani (LB) media and incubated at 37 °C for 45 min (200 rpm). 50 μl of 
transformation reaction was plated out on LB agar containing an appropriate selection 
antibiotic.  
2.2.4 Plasmid DNA isolation 
Plasmid DNA was isolated from overnight 5 ml LB cultures, centrifuged at 4000 x g 10 min. The 
cell pellet was processed and plasmid purified in accordance to the manufacturer’s instructions 
using QIAprep Spin Miniprep Kit (QIAGEN). DNA was eluted in 50 µl 10 mM Tris-HCl pH 8.5. 
2.2.5 PCR/DNA digest clean up 
To remove enzymes and reaction components, samples were processed using QIA Quick PCR 
Purification Kit (QIAGEN) in accordance with the manufacturer’s instructions. DNA was eluted 





2.2.6 Restriction digest 
For analytical digests or to obtain digested DNA to be used for cloning, ~0.5 - 1.5 µg of DNA was 
digested with 20 units of restriction enzyme in a final volume of between 10 - 50 µl. Reactions 
were carried out in the NEB Cutsmart buffer for 4 H. 
2.2.7 Agarose gel electrophoresis  
Agarose 1 x gels were prepared in 1 x Tris-borate-EDTA (TBE = 90 mM Tris, 64.6 mM boric acid, 
2.5 mM EDTA) buffer with 0.1 µg ml-1 ethidium bromide. DNA samples were mixed with 6 X gel 
loading buffer (NEB) and run at 100 v, 400 mA for 45 min. A 1 KB ladder was used as a 
reference (NEB). DNA was visualised using a UV transilluminator system (BioRad). 
2.2.8 In-Fusion Cloning 
InFusion Cloning was carried out in accordance with the manufacturer’s instructions. Assembly 
of the reaction required 50-100 ng of vector DNA and PCR insert(s), 2 µl of HD Infusion enzyme 
and ddH20 to make the reaction up to 10 µl. Reactions were incubated for 15 min (50 °C), after 
which 5 µl of the product was used to transform into E. coli competent cells.  
2.2.9 ppm1 cloning into pIJ10257 
In order to clone the mutated S. coelicolor ppm1 alleles from pET28a into pIJ10257, they were 
first amplified by PCR with the Ippm1F and Ippm1R primers. Phusion Hi-Fidelity Polymerase 
(ThermoFisher) was used according to the manufacturer's instructions with the following 
reaction conditions: 98 °C/1 min, 25 cycles of 98 °C/10 s, 72 °C/30 s, 72 °C/1 min and 72 °C/ 10 
min using a Biometra TProfessional Basic Thermocycler (Thistle Scientific). PCR products were 
digested with DpnI (NEB), purified using QIA Quick PCR Purification Kit (QIAGEN) and cloned 
into NdeI (NEB) digested pIJ10257 using the In-Fusion HD Cloning Kit (Clontech), all in 
accordance with the manufacturers’ instructions. 5 μl of each reaction product was introduced 
into chemically competent DH5α E. coli by transformation.  
2.2.10 pmt mutagenesis and cloning into pIJ10257 
J1929 genomic DNA was used as the template to amplify pmt and introduce each mutation in 
tandem via two separate PCR reactions. The first reaction containing IpmtF to begin amplifying 
from the 5’ end of the gene alongside a reverse mutagenic primer e.g. R82AR. The second 
reaction would use IpmtR to begin amplifying from the 3’end of the gene alongside a forward 
mutagenic primer e.g. R82AF. Consequently, there were two amplified products for each mutant 
allele. Phusion Hi-Fidelity Polymerase (ThermoFisher) was used according to the 
manufacturer's instructions with the following reaction conditions: 98 °C/1 min, 30 cycles of 98  
°C/10 s, 60 °C/30 s, 72 °C/2 min and 72 °C/10 min using a Biometra TProfessional Basic 
Thermocycler (Thistle Scientific).  
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PCR products were digested with DpnI (NEB), purified using QIA Quick PCR Purification Kit 
(QIAGEN). The two amplified products corresponding to each mutant were joined together and 
then cloned into NdeI (NEB) digested pIJ10257 using the In-Fusion HD Cloning Kit (Clontech), 
all in accordance with the manufacturers’ instructions. 5 μl of each reaction product was 
introduced into chemically competent DH5α E. coli by transformation.  
 
2.3 Streptomyces work 
2.3.1 Conjugation from E. coli and S. coelicolor spore harvesting  
The method of intergeneric conjugation used in this work was previously described by Gust et 
al., (2003). E. coli ET12567 (pUZ8002) competent cells were prepared after growing LB broth 
(37°C, 180 rpm) containing kanamycin (50 µg/ml) and chloramphenicol (25 µg/ml) to select for 
pUZ8002 and the dam mutation respectively. Following plasmid transformation, transformants 
were inoculated in 10 ml of LB both containing kanamycin (50 µg/ml), chloramphenicol (25 
µg/ml) and 50 µg/ml hygromycin to select for the vector and grown overnight at 37 °C with 
shaking (180 rpm). The overnight culture was diluted 1/100 into 10 ml of fresh LB broth plus 
antibiotics and grown to an OD600nm of ~0.4 at 37 °C. The cells were pelleted, washed twice with 
10 ml LB both and then resuspended in 1 ml fresh LB broth. Approximately 108 cfu ml-1 S. 
coelicolor spores were added to 500 µL of the E. coli cells in LB broth. The mixture was 
centrifuged, the supernatant discarded and the pellet was resuspended in 100 µL LB broth. 
Using sterile MilliQ H20, a dilution series from 10-1 to 10-4 was prepared, each step in a final 
volume of 100 µL. The 100 µL aliquots of each dilution were plated onto MSA + 10 mM MgCl2 
and incubated at 30 °C for 18 H. The plates were overlayed with 1 ml sterile MilliQ H20 
containing 0.5 mg Nalidixic acid and 0.5 mg hygromycin. The plates were further incubated for 7 
days at 30 °C until antibiotic resistance S. coelicolor colonies were identified. Four 
exoconjugants corresponding (each representing a biological replicate) to each mutant allele 
were picked, resuspended in 100 μl water and streak plates made on soya mannitol (SM) agar 
(50 μg ml-1 hygromycin). The plates were incubated for seven days at 30 °C. Single colonies were 
then picked, resuspended in 100 μl water and spread plates made on SM agar (50 μg ml-1 
hygromycin). The plates incubated for seven days at 30 °C. The spores were harvested by gentle 
resuspension in 20 % glycerol using cotton buds and stored at -30 °C. A revised protocol for 
Ppm1 mutant spore harvesting was also used. Following conjugations, antibiotic overlay and 
incubation for five days, four single colonies were picked (each representing a biological 
replicate). The picked colonies were crushed in water and corresponding spread plates 




2.3.2 Antibiotic disc diffusion assay 
Approximately 1 x 107 Streptomyces spores were spread on a DN plate. Sterile filter discs were 
placed on the plate surface and 10 μl of antibiotic stock solution absorbed to the disc. Plates 
were incubated at 30 °C for 36 H and the zone of clearance diameter measured in order to 
quantify antibiotic susceptibility. Four biological replicates were tested for each strain.  
2.3.3 Phage plaque assay 
The phage plaque assay was carried in accordance with the protocols described by Kieser and 
co-workers (Kieser et al., 2000). A dilution series from the ΦC31 phage was prepared (10-1 - 10-
6) in DNB and 0.1 ml of each dilution was plated on a freshly poured 5 cm plate of DNA 
supplemented with 0.5 % glucose, 10 mM MgSO4 and 8 mM Ca(NO3)2 . ΦC31 phage was 
originally isolated by Lomovskaya and co-workers in Moscow (Lomovskaya et al., 1972). 0.8 ml 
SN agar containing approximately 1 x 107 Streptomyces spores was added to each plate and 
swirled to ensure even coverage. The plates were incubated at 30 °C for 18 H and the plaques 
scored.  
2.3.4 Phage streak assay 
An undiluted stock of ΦC31 CΔ25 mutant was plated on half a freshly poured 10 cm square 
plate of DN agar supplemented with 0.5 % glucose, 10 mM MgSO4 and 8 mM Ca(NO3)2 . A streak 
of 1 x 107 of streptomyces spores was made starting from the phage free region and moving into 
the phage present region. The plates were incubated at 30 °C for 18 H. 
2.3.5 Isolation of genomic DNA from S. coelicolor  
S. coelicolor genomic DNA was isolated according to the salting out procedure described by 
Pospiech and Neumann (1995). The mycelium from a 30 ml culture grown in DNB was pelleted 
by centrifugation (4000 x g, 4 °C, 5 min) and resuspended in 5 ml SET buffer (75 mM NaCl, 25 
mM EDTA pH 8, 20 mM Tris-HCl pH 7.5). 100 µl of lysozyme solution (50 mg ml-1 ddH20) was 
added and the suspension incubated for 60 min at 37°C. 140 µl of proteinase K solution (50 mg 
ml-1 in ddH20) was added and mixed by inversion. 600 µl 10 % SDS was then added, the 
suspension was mixed by inversion and incubated at 55 °C for 60 min. 2 ml 5 M NaCl was added 
and the suspension mixed by inversion and then cooled to ~37 °C. 5 ml chloroform was added 
and the suspension mixed by inversion for 30 min at 20 °C. Samples were centrifuged (4500 x g, 
20 °C, 15 min). The supernatant was transferred to a fresh tube and 0.6 volume isopropanol was 
added. Samples were mixed by inversion. After 3 min the DNA was spooled onto a sealed 
Pasteur pipette. The DNA was rinsed in 5 ml 70% ethanol, air dried and dissolved in ddH20 at 55 
°C for 5 min.  
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2.3.6 ppm1 revertent analysis 
Colonies present within the vancomycin zones of clearance on the disc diffusion assays plates 
were picked (one colony for each biological replicate), resuspended in 100 μl of H20 and 
streaked on SM agar plates supplemented with 40 μg ml-1 hygromycin and vancomycin. The 
plates were incubated at 30 °C for 7 days.  
Phusion Hi-Fidelity Polymerase (ThermoFisher) was used to amplify the native locus ppm1 and 
integration site ppm1 alleles according to the manufacturer's instructions. Template DNA was 
provided by crushing a spore in 100 μl of H20, 1 μl was then added to the PCR tube. 
To amplify the native locus ppm1, Nppm1F and Nppm1R primers were used with the following 
reaction conditions:  98 °C/3 min, 25 cycles of 98 °C/10 s, 60 °C/30 s, 72 °C/1.5 min and 72 
°C/10 min. To amplify the integration site ppm1, Ippm1F and Ippm1R primers were used with 
the following reactions conditions:  98°C/3 min, 25 cycles of 98 °C/10 s, 60 °C/30 s, 72 °C/1 min 
and 72 °C/10 min. A Biometra TProfessional Basic thermocycler (Thistle Scientific) was used. 
PCR products were digested with DpnI and purified using QIA Quick PCR Purification Kit 
(QIAGEN). Presence or absence of reversion was confirmed by Sanger sequencing (GATC 
Biotech Ltd., London, UK). 
 
2.4 Protein methods  
2.4.1 SDS-PAGE 
5 µl of RunBlue 4 x LDS buffer (Expedeon) and 1 µl of 100 % 2-Mercaptoethanol (Sigma) were 
added to the protein samples. The samples were boiled at 80 °C for 10 min. Samples were 
loaded onto RunBlue 4 - 12 % Bis Tris protein gels (Expedeon) and run at 160 V for 1 H using 
XCell SureLock Mini-Cell Electrophoresis System (Thermo Fisher Scientific). InstantBlue 
(Expedon) was used to simultaneously stain and destain the gels.  
2.4.2 Harvesting membrane/soluble fractions for Western blotting 
Mycelium from streptomyces cultures grown at 37°C for 48 H were centrifuged (2 min, 3500 x 
g), washed (20 mM Tris-HCl pH 8, 4°C) and stored at -80 °C. To prepare soluble and membrane 
fractions, mycelial pellets were resuspended in double the volume of lysis buffer (20 mM Tris-
HCl pH 8, 4 mM MgCl2, 4 mM DTT and protease inhibitors tablets by volume (Roche)). 
Mycelium was lysed by sonication using a Sonicator 3000 (Misonix) (10 cycles of 30 s pulse and 
60 s cooling). Debris was removed by centrifugation (30 min, 5525 x g followed by 30 min at 
13500 x g, 4 °C). Membranes were finally pelleted by ultracentrifugation (1 H at 100,000 x g, 4 
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°C) The membrane pellet was resuspended in 20 mM Tris-HCl pH 8 to yield the membrane 
fraction while the supernatant constituted the soluble fraction.  
Protein concentrations were determined using the Nanodrop 2000 instrument (Thermo 
Scientific). Each membrane and soluble fraction was diluted to ~3 mg/ml and to 15 µl of each 
sample and SDS-PAGE performed, however instead of boiling, samples were incubated at 37 °C 
for 1 H. 
Proteins were then transferred to 0.45 µM Amersham Hybond PVDF Blotting Membrane (GE 
healthcare) using the XCell II Blot Module (Invitrogen). Transfer was carried out at 30 V for 1 H. 
The preparation of the membrane for Western blotting was carried out according to the 
instructions for the Strep Tag II antibody HRP conjugate (Novagen). Membranes were washed 
with 1 x PBS twice and incubated in 20 ml blocking solution (3 % BSA, 0.5 % Tween-20 in 1 x 
PBS) overnight at 4 °C with gentle agitation. The membranes were washed 3 times with 20 ml 
PBST. 10 ml diluted Strep Tag II antibody (Novagen) in PBST (1:4000 dilution) was added to the 
membrane and incubated for 1 H at room temperature with gentle agitation. The membranes 
were washed twice, each for 10 min with 20ml PBST and finally washed twice for 10 min each 
with 20 ml PBS.   
Chemiluminescent substrate for the Western blot was prepared as follows. Solution A: 13.3 µl of 
90 mM p-coumaric in DMSO, 16.6 µl of 30 % H202  and 3 ml of 100 mM Tris (pH 8.5). Solution B: 
30 µl of 250 mM luminol in DMSO and 3 ml of 100 mM Tris (pH 8.5). The combined volume of 
solutions A and B is enough to process a single blot. Under dark room conditions, membranes 
were incubated with chemiluminescent solutions A and B for 1 min. After exposure to the blot, 
X-ray film (GE healthcare) was incubated for 1 - 3 min in developer solution (Kodak) and 30 s in 
fixer solution (Kodak). The film was rinsed in water and allowed to dry.  
2.4.3 Ppm1 and Pmt Bioinformatics  
Primary structure pairwise and multiple sequence alignments were produced using EMBOSS 
Needle and Clustal Omega (Rice et al., 2000; Sievers et al., 2011).  
S. coelicolor Pmt and Ppm1 homology models were produced using Phyre2 (Kelley et al., 2015). 
The Pmt homology models was generated using Cupriavidus metallidurans ArnT (PDB ID: 
5ezmA) as the template (Petrou et al., 2016) and S. cerevisiae as the template Pmt1-Pmt2 (Bai et 
al., 2019). Ppm1 model was generated using P. furiosus Dpm synthase (PDB ID: 5MM1) as the 
template (Gandini et al., 2017). 
Protein structures were visualised using CCP4mg (McNicholas et al., 2011). Construct design 
and sequence trace analysis was carried out using SnapGene (GSL Biotech). 
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2.4.5 Ppm1 expression and purification  
A single colony of E. coli BL21 (DE3) transformed with the construct plasmid was selected and 
used to inoculate a 5 ml volume of autoclaved LB containing 50 µg/ml of kanamycin. After 18 H, 
1 ml of the culture was used to inoculate 1 L of LB media. Cultures were incubated at 37 °C until 
the 0D600nm was between 0.4 and 0.6. At this point IPTG was added (0.5 mM final concentration) 
and the flasks incubated at 20 °C for 18 H. Cells were harvested by centrifugation at 5000 x G at 
4 °C for 10 min and the pellets were stored at -20 °C.  
2.4.6 Ni2+ affinity chromatography  
Prior to chromatography, cells were resuspended in freshly prepared lysis buffer containing 
protease inhibitor cocktail (Roche), one tablet was added for every 100 ml of buffer. Lysis buffer 
was added at 3 ml/g of pellet and supplemented with lysozyme added to a final concentration of 
0.2 mg/ml. 
The cell suspension was disrupted by sonication using a Sonicator 3000 (Misonix). The 
sonication protocol was 3 s on, 7 s off for a total of 7 min using a MicroTip horn with an initial 
output setting of 7.0. The lysed cells were pelleted at 5000 x g at 4 °C for 15 min.  
The soluble protein was then loaded onto a HisTrap FF (5 ml) column and purification 
performed using an ÄKTA pure protein purification system. The flow rate was fixed at 5 ml/min 
and a 150 ml superloop was used for loading the protein onto the column. The column was 
washed 160 ml of binding buffer. Using elution buffer, the bound protein was eluted using an 
imidazole gradient (50 - 500 mM). Peak fractions were combined, concentrated to a final 
volume of 2 ml using Vivaspin 15R spin columns (Sartorius) by centrifugation (6000 x g, 4 °C).  
2.4.7 Dialysis 
SpectraPor molecular porous membrane tubing 3.5 kDa cut-off (Spectrum) was used for dialysis 
to remove the imidazole and exchange elution buffer for gel filtration buffer. Protein 
concentrations were determined using the Nanodrop 2000 spectrophotometer (Thermo). 
2.4.8 Gel filtration chromatography  
Overnight the Gel filtration column was equilibrated with 220 ml of gel filtration buffer and 
sample loaded onto a 16/60 Superdex 200 pg column and purification performed using an 
ÄKTA pure protein purification system. The flow rate was fixed at 1 ml/min and a 10 ml 
superloop was used for loading the protein onto the column and the column washed with 190 
ml of elution buffer. Peak fractions were combined, concentrated to a final volume of 2 ml using 
Vivaspin 15R spin columns (Sartorius) by centrifugation (6000 x g, 4 °C). 
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2.4.9 Gel filtration (size exclusion) chromatography coupled with multi angle laser light 
scattering (SEC-MALLS) 
Size exclusion chromatography was carried out on a Shimadzu HPLC system with a flow rate of 
0.5 ml/min. The elution was monitored at 280 nm by a SPD20A UV/Vis detector. Light 
scattering data were recorded by a Dawn HELEOS-II 18 – angle and the concentration of the 
eluting protein was measured by an in-line Optilab rEX refractive index monitor (Wyatt 
Technology). Data was analysed using the ASTRA V software package. 
2.4.10 Protein purification buffers 
Lysis buffer: (50 mM sodium hydrogen phosphate, 300 mM sodium chloride, 0.3 mM 
magnesium chloride, 10 mM imidazole, 10 % glycerol, pH 7.5). 
Binding buffer: 50 mM sodium hydrogen phosphate, 300 mM sodium chloride, 0.3 mM 
magnesium chloride, 20 mM imidazole, 10 % glycerol, pH 7.5 
Elution buffer: (50 mM sodium hydrogen phosphate, 300 mM sodium chloride, 0.3 mM 
magnesium chloride, 250 mM imidazole, 10 % glycerol, pH 7.5) 






















Chapter 3 – Expression and purification of S. coelicolor Ppm1 
 
S. coelicolor Ppm1 is a GT-A fold glycosyl transferase that catalyses mannose transfer from GDP-
mannose to polyprenol phosphate and critically, ppm1 null mutants of S. coelicolor are hyper 
susceptible to multiple antibiotics (Howlett et al., 2018). Inhibitors of this enzyme could 
therefore be used in combination with existing antibiotics that, as a consequence of 
mannosylation perturbation, are more efficacious. In order to evaluate the potential of this 
enzyme as a target for novel antibiotics, its structure would first need to be determined. 
Currently no structure exists in the PDB for S. coelicolor Ppm1. The gene would therefore first 
need to be cloned into a plasmid for E. coli expression. With the development of optimised 
purification protocols, soluble, homogenous and pure protein could then be obtained for the 
requisite structure and function studies.  
Characterisation of Ppm1, specifically an experimentally determined 3D structure, would then 
pave the way for fragment based screening to identify novel inhibitors of this enzyme, existing 
libraries could also be screened. There is notable sequence similarity and identity between S. 
coelicolor Ppm1 and their homologues in pathogens such as M. tuberculosis and M. leprae, it is 
therefore feasible that fragment inhibitors of S. coelicolor could be used to facilitate the 
identification or development of fragments active against mycobacterial Ppm1. During the 
course of the work described here, an experimentally determined 3D structure of the dolichol 
phosphate mannose synthase homologue (5MLZ) from P. furiosus was published (Gandini et al., 
2017). This represents the first published structure of a dolichol/polyprenol phosphate 
mannose synthase. 
The aim of this chapter was to obtain soluble, pure, homogenous S. coelicolor Ppm1 protein for 
structure and function studies. Thus the following objectives were set: 
1. Clone the S. coelicolor ppm1 gene into suitable expression vectors 
2. Optimise expression conditions for Ppm1 
3. Purify Ppm1 that is suitable for structure and function studies 
4. Investigate mutants of Ppm1 to determine if there could be more suitable candidates for 







3.1 Expression and purification of S. coelicolor Ppm1 
3.1.1 Optimising small scale expression  
 
The S. coelicolor ppm1 open reading frame had previously been cloned into pETFPP_49 (HIS-
ORF) using InFusion cloning. Sequencing confirmed successful construction of the recombinant 
expression plasmid, with no mutations in the ORF or the flanking regions immediately upstream 
and downstream. The plasmid was introduced into the expression strain E. coli BL21 (DE3) by 
chemical transformation.  The protocol used for expression is described in detail in the Material 
and Methods section. Overnight cultures of E. coli carrying the plasmid were added to 50 ml LB 
plus kanamycin (in 250 ml flasks). The flasks were incubated at 37 °C until the 0D600 was 
between 0.4 and 0.6. At this point IPTG was added (0.5 mM or 0.25 mM final concentration) and 
the flasks incubated for 18 H at either 20 °C, 27 °C or 37 °C. Samples were taken for SDS PAGE 
pre IPTG induction, 4 H post induction and 18 H post induction (Figure 3.1). 
In each case, no notable protein band at roughly the expected molecular weight (MW) was 
obtained pre IPTG induction, indicating a lack of detectable leaky expression from the promoter. 
With the exception of 20 °C, 18 H, 0.25 mM IPTG, every sample post IPTG induction at either 4 
or 18 H showed a clear protein band with intensity clearly higher than that of the background. 
The mobility of bands in each case were between the 46 kDa and 33 kDa reference bands, 
however the bands were positioned closer to the 46 kDa reference. Since Ppm1 with the 6xHis-
tag and linker is ~37 kDa, the tagged Ppm1 had not migrated as far down the gel as expected. 
The migration pattern was reproducible in multiple gels and was also observed in the two 
similar BL21 (DE3) E. coli expression strains pLysS and ArcticExpress (DE3)  (data not shown). 
Small scale expression experiments showed that 1) there was no notable difference between the 
quantities of protein produced at the three temperatures, 2) 18 H expression consistently 
showed greater expression of protein 3) there was no notable difference in expression at the 
two IPTG concentrations tested. The decision was then made to proceed with large scale 
expression of Ppm1 (0.5 to 1 L culture volumes in 4-6 x 2000 ml baffled flasks). Ppm1 
expression would be induced at 0.25 mM IPTG and would last for a duration of 18 H at 20 °C. 


































135 kDa - 
100 kDa - 
75 kDa - 
58 kDa - 
46 kDa - 
33 kDa - 
11 kDa - 
25 kDa - 
22 kDa - 
17 kDa - 
190 kDa - 
A 
Figure 3.1: S. coelicolor Ppm1 successfully produced following IPTG induction. 0.5 (A) 
and 0.25 mM IPTG was used to induce expression at 20, 27 and 37 °C. Whole cell extract 
samples were taken for SDS-PAGE prior to induction, in addition to 4 and 18 h post induction. 
The MW ladder used was Blue Prestained Protein Standard, Broad Range (NEB). 
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3.1.2 Ni2+ affinity and gel filtration purification of WT S. coelicolor Ppm1  
 
The overexpression and purification strategy for WT Pmt is explained in detail in the Materials 
and Methods section. WT Ppm1 was purified using a two-step purification process following 
overproduction in E. coli BL21 (DE3). After harvesting, cells were lysed by sonication and 
soluble protein was purified by Ni2+ affinity (Figure 3.2) and gel filtration chromatography 
(Figure 3.3), eluted protein was monitored using an absorbance trace at 280 nm. Using an 
imidazole gradient, His6-tagged Ppm1 was eluted as a single broad peak. Fractions were 
analysed by SDS PAGE, which confirmed the presence of protein with a mobility between 32 and 
46 kDa reference marker bands. The tagged Ppm1 has a calculated MW of 37 kDa consistent 
with the mobility of the band seen on the gel. Other background (non-specifically bound) 
proteins were also observed in the fractions, necessitating an addition gel filtration purification 
step to obtain purer Ppm1 protein. Gel filtration was also used on the basis that it would give an 
indication of the oligomeric state of the expressed protein. 
Following concentration and dialysis, the protein was purified by gel filtration chromatography 
(Figure 3.3). Three elution peaks were obtained and fractions analysed by SDS PAGE, the third 
peak was eluted with a volume of ~ 125 ml and contained no protein, this could represent a 
DTT impurity (data not shown). The first and most prominent peak with a height of 420 mAU 
yielded intense bands at the expected MW and fewer contaminants. At the right hand tail of this 
peak, an additional smaller peak at ~60 mAU was obtained. Fainter bands presumably 
corresponding to Ppm1 were again obtained but they were of comparable intensity to two 
possible contaminant proteins between 22 kDa and 25 kDa. Since bands corresponding to Ppm1 
were obtained in multiple elution peaks, it was important to ascertain the oligomeric state of 
the enzyme.  
Protein standards of known MW were therefore loaded onto the gel filtration column and the 
elution volume necessary to elute each protein was noted (Figure 3.4). Of greatest interest were 
peaks C (158 kDa bovine γ globulin) and D (44 kDa chicken ovalbumin) which were eluted at 
volumes of ~ 65 and 85 ml respectively. These peaks were comparable in position to the two 
peaks obtained for the Ppm1 purification. The implication was therefore that the tallest peak 
obtained corresponded to a combination of tetramers and higher MW aggregates of Ppm1, 
while the subsequent smaller peak was composed of monomer and/or dimer. Since S. coelicolor 
Ppm1 is unlikely to be present as a tetramer, this may signify unwanted aggregation. 
The peak height distribution was however very clear and indicated that the majority of purified 
Ppm1 obtained by gel filtration might be unwanted larger oligomers (e.g. tetramers) or high 
MW aggregates, both would likely be of little physiological relevance.  There was no 
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precipitation of the aggregates and they remained stable. As well as taking samples for gel 
filtration, samples were also taken for light scattering to more directly probe the MW, Gel 
filtration chromatography coupled to multi-angle light scattering (SEC-MALLS) was chosen for 
this (Figure 3.5). Similar to the gel filtration chromatogram, one major and one minor peak were 
obtained. The major peak showed a wide distribution of species with an estimated average MW 
range of roughly 165 kDa to 600 kDa, with the majority of material in this major peak estimated 
to be greater than 240 kDa. Interestingly, the minor peak average MW is roughly 45 kDa, which 
is quite close to that of monomeric Ppm1 (~36 kDa). Notably, there is an initial shoulder of the 

















































190 kDa - 
135 kDa - 
100 kDa - 
75 kDa - 
58 kDa - 
46 kDa - 
17 kDa - 
32 kDa - 
25 kDa - 
22 kDa - 
11 kDa - 
Figure 3.2: Ppm1 was successfully purified by Ni2+ affinity chromatography. (A) Ni2+ 
affinity chromatogram showing elution with an imidazole gradient. (B) Fractions collected 
from the elution peak were run on a 12 % SDS-PAGE gel. Load contained clarified lysate which 
was loaded onto the Ni2+ column. Flow through (FT) was collected upon washing the column 
with binding buffer. Remaining lanes contain fractions from the elution peaks. The MW ladder 
used was Blue Prestained Protein Standard, Broad Range (NEB). Purification was conducted 
































190 kDa - 
135 kDa - 
100 kDa - 
75 kDa - 
58 kDa - 
46 kDa - 
17 kDa - 
32 kDa - 
25 kDa - 
22 kDa - 
11 kDa - 
Figure 3.3: Ppm1 was successfully purified using gel filtration chromatography. (A) Gel 
filtration chromatogram of Ppm1, Experiments were conducted on an AKTA Pure FPLC system 
system using a HiLoad 16/60 superdex 200 pg column with a flow rate of  1 ml/min.  (B) 
Fractions were collected and run on a 12 % SDS-PAGE gel. Load contained pooled Ni2+ affinity 
purified Ppm1 which was loaded onto the gel filtration column. Remaining lanes contained 
fractions from the first and second gel filtration elution peaks. The MW ladder used was Blue 
































Figure 3.4: Standards of known MW were eluted at expected elution volumes. Gel 
filtration chromatogram for protein standards: (A) protein aggregates, (B) 670 kDa bovine 
thyroglobulin, (C) 158 kDa bovine γ globulin, (D) 44 kDa chicken ovalbumin, (E) 17 kDa horse 
myoglobin and (F) 1.3 kDa Vitamin B12. Experiments were conducted on an AKTA Pure FPLC 



































Figure 3.5: Purified Ppm1 shows a wide distribution of aggregates and oligomers. 
Experiments were conducted on a system comprising a Wyatt HELEOS-II multi-angle light 
scattering detector and a Wyatt rEX refractive index detector linked to a Shimadzu HPLC system 
with a 10/300 Superdex 200 pg column and a flow rate of 0.5 ml/min. (A) The elution profile and 
peak positions plot shows UV (280 nm) in green, refractive index (RI) in blue, light scattering 
(LS) in red and QELS in magenta. (B) The Molar Mass plot shows the LS trace as a solid red line, 
the RI trace as a dashed red line, and the UV trace as a dotted red line. These are normalised to 
the largest peak. 
 
 





3.2 Mitigating oligomerisation and aggregation     
3.2.1 Troubleshooting expression and purification 
In a subsequent experiment, the same expression and purification protocol was followed and 
comparable Ni2+ affinity (Figure 3.6) and gel filtration chromatograms (Figure 3.7) were 
obtained. On this occasion, fractions from each of these two peaks were obtained, pooled and 
run on the gel filtration column a second time on the same day (Figure 3.8), there were no 
changes to the positions of the elution peaks obtained, indicating that the oligomerisation state 
of the protein was stable. Comparable results were obtained when the gel filtration run was 
repeated on a second or third day (data not shown). The only notable change from the first to 
second gel filtration runs was that the mAU values were reduced, which can likely be attributed 
to sample loss. 
Troubleshooting efforts to minimise oligomerisation and aggregation first focussed on 
experimenting with different protein storage conditions (data not shown) including (1) storage 
at 4 °C, (2) addition of 50 % glycerol/storage at -80 °C and (3) snap freezing 50 µL aliquots in 
liquid nitrogen/storage at -80 °C. None of these variations affected the peak distributions. 
Following this, buffer components were changed including varying the concentrations of 
sodium chloride, glycerol and DTT, these variations also had no notable effect. Finally, it was 
also thought that the use of spin concentrators might promote oligomerisation/ aggregation. 
Spin concentrators were therefore avoided in favour of dialysis or desalting columns to 
concentrate the protein, no deleterious effects were noted. In summary, multiple variations in 
the experimental protocol post lysis had no notable effect on the peak distributions obtained in 
gel filtration. SEC-MALLS confirmed that the amount of oligomers/high MW aggregates, greatly 
exceeded the amount of monomer in every case.  
Conditions were however noted that increased the amount of high MW aggregates relative to 
monomer.  In medium scale expression experiments, the peak height ratios were typically 
around 0.2:1 while for larger scale expressions (6 x 1 L cultures rather than 6 x 0.5 L) the 
difference in peak heights was as much as 0.1:1. The greater difference was also seen with the 
use of AI media. High concentrations of protein, in addition to rapid protein expression, 
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Figure 3.6: Ppm1 was successfully purified using Ni2+ affinity chromatography. (A) Ni2+ 
affinity chromatogram showing elution with an imidazole gradient. (B) Fractions collected 
from the elution peak were run on a 12 % SDS-PAGE gel. Load contained clarified lysate which 
was loaded onto the Ni2+ column. FT was collected upon washing the column with binding 
buffer. Remaining lanes contained fractions from the elution peaks. The MW ladder used was 
Blue Prestained Protein Standard, Broad Range (NEB).  Experiments were conducted on an 

































200 kDa - 
100 kDa - 
70 kDa - 
50 kDa - 
40 kDa - 
10 kDa - 
25 kDa - 
15 kDa - 
Figure 3.7: Ppm1 was successfully purified using gel filtration chromatography. (A) Gel 
filtration chromatogram of Ppm1. Experiments were conducted on an AKTA Pure FPLC system 
using a HiLoad 16/60 superdex 200 pg column with a flow rate of  1 ml/min.  (B) Fractions 
were collected and run on a 12 % SDS-PAGE gel. The MW ladder used was Unstained Protein 
Marker, Broad Range (NEB). Fractions collected from the first and second gel filtration elution 




































Figure 3.8: Fractions previously collected, pooled and reloaded onto the column were 
eluted with same volumes of buffer. Gel filtration chromatograms of Ppm1. Experiments 
were conducted on an AKTA Pure FPLC system using a HiLoad 16/60 superdex 200 pg column 
with a flow rate of 1 ml/min. 
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3.2.2 Investigation of Ppm1 N-terminal truncation mutants  
Since troubleshooting with S. coelicolor WT Ppm1 had failed to yield any notable improvements 
to the amount of purified monomer, truncation mutants were made. A portion of the N-terminus 
is predicted to be disordered, the removal of this disordered region in addition to the adjacent 
upstream region could yield a Ppm1 protein with a reduced propensity to form the high MW 
soluble aggregates. The predicted disordered region comprises 14 amino acid residues (Figure 
3.9). These residues were removed to yield a Δ14 truncation mutant. Additional residues were 
removed yielding Δ21 and Δ30 residue truncation mutants. Small scale expression experiments 
were first carried out under the same conditions previously described and the expression 
profile compared with that from the WT (Figures 3.10 and 3.11).  
Expression of WT and 14/21 residue truncations all gave comparable results, whereby 
expression was typically highest at 27 °C, but was also obtained at 20 and 37 °C.  Since there 
was no notable difference in the expression profile Δ14, Δ20 and WT proteins with the 
conditions tested, the same conditions for large scale expression could be used for the three 
proteins. A 20 °C overnight expression for large scale expression was chosen since overnight 
expression at lower temperatures would minimise over production of protein and unwanted 
aggregation.  In each case there was no clear expression of protein with MW comparable to 
Ppm1 prior to IPTG induction, again confirming the lack of leaky expression from the promoter.  
The Δ30 truncation mutant failed to express at 0.5 mM IPTG with all temperatures tested, the 
same was also true with 0.25 and 0.125 mM IPTG (data not shown). The failure of the Δ30 
residue truncation to properly express indicates that between residues 22 and 30, there is 
presumably at least one amino acid residue critical for stability and/or correct protein folding. 
Failure to express is indicative of either poor stability of the folded protein, or incorrect protein 
folding to yield a toxic product which is cleared by the cell. 
The same expression and purification protocols previously used were followed for Ppm1WT  
Ppm1Δ14 and Ppm1Δ21. Following Ni2+ purification, gel filtration purification was carried out 
(Figure 3.12). The chromatograms for the WT and two truncations mutants were largely 
identical, indicating that removal of the disordered region (Ppm1Δ14), in addition to six further 
residues (Ppm1Δ21) did not alleviate the oligomerisation/aggregation previously obtained. 
SEC-MALLS analysis showed comparable peak profiles (major followed by a smaller minor 
peak) and MW distributions within said peaks that were comparable to the values previously 






















Figure 3.9: S. coelicolor Ppm1 has a disordered N-terminus. (A) IUPred2A plot shows 
the score of each residue in the protein from 0 to 1 (low to high predicted disorder 
respectively). A residue with a score of ≥0.5 is considered to have more disordered 














































Figure 3.10: S. coelicolor Ppm1WT, Ppm1Δ14 and Ppm1Δ20 were successfully 
produced. 0.5 mM IPTG was used to induce expression Ppm1WT (A) Ppm1Δ14 (B), Ppm1Δ21 
(C) and Ppm1Δ30 (D) 20, 27 and 37 °C. Whole cell extract samples were taken for SDS-PAGE 
prior to IPTG induction, in addition to 4 and 18 H post induction. The MW ladder used was 
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Figure 3.11: S. coelicolor Ppm1WT, Ppm1Δ14 and Ppm1Δ21 were successfully 
produced. 0.5 mM IPTG was used to induce expression Ppm1WT (A) Ppm1Δ14 (B), Ppm1Δ21 
(C) and Ppm1Δ30 (D) 20, 27 and 37 °C. Whole cell extract samples were taken for SDS-PAGE 
prior to IPTG induction and 18 h post induction. The MW ladder used was Blue Prestained 

































Figure 3.12: Ppm1 gel filtration chromatogram for WT (A) is comparable with Δ14 (B) 
and Δ21 chromatograms (C). Experiments were conducted on an AKTA Pure FPLC system 





S. coelicolor ppm1 – strains DT1020, DT1029 and DT3017 were previously shown to have 
antibiotic hyper susceptibility phenotypes (Howlett et al., 2018; Wehmeier et al., 2009). In 
addition, these strains have growth retarded phenotypes and resistance to ΦC31 cΔ25 infection 
(Howlett et al., 2018; Cowlishaw and Smith 2001; Cowlishaw and Smith 2002). These antibiotic 
hyper susceptibility phenotype observations suggested that Ppm1, could be a good target for 
antimicrobials to be used in combination therapy with our existing arsenal of antibiotics. No 
structure of S. coelicolor Ppm1 or homologues in mycobacterial pathogens currently exists in 
the PDB. In order to identify inhibitors of S. coelicolor Ppm1 with therapeutic potential, 
structure and function studies are necessary.  
 
Initially, the S. coelicolor ppm1 gene was cloned into the expression plasmid pETFPP_49 (HIS-
ORF). Following expression, Ppm1 was purified by Ni2+ affinity chromatography eluting as a 
single broad peak. However, gel filtration chromatography indicated that the purified Ppm1 was 
present as a mixture of oligomeric species and aggregates. This was confirmed using SEC-
MALLS. 
 
SEC-MALLS showed a wide distribution of MWs in the sample, with the major peak being 
particularly heterogeneous. The extended tail on the right of the minor peak indicated 
heterogeneity and based on the MW estimation (~45 kDa), can likely be attributed to 
monomeric (~36 kDa) and dimeric (~72 kDa) Ppm1, assuming they are present in roughly the 
same proportions with no other impurities present. Ppm1 functions as a dimer in M. smegmatis 
and M. leprae (Gurcha et al., 2002). In C. glutamicum and M. tuberculosis the protein possesses a 
two-domain architecture with separate catalytic and membrane domains (Gibson et al., 2003; 
Gurcha et al., 2002). The possibility cannot be excluded that S. coelicolor Ppm1 also functions as 
a dimer, but further investigation is required here. It should be stressed that even if S. coelicolor 
Ppm1 has been purified as a dimer, it may not be physiologically relevant. The presence of the 
dimer could instead be indicative of a poorly optimised expression and purification protocol 
that has driven oligomerisation. Unfortunately, the protein concentration loaded was less than 1 
mg/ml, which has likely contributed to noise in the RI trace, consequently making the MW 
estimates more erratic. 
Multiple attempts were made to increase the yield of purified protein collected from the gel 
filtration column at roughly 80 ml, corresponding to the tailed minor peak. This region was of 
interest due to conventional calibration and SEC-MALLS indicating that purified Ppm1 
constituting this peak is a possible combination of dimer and monomer. Fractions 
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corresponding to this peak could then be purified away from the larger oligomers and higher-
order aggregates and the dimer and monomer resolved using a more suitable column (Superdex 
75 10/300GL column). This step would be necessary to obtain homogenous protein necessary 
for structure and function studies. In order to take this approach, the yield of protein in this 
peak had to be increased and optimisation efforts were made to obtain greater yields of Ppm1 in 
monomeric and/or dimeric form. 
Glycerol was added to the buffers up to 30 % in an effort to stabilise Ppm1 and therefore 
prevent its aggregation. The use of glycerol as an additive has been widely reported in the 
literature (Vagenende et al., 2009). It induces protein compaction (Priev et al., 1996), reduces 
flexibility (Gregory et al., 1988) and stabilises partially unfolded intermediates (Mishra et al., 
2007).  When glycerol was not added, the height of the major peak (corresponding to large 
oligomers and higher-order aggregates) increased on some occasions but this was not 
particularly reproducible. Glycerol was not added above 30 % due to concerns about FPLC 
overpressure. 
NaCl is another useful additive conventionally added to buffers to help reduce non-specific 
binding of proteins to chromatographic resins, however at high concentrations it has been 
known to enhance aggregation and consequently precipitate protein (salting out). Based on the 
Ppm1 homology model (described in Chapter 4), there are only a limited number of solvent 
exposed aspartates and glutamates.  It is therefore not too surprising that varying the NaCl 
concentration between 0.1 and 0.5 M did not change the chromatographic profiles significantly. 
Furthermore, low concentrations of NaCl (<0.1 M) increased the amount of non-specific column 
binding, showed by greater background in SDS-PAGE. At concentrations >0.5 M precipitation 
was noted in some cases. Aggregation can be driven by electrostatic and hydrophobic 
interactions acting in tandem or individually, increasing ionic strength would help prevent 
aggregation driven by electrostatics but conversely promote aggregation if it was primarily 
driven by hydrophobic interactions. 
It is well known that even a single freeze thaw cycle can destabilise a protein by changing the 
buffer environment, this includes the formation of ice-water interfaces, adsorption to container 
surfaces, pH changes and other factors (Xiang et al., 2015). Ppm1 was snap frozen in 20 µl 
aliquots in liquid nitrogen and stored at -80°C. Snap freezing proteins has been shown to reduce 
protein aggregation, which can be attributed mainly to the reduced length of the solid-liquid 
phase transition (Xiang et al., 2015). However, this protocol failed to change the 
chromatographic profiles of Ppm1. Attempts to bypass a freeze thaw cycle completely by 
progressing immediately from Ni2+ affinity chromatography to buffer exchange and gel filtration 
chromatography in the same day similarly had no impact. This indicates that a single freeze 
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thaw cycle was not the primary reason for the observed oligomerisation and aggregation. It 
should be stressed that freeze thaw cycles can reduce and even completely eliminate activities 
of enzymes without inducing a change in the oligomeric state of the protein (Bartolin et al., 
2017). 
Efforts were also made to avoid the use of spin concentrators, since it is known that 
concentrated protein can build up near the membranes and will need to be regularly 
recirculated to both maintain an adequate flow rate, and minimise any potential concentration 
dependent aggregation. Efforts to recirculate protein in the upper chamber were made to 
minimise the time spent concentrating and prevent proteins building up on the membrane, 
however it failed to change the chromatographic profiles. Dialysis, admittedly a less harsh 
technique for simultaneous buffer exchange and concentrating, also failed to have any notable 
impact. 
The impact of concentration on aggregation has been extensively probed in amyloid proteins 
and it was thought that the presence of large oligomers and higher-order aggregates could 
themselves promote oligomerisation and/or aggregation (Zhang et al., 2013). Fractions taken 
corresponding to the 1) major peak 2) left shoulder of the minor peak) and 3) right shoulder of 
the minor peak were re-run on the same gel filtration column and the positions of the eluted 
peaks did not change. This indicates that the oligomers and higher-order aggregates once 
formed, are stable and maintain their form. 
Troubleshooting with S. coelicolor WT Ppm1 ultimately failed to yield improvements in the 
amount of purified monomer and dimer obtained. The next step was to produce several N-
terminal truncation variants. The basis for targeting the N-terminus was the IUPRED 
identification of disorder in the first 14 residues of the Ppm1 N-terminus. The contribution of 
intrinsically disordered regions to protein aggregation has for example been studied extensively 
in S100 Proteins (Carvalho et al., 2013). If these disordered regions are (under certain 
conditions) prone to local unfolding or adopting a conformation that exposes the hydrophobic 
core of the globular protein to the solvent, aggregation would likely result. Given the 
documented role of intrinsically disordered regions in promoting aggregation , the removal of 
the entire disordered region (14 residues), in addition to the adjacent upstream region (21 and 
30 residues) was undertaken in a search for a Ppm1 variant with a reduced propensity to form 
larger oligomers and higher-order aggregates. The 14 and 21 residue truncations variants 
expressed at comparable levels to the WT, protein whereas no evidence of expression was 
obtained for the 30 residue truncation variant. Failure to express is usually indicative of either 
poor stability of the folded protein, or incorrect protein folding to yield a toxic product which is 
cleared by the cell. At any rate, at least one residue in this region (residue 22-30) is likely critical 
74 
 
for correct protein form and function. Unfortunately, gel filtration chromatography showed that 
neither the 14 nor the 21 residue truncation variants behaved differently to the WT; the 
distribution of peaks and MW were consistent to that which was previously obtained.  
Preliminary work then started with the screening of a number of detergents. While lacking 
transmembrane helices, Ppm1 is expected to be membrane associated. It was therefore 
expected that detergents might stabilise Ppm1. The detergent screening analysis was 
terminated when a collaboration was launched with Dr Tosin’s research group at Warwick 
University. This group were able to develop a purification protocol similar to the one discussed 
here, the main difference being the use of the detergent DDM. DDM is a commonly used 
detergent for protein purification and crystallisation – it is non-ionic and has a low critical 
micellar concentration (CMC). Non-ionic detergents are less likely to denature the protein while 
low CMCs correspond to more stable detergent micelles (Stetsenko et al., 2017). Using DDM, 
Dube et al., were able to purify the WT and several variants of Ppm1 in monomeric (and 
occasionally dimeric) form in sufficient quantities for structure and function studies. While the 
structure of Ppm1 remains elusive, Ppm1 WT and variants have been biochemically 






















Chapter 4 - Identification of essential residues for polyprenol 
phosphate mannose synthase function 
 
The ppm1 – strains: DT1020, DT1029 and DT3017 were previously isolated by Smith and co-
workers, and sequencing confirmed the presence of point mutations: H116D S163L and E218V 
in ppm1, respectively (Wehmeier et al., 2009). The efficiency of ΦC31 phage formation is 
severely reduced on the three aforementioned ppm1 – strains, compared to the phage 
susceptible parent strain, J1929 (Cowlishaw and Smith 2001; Cowlishaw and Smith 2002). 
These ppm1 – strains also exhibit growth retarded phenotypes and hyper-susceptibility to 
multiple antibiotics, notably -lactams and vancomycin (Howlett et al., 2018a). A detailed 
rational mutagenesis study of S. coelicolor Ppm1 has yet to be carried out and the functional 
significance of the three residues that confer the null mutant phenotype is not understood.  
In addition to S. coelicolor, actinobacterial homologues of Ppm1 have been experimentally 
probed in corynebacteria and mycobacteria. In Corynebacterium glutamicum the protein 
possesses a two-domain architecture with separate catalytic and membrane domains (Gibson et 
al., 2003). Inactivation of the catalytic domain leads to a lipoglycan-less phenotype and a 
reduction in growth rate (Gibson et al., 2003). The two-domain architecture is also present in 
Ppm1 from M. tuberculosis, but not those in M. smegmatis or M. leprae, which instead produce 
two separate proteins encoded by adjacent genes (Gurcha et al., 2002). Furthermore, the M. 
smegmatis Ppm1 homologue of the M. tuberculosis catalytic domain is essential for survival   
(Gurcha et al., 2002). Further experiments have shown that the introduction of a functional copy 
of the gene encoding M. tuberculosis PpmD2, the catalytic domain, is also sufficient to rescue the 
phenotype of M. smegmatis Ppm1 mutants (Rana et al., 2012). Current evidence indicates that S. 
coelicolor Ppm1 lacks a membrane associated domain and that there is only one protein 
involved in polyprenol mannosylation, contrasting with M. tuberculosis and M. smegmatis/M. 
leprae respectively. S. coelicolor does have a homologue to the membrane domain of M. 
tuberculosis PpmD1, SCO1014. However, this gene is not required for protein glycosylation in S. 
coelicolor (Cordova-Davalos et al., 2013). The mechanism of membrane association of Ppm1 in 
S. coelicolor consequently remains unknown.  
 
The aim of this chapter was to develop a biochemical mechanistic model for Ppm1, with the 
following objectives:  
1. Introduction of S. coelicolor mutant ppm1 alleles into S. coelicolor DT3017 and J1929 
strains,  followed by spore preparation/harvesting 
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2. In vivo characterisation to probe essentiality of the targeted residues   
3. Utilisation of structural bioinformatics approaches combined with biochemical data 
from our collaborators (Manuela Tosin and Pamela Dube, University of Warwick), to 

























4.1 Cloning mutant alleles into pIJ10257 and introduction of recombinant 
plasmids into S. coelicolor J1929 and DT3017 strains 
To probe residues essential for Ppm1 function, our collaborators at Warwick University had 
previously used site-directed mutagenesis to direct residue substitutions into Ppm1 (Dube et 
al., 2019). In total nine residue substitutions were made (D57A, R82A, D111, D113, H116D, 
R138, G143V, S163L, R228). The residue equivalent to D57 contributes to GDP mannose binding 
in the P. furiosus homologue, while residues equivalent to R138 and R226 are known to bind the 
lipid phosphate, orientating the nucleophilic phosphate head group (Gandini et al., 2017). In the 
human homologue of Ppm1, substitutions of residues equivalent to R82 and G143 are 
associated with congenital disorders of glycosylation (CDG) (Garcia-Silva et al., 2004, Yang et al., 
2013). D111 and D113 constitute the DXD motif, which is highly conserved in the GT-A family of 
glycosyl transferases (Lairson et al., 2008). H116 and S163 substitutions were already known to 
eliminate Ppm1 function in S. coelicolor (Wehmeier et al., 2009). In addition to the nine 
substitutions, a single truncation mutant was also made resulting in the removal of 42 residues 
from the C-terminus of Ppm1 that is predicted to be highly disordered in S. coelicolor (Figure 
4.1).   
Homologues of Ppm1 are found across both the prokaryotic and eukaryotic kingdoms. Using 
Clustal Omega the GT-2 catalytic domain of S. coelicolor was aligned with those of M. smegmatis, 
M. tuberculosis, P. furiosus, S. cerevisiae and H. sapiens.  With the exception of S163, all of the S. 
coelicolor Ppm1 residues targeted for mutation in this study are tightly conserved across the 
prokaryotic and eukaryotic kingdoms (Figure 4.1).  
The 10 mutant alleles had previously been made by Pamela Dube and cloned into pETFPP_1 for 
protein production. To facilitate introduction of these mutant alleles into S. coelicolor strains, 
they were cloned into the integration plasmid pIJ10257. The inserts were sequenced to verify 
the absence of frame shifts and other unwanted mutations. The plasmids were then introduced 
firstly into the methylation-deficient E. coli strain ET12567 (pUZ8002) to generate the donor 
strains. Plasmids from the transformants were purified and digested with the restriction 
endonucleases Nde1 and Dpn1 to confirm presence of the insert and the absence of methylation 
respectively (Figure 4.2). The ppm1 open reading frame is flanked by a pair of Nde1 sites; there 
are no other Nde1 sites present in the plasmid. Thus the Nde1 digestion products precisely 
correspond to the insert (~906 bp) and the plasmid backbone (6430 bp). All plasmids were 
confirmed to be recombinant. Furthermore, the absence of Dpn1 digestion products confirmed 
the plasmids were not methylated, and therefore would not be subject to S. coelicolor’s methyl 
sensing restriction system. The E. coli donor strains were subsequently used in conjugation 
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Figure 4.1: S. coelicolor Ppm1 has a GT-2 domain that is broadly conserved, in addition to a 
highly disordered C-terminus. (A) Clustal Omega alignment of the S. coelicolor GT-2 domain 
(Uniprot entry: Q9RKY2_STRCO) with M. smegmatis (PPM1_MYCS2), M. tuberculosis 
(PPMNT_MYCTU), P. furiosus (Q8U4M3_PYRFU), S. cerevisiae (DPM1_YEAST) and H. sapiens 
(DPM_HUMAN). The S. coelicolor residues targeted for substitution are underlined in green. (B) 
IUPred2A plot shows the score of each residue in the protein from 0 to 1 (low to high disorder 








































Figure 4.2: E. coli purified plasmids are recombinant and non-methylated. pIJ10257 
plasmid containing no ppm1 allele, WT allele and mutant alleles derived from the non-
methylating E. coli donor strain ET12567 (pUZ8002). The pIJ10257 control was derived from 
the methylating BL21 (DE3) E. coli strain.  All plasmids were digested with both Nde1 and 
Dpn1 to confirm insert presence and methylation status respectively. The NEB 1 KB ladder is 
used for reference.  
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4.2 Effect of ppm1 alleles on the phenotype and growth of Streptomyces  
 
4.2.1 Streptomyces spore growth and antibiotic hyper susceptibility 
Following introduction of the recombinant plasmids into the DT3017 and J1929 strains, the 
conjugation plates were overlaid with nalidixic acid and hygromycin to eliminate the E. coli 
plasmid donors and select for Streptomyces plasmid recipients respectively. Four independent 
exconjugant Streptomyces lines were isolated from each conjugation and stock spore 
preparations were generated.   
Disc diffusion assays were performed with each spore preparation. Within the antibiotic zones 
of inhibition for DT3017 mutant strains, colonies could be identified that were suspected to be 
revertents and/or antibiotic suppressors (Figure 4.3). While identifiable for all antibiotics used 
in this study, the number of colonies was notably greater for antibiotics that showed the 
greatest difference in sensitivity between J1929 and DT3017, for example vancomycin and 
ampicillin. The zones of clearance for all the antibiotics tested were completely clear in the 
empty plasmid negative control, indicating that the presence of two ppm1 alleles in the same 
cell could be responsible for this unexpected phenotype. In extreme cases, the proportion of 
putative revertents was so high that it was very difficult to accurately measure the diameter of 
the zones of clearance. To confirm that reversion of one of the ppm1 alleles was cause of these 
phenomena, colonies growing within the vancomycin zones of clearance for the DT3017 strains 
harbouring the D111A and D113A alleles were picked and further analysed. One colony for each 
of the four biological replicates was analysed using two PCR primer pairs to amplify both the 
native and integration locus ppm1 alleles separately (Figure 4.4).  Sequencing showed that the 
ppm1 at the native locus was unchanged, (encoding Ppm1E218V). However, the ppm1 mutant at 
the integration site (introduced by pIJ10257) had undergone reversion, the wild type (WT) GAC 
codon was therefore present rather than the mutant GCC codon. The frequency of this 
phenomenon suggests that the gene introduced at the integration site may be subject to a DNA 
repair mechanism that does not affect the native locus ppm1. The native locus ppm1 might 
therefore be used as a template to repair the mutation in the integration locus ppm1, but not 
vice versa. To test this hypothesis, an identical ppm1 allele to that present in DT3017 (encoding 
Ppm1E218V) was introduced into DT3017. Now both the integration locus and native locus 
ppm1 genes would harbour the same mutation. DT3017exoconjugants containing an additional 
copy of the ppm1 allele encoding Ppm1E218V at the integration site showed no evidence of 
reversion in the disc diffusion assays.  
Since, the revertents (encoding WT Ppm1) were already known to grow faster than the ppm1- 
mutants, Streptomyces spore preparation procedure was modified to allow less time for fitter 
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revertants to outgrow the less fit ppm1- alleles. The seven day incubations after conjugation and 
during amplification of spore preparations were reduced to five days and exconjugant colonies 
were squashed and plated directly to generate the stock spore preparation (eliminating one 






















































Figure 4.3: DT3017 strains that are not complemented with an active ppm1 allele exhibit 
increased susceptibility to antibiotic insult. Revertent colonies can be identified clearly in 
the ampicillin and vancomycin zones of clearance. S. coelicolor DT3017 spores were plated out 
on DN agar and 40 µg of bacitracin (top right), hygromycin (top left), ampicillin (bottom right) 
and vancomycin (bottom left) were added to each disc. The plates were then incubated at 30 °C 
for 48 hours. Images are representative of 4 biological replicates. 
DT3017 
Figure 4.4: Amplification of the native and integration site ppm1 alleles. Alleles were 
amplified from four revertent DT3017 colonies containing the integrated D113A ppm1 allele 
and four containing the D111A ppm1 alleles. The NEB 1 KB ladder is used for reference. 






DT3017 + WT DT3017 + D111A 
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4.2.2 Identification of ppm1 mutants unable to alleviate the antibiotic susceptibility 
phenotype of DT3017 
Six of the ppm1 mutants tested failed to complement DT3017: D111A, D113A, H116D, R138A, 
S163L, R226A in disc diffusion assays (Figures 4.5 and 4.6). These strains showed significantly 
increased susceptibility to all cell wall and/or membrane targeting antibiotics tested when 
compared to the J1929 parent strain, and therefore resembled the ppm1 – mutant (p < 0.05).  
Ppm1 defective strains of S. coelicolor are highly susceptible to vancomycin, with zone of 
inhibition diameters >25 mm. In comparison bacitracin yielded the smallest increase at ~10 
mm.  Alleles encoding the WT, or Ppm1Δ42 and Ppm1R82A were able to complement DT3017, 
alleviating the antibiotic susceptibility phenotype. The antibiotic susceptibility for the 
complemented stains was consequently not significantly different to J1929 for any of the 
antibiotics tested (p < 0.05). The alleles encoding Ppm1D57A and Ppm1G143V partially 
complemented DT3017 exhibiting mildly less susceptible phenotypes than DT3017.  
Out of curiosity, I tested the susceptibility of the ppm1 – strains to a wider range of antibiotics. 
The ppm1 – strains exhibited significantly increased susceptibility to antibiotics inhibiting DNA 
replication, transcription and translation when compared to the J1929 parent strain (p < 0.05) 
(Figure 4.7). The zones of inhibition typically ranged from 10-15 mm and while significant, the 
differences in susceptibility for these antibiotics are not as drastic when compared to ampicillin, 
carbenicillin, vancomycin, imipenem, meropenem and daptomycin, which all gave susceptibility 
differences of >20 mm. The ppm1 alleles encoding the WT, Ppm1Δ42 and Ppm1R82A 
complemented DT3017ppm1 and with the exception doxycycline and ciprofloxacin for Δ42 and 
R82A respectively, the strains showed no significant increase in antibiotic susceptibility 
compared to J1929. The partially complementing alleles encoding D57A and G143V showed 
significantly increased susceptibility to all antibiotics with the exception of ciprofloxacin and 
mitomycin C respectively (p < 0.05). As observed for the cell wall and/or membrane targeting 
antibiotics, the increase in susceptibility is again lower than the non-complementing strains for 
multiple antibiotics, the most notable examples being mitomycin C for G143V and doxycycline 
and minocycline for D57A. 
All mutant ppm1 alleles were additionally introduced into the J1929 parent strain and there was 
no difference in susceptibility to any antibiotic tested (Figures A4.1 and 4.2). This demonstrates 
that the expression of the non-complementing and complementing ppm1 mutants in the parent 




DT3017 + H116D 
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Figure 4.5: DT3017 strains that are not complemented with an active ppm1 allele exhibit 
increased susceptibility to antibiotic insult.  S. coelicolor DT3017 spores were plated out on 
DN agar and 40 µg of vancomycin (top left), 80 µg ampicillin (top right), 4 µg meropenem 
(bottom left) and 40 µg daptomycin (bottom right) were added to each disc. The plates were 
then incubated at 30 °C for 48 hours. Images are representative of 4 biological replicates. 
 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.2.3 Complemented DT3017 are vulnerable to ΦC31 cΔ25 phage infection and exhibit 
increased growth rates 
To further test the aforementioned strains, ΦC31 phage infection assays were performed 
(Figure 4.8 and Table 4.1).  If the integrity of the glycosylation cascade has been restored, the 
complemented strains should be vulnerable to infection by this phage. As expected, the no gene 
negative control and the mutants that failed to alleviate the DT3017 antibiotic susceptibility 
phenotype: encoding Ppm1D111A, Ppm1D113A, Ppm1H116D, Ppm1R138A, Ppm1S163L and 
Ppm1R226A showed no evidence of infection within the phage dilution range tested. The WT 
positive control and the ppm1 alleles (encoding Ppm1Δ42 and Ppm1R82A) that restored the 
antibiotic susceptibility to that of the J1929 parent strain were vulnerable to phage infection, 
with countable plaques obtained at a 10-6 phage stock dilution. Interestingly, plaques at this 
dilution were also obtained for strains containing Ppm1D57A and Ppm1G143V. The plaques 
obtained for the complemented strains were comparable in their size and clarity to the J1929 
parent strain. Clear plaques are a hallmark of infection by a lytic phage such as ΦC31 cΔ25 
(Lomovskaya et al., 1972). Introduction of the alleles in the J1929 parent strain had no effect on 
phage susceptibility (Table A4.1). 
DT3017 possesses a small colony phenotype when grown on DN agar (Figure 4.9), the strains 
containing WT, Ppm1Δ42, Ppm1D57A, Ppm1R82A and Ppm1G143V alleles grew faster yielding 
large colonies similar to those produced by J1929. Ppm1D111A, Ppm1D113A, Ppm1H116D, 
Ppm1R138, Ppm1S163L and Ppm1R226A failed to complement in DT3017, as indicated by the 























































Figure 4.8: Complemented DT3017 strains are vulnerable to ΦC31 phage infection. Phage 
were plated out on a portion of DN agar and then DT3017 (A) or J1929 (B) spores containing 
the alleles were streaked from the phage absent region to the phage present region. Plates were 
incubated at 30 °C for 48 hours. Images are representative of 4 biological replicates. 
 




















































Strain Titre (PFU/ml) 
DT3017 + WT (1.05 ± 0.06) x 108 
DT3017  < 1 x 102 
DT3017 + Δ42 (1.25 ± 0.08) x 108 
DT3017 + D57A (1.38 ± 0.08) x 108 
DT3017 + R82A (1.43 ± 0.11) x 108 
DT3017 + D111A < 1 x 102 
DT3017 + D113A < 1 x 102 
DT3017 + H116D < 1 x 102 
DT3017 + R138A < 1 x 102 
DT3017 + G143V (1.30 ± 0.04) x 108 
DT3017 + S163L < 1 x 102 
DT3017 + R226A < 1 x 102 
Table 4.1: Complemented DT3017 strains are vulnerable to ΦC31 cΔ25 phage infection. 
Phage were plated out on DN agar and then SN agar containing spores was added to the top 
with the plates incubated at 30 °C for 18 hours. The average titre is shown ± SEM from 4 
biological replicates. 0.1 ml of a 10-6 phage stock dilution was used to obtain countable plaques 
for phage sensitive strains.  Strains that showed no plaques at the lowest phage stock dilution 
tested (10-1) are represented as having a PFU/ml < 1x 102. 
 
Figure 4.9: Complemented DT3017 strains show a large colony phenotype. Strains were 
grown on DN agar and incubated at 30 °C for 48 hours. Images are representative of 4 
biological replicates. 
DT3017 + D111A 
DT3017  
DT3017 + D113A 
DT3017 + WT DT3017 + Δ42 DT3017 + D57A 
DT3017 + R226A 
DT3017 + G143V DT3017 + R138A 
DT3017 + S163L 
DT3017 + H116D 
DT3017 + R82A 
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4.3 Ppm1 structural bioinformatics and mechanistic modelling  
 
Recently crystal structures were obtained of the dolichol phosphate mannose synthase (DPMS) 
from P. furiosus (PDB 5MLZ, 5MM0, 5MM1) (Gandini et al., 2017). As expected, sequence 
conservation with S. coelicolor Ppm1 is high with sequence identity and similarity being 39.9 
and 59.3% respectively (Figure 4.12).  Using Phyre2, the PDB structure of the archaeal Dpm 
synthase in its post catalytic state (5MLZ) was used as a template to generate a homology model 
for S. coelicolor Ppm1 (Figure 4.10). The C-terminal portion is predicted to be disordered 
according to IUPred2A (Figure 4.1) and both termini are weakly conserved; consequently in this 
302 residue protein, only residues 25-256 were modelled. 
The model clearly shows the catalytic DXD motif and a Rossmann fold encompassing it, with 
parallel β stands in the characteristic secondary structure topology β-α-β-α-β (Lairson et al., 
2008). This model (including GDP and dolichyl phosphate mannose substrates) was then 
aligned with the template. In addition to the strongly conserved catalytic domain, the model and 
template both possess parallel helices at the base of the Rossmann fold, in the latter they are 
orientated towards the membrane. Towards the C-terminus of the P. furiosus DPMS there are 
four transmembrane domains, over a stretch of 100 residues, that serve to anchor the protein to 
the membrane. S. coelicolor Ppm1 lacks transmembrane helices and the mechanism of 
membrane association remains unknown. With the exception of G143, all residues targeted for 
mutation are closely located to the superimposed GDP donor or Und-P acceptor substrate. The 
template is in the post catalysis state of the reaction, whereby mannose has been transferred to 
Und-P and GDP has been released.   
The P. furiosus DPMS structure and Ppm1 S. coelicolor model, in combination with the in vivo 
and in vitro data for all 10 mutants (Dube et al., 2019), can be used as a framework for assigning 
roles to individual residues in a mechanistic model (figure 4.13). Six point mutants completely 
failed to complement DT3017 and of these, biochemical roles can be assigned to five (D111, 
D113, H116, R226 and R138). For the two mutants with intermediate phenotypes, a 
biochemical role can be assigned to D57 and a structural role to G143. It still remains 
mechanistically unclear why Ppm1S163L in DT1029 is inactive and consequently, no 



















































Figure 4.10: S. coelicolor Ppm1 homology model exhibits typical facets of GT-A fold 
glycosyl transferase. Using Phyre2, the PDB structure of the archaeal P.  furiosus DPMS (5MLZ) 
was used as a template to generate a homology model for S. coelicolor Ppm1 (residues 25-256 
modelled). Residues targeted for mutation are highlighted as cylinders. The model and template 
are coloured green and grey respectively. The template derived Und-P mannose, Mg2+ and GDP 
are coloured dark purple, yellow and gold respectively. (A). Ppm1 homology model with 
cofactor, donor and acceptor substrates from the template, in addition to the mutagenised S. 
coelicolor residues are highlighted. (B) Ribbon overlays of the template and model are 




































Figure 4.11: G143 is within a loop. Using Phyre2, the PDB structure of the archaeal P.  furiosus 
DPMS (5MLZ) was used as a template to generate a homology model for S. coelicolor Ppm1 
(residues 25-256 modelled). Residues targeted for mutation are highlighted as cylinders. The 
model is coloured green. The template derived Und-P mannose, Mg2+ and GDP are coloured 
dark purple, yellow and gold respectively. (A). Ppm1 homology model with cofactor, donor and 









































Figure 4.12: Strong conservation of the GT-2 domain in S. coelicolor Ppm1 and P. furiosus 
DPMS. EMBOSS Needle alignment of the S. coelicolor GT-2 domain (Uniprot entry: 
Q9RKY2_STRCO) with P. furiosus (Q8U4M3_PYRFU). The S. coelicolor residues targeted for 














Figure 4.13: Proposed mechanism for Ppm1, an inverting glycosyl transferase that 
utilises a single step SN2 mechanism. Nucleophilic attack by the Und-P phosphate oxygen on 
the C1 mannose carbon yields GDP and -P-Man. D113 coordinates the GDP-Man diphosphate 
groups via a metal cation. Residues D111 and D57 help to fix GDP in place by making contact 
with the ribose sugar and nucleoside guanosine respectively. Key side chains for positioning the 
Und-P phosphate group for mannose transfer include R138 and R228. residues/divalent cation, 





S. coelicolor ppm1 – strains DT1020, DT1029 and DT3017 were previously shown to have 
antibiotic hyper susceptibility phenotypes that were more extreme than that observed for the 
pmt – strains (DT1025 and DT2008) (Howlett et al., 2018a; Wehmeier et al., 2009). In addition, 
these strains had growth retarded phenotypes and resistance to ΦC31 cΔ25 infection (Howlett 
et al., 2018a; Cowlishaw and Smith 2001; Cowlishaw and Smith 2002). These antibiotic hyper 
susceptibility phenotype observations suggested that both enzymes, are good targets for 
antimicrobials to be used in combination therapy with our existing arsenal of antibiotics. At the 
outset, only limited mutagenesis had been done on Ppm1/Dpm homologues with previous 
efforts focussed on the catalytically conserved DXD motif (Lairson et al., 2008).  Analysis of 
panels of mutants through in vivo molecular microbiology and in vitro biochemical assays has 
assigned roles for several critical residues. These assignments are consistent with the structure 
of Dpm synthase from P. furiosus (Gandini et al., 2017) published mid-way through the work 
described in this Chapter which was carried out independently. 
 
Our collaborator Pamela Dube at Warwick University made the following Ppm1 substitutions: 
D57A, R82A, D111A, D11A, H116D, R138A, G143V, S163L, R228A, in addition to a 42 residue C-
terminal truncation (Δ42) (Dube et al., 2019). The alleles encoding these mutants were 
introduced into the ppm1 – S. coelicolor strain DT3017. Antibiotic susceptibility testing showed 
that: Ppm1D111A, Ppm1D113A, Ppm1H116D, Ppm1R138A, Ppm1S163L and Ppm1R228A failed 
to complement DT3017. These strains therefore have an increased antibiotic susceptibility 
profile that matches the empty plasmid negative control for every antibiotic tested, in addition 
to growth retarded phenotypes and resistance to ΦC31 cΔ25 infection (observations also 
consistent with the empty plasmid negative control).  Pamela Dube’s biochemical data from the 
malachite green phosphate liberation assay showed the following in vitro normalised activities: 
Ppm1D111A (18 %), Ppm1D113A (4 %), Ppm1R138A (8 %), Ppm1R228 (7 %) and S163L (28 
%), relative to the WT enzyme (Dube et al., 2019). The mutants Ppm1Δ42 and Ppm1R82A 
successfully complemented DT3017 alleviating the antibiotic hypersusceptible phenotype, 
resensitising the bacteria to phage infection and restoring normal growth. The in vitro activities 
for Ppm1Δ42 and Ppm1R82A were 92 and 81 % respectively (Dube et al., 2019). D57A showed 
sensitivity to phage infection and exhibited a healthy colony phenotype, however we observed 
significant increases in sensitivity to several cell wall targeting antibiotics, most notably, 
vancomycin. The sensitivity profile for D57A strains was intermediate between that observed 
for the WT complemented positive control and empty plasmid negative control. Strains 
containing G143V, like D57A, were sensitive to phage infection and had a large colony 
phenotype, however the antibiotic susceptibility profile was much closer to the empty plasmid 
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negative control.  For Ppm1G143V and Ppm1D57A, the in vitro normalised activities were 42 
and 36 % respectively, these intermediate reductions in activity are in general agreement with 
the partial complementation phenotypes observed in vivo for these mutants. In the study by 
Howlett (2018a), many of the antibiotics tested in this study were used to characterise ppm1 – 
and pmt – strains. Where the amount of antibiotic added to the disc was the same in the two 
studies, the diameters of the zones of clearance were consistent, ranging from ~20-25 mm. This 
consistency between the studies, in addition to the good reproducibility (small SEM bars) gives 
confidence in the data obtained. The zone of clearance diameters for the non-complemented 
DT3017 strains are also comparable with the S. coelicolor manB – and manC – strains as 
expected. Indeed, it is known that strains depleted in enzyme activities used to generate 
polyprenol phosphate mannose (ManB, ManC and Ppm1) exhibited greater susceptibility to 
antibiotics than strains with depleted Pmt activity.  
The residue corresponding to D57 of S. coelicolor Ppm1 was mutated to alanine in Pyrococcus 
horikoshii Ppm1 (D39A) (Urushibata et al., 2008). The resulting mutant showed 2 % of the 
activity of the WT.  Two other mutants of P. horikoshii Ppm1, D89A and D91A, (corresponding to 
S. coelicolor Ppm1 D111 and D113) showed 0.09 and 0.17 % activity of the WT enzyme 
respectively. The authors’ conclusions were that this DXD motif was catalytic, a reasonable 
conclusion since the DXD motif is conserved in the GT-A family of glycosyl transferases (Lairson 
et al., 2008). They also concluded that D39 plays an important role activity, but this residue may 
not participate directly in catalysis. This is to some extent supported by the homology model of 
Ppm1, from which we propose that D57 is remote from the DXD motif and would appear to 
make less critical interactions with the pyrimidine ring of the mannose donor GDP-Man. The 
intermediate or partial complementation phenotype (as discussed in Keenan et al., 2019) in our 
in vivo assays strengthens the argument made by Urushibata and co-workers (2008) that while 
important for the enzymatic reaction, D57 is probably not a catalytic residue. When the 
structure of the P. furiosus Ppm1 was solved, Gandini et al., (2017) also carried out SDM on the 
DXD motif. The activity of P. furiosus Ppm1 D89A and D91A mutants (S. coelicolor D111A and 
D113A) was ~25 % and ~50 % of WT levels respectively. The authors’ hypothesised that the 
residual activity obtained (specifically for D91A) is due to Q93 and R202 rescuing some of the 
metal binding capacity of D91A. R202 but not Q93 is conserved in S. coelicolor Ppm1 (R226), 
where its substitution by alanine yielded a non-complementing mutant. Here we propose that, 
in accordance with the P. furiosus structure, the interaction of D113 with the anionic 
diphosphate group is mediated through a divalent metal cation. D111 in contrast directly 
interacts with the hydroxyl groups of the ribose sugar. The DXD motif therefore serves to fix the 
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GDP mannose firmly in place so that the C1 carbon of the mannose is correctly positioned for 
the reaction chemistry.  
It is noteworthy that for P. horikoshii Ppm1, the DXD motif mutant activity was decreased to less 
than 1 % of that of the WT, while it was between ~25 % and 50 % respectively in the P. furiosus 
study (Urushibata et al., 2008; Gandini et al., 2017). This notably large discrepancy may be 
attributable to the different biochemical approaches taken by the authors. In the P. furiosus 
Ppm1 study a malachite green assay was used to monitor activity (Gandini et al., 2017). In this 
assay, following the transfer of mannose to dolichol phosphate, the terminal phosphate 
(orthophosphate) is cleaved off GDP by a phosphatase and reacts with Malachite green and 
molybdate to create a complex that is detectable spectrophotometrically (Veldhoven et al., 
1987). In contrast, for the P. horikoshii Ppm1 study (Urushibata et al., 2008), a radiometric assay 
method originally described by Orlean (1988) was used, whereby mannose is transferred from 
GDP-14C-mannose, to dolichol phosphate, with the Dol-P-14C-mannose product extracted and its 
radioactivity measured by scintillation counting. Analysis of data from Pi based assays like 
Malachite Green can be complicated by high background (caused by contamination by non-
enzymatically produced Pi) and enzymatic hydrolysis of the substrate in assays conditions. 
Radiometric assays are arguably more sensitive, precise and have the advantage of directly 
monitoring mannose transfer. Based on this, in addition to the reductions being more consistent 
with the in vitro data obtained for the S. coelicolor DXD motif mutants (Dube et al., 2019), the P. 
horikoshii Ppm1 study is probably more trustworthy (Urushibata et al., 2008). 
While the arginines corresponding to R138 and R226 in S. coelicolor Ppm1 (P. furiosus R117 and 
R202) were not substituted in the Gandini study, the close proximity of R226 to the DXD motif 
suggests a role in the enzymatic mechanism. This residue was proposed by Gandini et al., (2017) 
to compensate for a DXD motif mutation, another possible role could be to assist R138 in 
orientating the nucleophilic phosphate head group of polyprenol phosphate. Correct orientation 
of this head group is needed to ensure the nucleophile is suitably positioned to attack the C1 
carbon. This role was proposed for P. furiosus Ppm1 R117 rather than R202 (S. coelicolor R138 
and R226). In our biochemical model, we propose that both R138 and R226 are involved in 
orientating the nucleophilic phosphate.  
In human Dpm1, a G152V substitution was found in a human congenital disorder of 
glycosylation (CDG) patient (Yang et al., 2013). The homologous residue in S. coelicolor Ppm1 
(G143) was substituted to valine to mimic this mutation. In the homology model, G143 is part of 
a loop comprising V140 P141, G142 and G143. The glycine to valine substitution introduces a 
bulkier CH2(CH3)2 side chain that is expected to alter the conformation of this loop, the resulting 
secondary structure change might then then destabilise the entire protein, or lead to an altered 
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conformation with reduced activity. Since this mutant only partially complements the DT3017 
strain, the latter consequence appears more likely.  
The remaining residues targeted and their substitutions were H116D and S163L. These 
substitutions reflect mutations previously identified in DT1020 and DT1029 respectively 
(Wehmeier et al., 2009). The histidine in the homology model is positioned very close to the 
catalytic DXD motif. In active sites, histidines frequently serve as bases that deprotonate a 
nucleophile, the serine proteases being a notable example (Carter et al., 1988). For GT-A 
catalysed reactions the phosphate head group of the acceptor does not require prior base 
activation, since it will already be deprotonated. This role of this conserved histidine has not 
been considered in the literature for any homologue. In the homology model, it is in hydrogen 
bonding distance of the C4 hydroxyl of the mannose (joined to polyprenol phosphate). It is 
therefore possible that H116 is able to stabilise both the donor substrate (pre catalysis) and the 
acceptor substrate (post catalysis). While not shown in the model, an alternate role could be to 
help orientate one of the aspartates within the DXD motif. 
A role for S163 was not defined in this study. It is possible that mutation of S163 destabilise the 
protein. In the model, there are no polar residues within hydrogen bonding distance of the 
serine, indicating that destabilisation of the fold through loss of hydrogen bonding is unlikely. 
Another explanation is that this residue could be important for membrane localisation; the 
homologous residue in P. furiosus Dpm resides on an amphipathic helix that sits on top of the 
membrane, forming a boundary between the transmembrane and catalytic domains (Gandini et 
al., 2017). It is therefore reasonable to propose a role in membrane localisation. The basis for 
membrane association of S. coelicolor Ppm1 remains unknown. Two mechanisms of membrane 
localisation have been identified in homologues, firstly C. glutamicum M. tuberculosis and P. 
furiosus Ppm1s comprise a single protein chain with separate catalytic and transmembrane 
membrane domains and secondly, M. leprae, Ppm1 comprises two separate proteins encoded by 
adjacent genes (Gandini et al., 2017; Gibson et al., 2003; Gurcha et al., 2002). Since S. coelicolor 
Ppm1 does not possess a two domain architecture, an interacting partner remains the most 
likely explanation for membrane localisation.  Further investigation is required to determine 
whether S163 (or another residue) is involved in this.  
The motivation for substituting R82 and making a separate C-terminal truncation was based on 
a medical study of two siblings who carried mutant alleles of the Dpm1 gene: 1) an R92A 
substitution and 2) a truncated C-terminus (Δ47) (Imbach et al., 2000). The homologous S. 
coelicolor residue (R82) was substituted to alanine in our study and the allele surprisingly 
complemented DT3017. In the homology model, R82 is close to D57 and both residues would be 
expected to occupy the GDP-Man binding pocket. Imbach et al., (2000), did not speculate on the 
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role of the arginine. The ability of the R82A mutant to fully complement DT3017 may be 
attributable to another nearby arginine or lysine (not conserved in human Dpm1) that can 
compensate for the loss of the residue.  
Regarding the truncation mutant, the cause is premature translation termination at codon 213, 
leading to a loss of 47 residues from the C-terminus. Due to technical difficulties, a 42 rather 
than a 47 residue truncation of S. coelicolor Ppm1 was made by our collaborators In S. coelicolor 
Ppm1, the C-terminal region is predicted to be disordered moreover, it is sparsely conserved 
across the prokaryotic and eukaryotic kingdoms. This truncated mutant nevertheless fully 
complemented DT3017. It is worth mentioning that the two children had both the R92A 
substitutions and the CΔ47 truncation (Imbach et al., 2000). Complementation studies (using 
dpm1 – murine Thy1 deficient cells) to identify the impact of each mutation found that R82A 
presented a milder phenotype, while the truncation mutant had an extreme phenotype 
comparable with the empty plasmid negative control. Based on this, it could be that the active 
phenotype associated with S. coelicolor Ppm1 R82A can be attributed to a lack of sensitivity of 
the in vivo assays, which are unable to reveal an intermediate phenotype. This explanation is 
supported by our collaborator’s biochemical data which show a 19 % reduction in activity. The 
oligomeric state of S. coelicolor Ppm1 is not known. It is understood that in H. sapiens DPM1 and 
DPM2 interact to form a complex in which DPM2 helps stabilise and correctly localise DPM1. It 
is known that the removal of the C-terminus in DPM1 inhibits this crucial oligomerisation. If S. 
coelicolor Ppm1 is monomeric (or the C-terminus is not involved in oligomerisation), this 
suggests an explanation of why the C-terminal truncation does not hinder the ability of the allele 
to complement DT3017. Another explanation is that the 42 residue truncation does not mimic 
the 47 residue truncation and that one or more of the intervening five residues is critical for 














Chapter 5 - Identification of essential residues for S. coelicolor protein 
O-mannosyl transferase function  
 
The pmt – strains: DT1025 and DT2008 were previously identified and isolated by Smith and co-
workers. DT1025 was confirmed to have a premature stop codon in Pmt while DT2008 was not 
sequenced (Wehmeier et al., 2009). Like the ppm1 – strains mentioned in the previous chapter, 
ΦC31 phage is unable to form plaques with high efficiency on DT1025 and DT2008 strains, in 
contrast to the phage susceptible J1929 parent strain. Again, similarly to the ppm1- strains, 
DT1025 and DT2008 show retarded growth phenotypes and increased susceptibility to a 
number of cell wall/membrane targeting antibiotics compared to J1929 (Howlett et al., 2018a). 
While ppm1- and pmt - colony phenotypes are broadly comparable, the pmt - strains are notably 
less susceptible to antibiotics than that obtained for the ppm1 – strains, the reasons for this 
differential susceptibility remain poorly understood (Howlett et al., 2018a). 
In S. cerevisiae, PMTs are known to form dimeric complexes; a complex readily observed is 
Pmt1p-Pmt2p (Lommel and Strahl 2009). The human equivalent to PMTs are the POMT family, 
Pomt1-Pomt2 complexes have been well studied and are essential for mannosyl transferase 
activity (Akasaka-Manya et al., 2006; Lommel and Strahl 2009). Complex formation therefore 
appears to be critical for PMT O-linked mannosylation activity in yeast and humans, whereas 
there is a lack of evidence indicating that this is a prerequisite for PMT activity in prokaryotes 
such as the actinobacteria. The question remains, does S. coelicolor Pmt need to form homo or 
heterodimers in order to function? In the more closely related mycobacterial pathogens M. 
tuberculosis and M. leprae, the oligomerisation state of Pmt is also unknown (VanderVen et al., 
2005). 
Mutagenesis of Pmt homologues from S. cerevisiae (Lommel et al., 2011, Girrbach et al., 2000) 
and M. tuberculosis (VanderVen et al., 2005), in addition to the homologue, ArnT from C. 
metallidurans (Petrou et al., 2016), point to a number of residues that are likely to be important 
for function. Six residues mutated in these studies are either fully or partially conserved in S. 
coelicolor. It is not known whether all six of these residues will be critical for activity of S. 
coelicolor Pmt. Furthermore, many more residues in Pmts from across the prokaryotic and 
eukaryotic kingdoms are strongly conserved that are yet to be mutagenised.  
The four objectives of this chapter were as follows:  
1. Production of an S. coelicolor pmt rational mutagenesis library, guided by the literature 
and structural bioinformatics 
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2. Introduction of S. coelicolor mutant pmt alleles into S. coelicolor DT1025, DT2008 and 
J1929 strains,  followed by spore preparation and strain harvesting 
3. In vivo characterisation to probe essentiality of the targeted residues   
4. Development of a robust mechanistic model for Pmt by combining in vivo data and 
























5.1 Pmt site directed mutagenesis 
5.1.1 Identification of site directed mutagenesis targets  
In order to probe amino acids essential for Pmt function, the Pmt sequence was aligned with 
homologues in prokaryotes (S. griseus, M. smegmatis and M. tuberculosis) and eukaryotes (S. 
cerevisiae and H. sapiens). The catalytic GT-2 domain is broadly conserved across the 
prokaryotic and eukaryotic kingdoms (Figure 5.1). Multiple conserved residues were identified, 
of which 27 were targeted and 23 changed to alanine: R82, D113, E114, V158, H159, P161, 
K164, R182, R201, R228, L231, L232, D233, K302, R338, P393, W400, H410, S421, W426, P503, 
R510, F564. Mutation of R100, Y156, Y356 and P569 to alanine was not achieved in spite of 
multiple attempts. The majority of these 27 residues were targeted on the basis of sequence 
conservation alone, with additional motivations to target seven residues (R100, D113, E114, 
H159, Y156, R182 and K302) as described below.  
D113 and E114 constitute the conserved DE motif, a hallmark of GT-C fold glycosyl transferases 
(Lairson et al., 2008). In S. cerevisiae Pmt1P, mutation of both homologous residues (D77, E78) 
led to notable reductions in in vivo glycosylation and complete elimination of in vitro mannosyl 
transferase activity (Lommel et al., 2011). In another paper, mutations in the DE motif of M. 
tuberculosis (D55, E56) Pmt were carried out and in vitro mannosyl transferase activity was 
reduced, but not completely eliminated (VanderVen et al., 2005). In an earlier study, R138 in S. 
cerevisiae Pmt1P (R182 in S. coelicolor) was shown to have an essential role in in vitro 
transferase activity (Girrbach et al., 2000).  Two other residues had been mutated: R64 (R100 in 
S. coelicolor) and L408, with both being essential for in vitro catalytic activity. R100 was not 
mutated and L408 is not conserved in prokaryotes. Finally, in Cupriavidus metallidurans ArnT, a 
lipid A glycosyl transferase, the mutation of D55, K85 and K203 (D113, H159 K302 in S. 
coelicolor respectively) eliminated in vivo function (Petrou et al., 2016). Y82 (Y156 in S. 
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Figure 5.1: The catalytic GT-2 domain is broadly conserved across the prokaryotic and 
eukaryotic kingdoms. Clustal Omega alignment of the S. coelicolor Pmt primary structure 
(Uniprot entry: Q9RKD3_STRCO) with S. griseus (A0A0D6UNW8_STRGR), M. smegmatis 
(PMT_MYCSE), M. tuberculosis (PMT_MYCTO), S. cerevisiae (PMT4_ & PMT2_ YEAST) and H. 
sapiens (POMT2_HUMAN). The S. coelicolor residues targeted for substitution to alanine are 




















































5.1.2 Mutagenesis of targets  
In order to make substitutions of the identified residues mentioned previously, initial efforts 
focussed on mutagenising the pmt allele and amplifying the recombinant plasmid. The pmt 
containing plasmid pDT10 was used as the template alongside the use of either back to back or 
partially overlapping primers to simultaneously introduce the mutation and amplify the entire 
plasmid in a single reaction.  This approach often led to non-specific amplification products 
(data not shown). In cases where amplification was successful, the high proportion of impurities 
necessitated gel purification to obtain clean DNA appropriate for cloning. The low yield of 
desired full length plasmid product from the gel purifications was often insufficient for cloning. 
In other rare cases where a recombinant plasmid had been made and purified, sequencing 
revealed unwanted errors in the primer annealing regions.  
 
Ultimately, amplification of the pmt allele via 2 PCR reactions proved successful:  
1.) Forward flanking primer plus mutagenesis reverse primer  
2.) Reverse flanking primer plus mutagenesis forward primer 
Using 2 separate PCR reactions allowed for considerably shorter extension times, this reduced 
the non-specific primer binding considerably allowing higher yields of desired DNA fragments 
of the expected size to be purified by PCR clean up kits (Figure 5.2). The two inserts were 
subsequently joined together and cloned into pIJ10257 DNA sequencing and restriction digests 
confirmed correct mutagenesis and cloning of the pmt alleles encoding the following 23 
changes: R82A, D113A, E114A, V158A, H159A, P161A, K164A, R182A, R201A, R228A, L231A, 




























































Figure 5.2: Introduction of the desired mutation by two separate PCR reactions gave 
high yields of correctly sized products. R100F refers to a PCR reaction using the forward 
mutagenesis primer, which would be used alongside the reverse flanking primer. The 
converse applies to R338R.  The NEB 1 KB ladder is used for reference.     
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5.2 Pmt structural bioinformatics  
 
5.2.1 Sequence analysis 
S. coelicolor Pmt is predicted to have 11 transmembrane helices according to TMHMM 
(Transmembrane Helices; Hidden Markov Model) (Figure 5.3). The loop regions connecting 
these helices vary in size, with the predicted extracellular loops 1 and 7 being the largest with 
82 and 94 residues respectively. The putative 11 transmembrane helices ranged in size from 17 
to 22 residues with a mode of 22 residues.  
In total 18 of the 23 residues substituted in this study are predicted to be located in 
extracellular loop domains. Seven residues (D113, E114, V158, H159, P161, K164 and R182) 
and five residues (P393, W400, H410, S421 and W426) are predicted to occupy loops 1 and 7 
respectively. Another four residues (R228, L231, L232 and D233) are on the comparatively 
smaller loop 3, while residues K302 and R510 occupy loops 5 and 9 respectively. The hallmark 
DE motif is located within loop domain 1, as is universally observed in Pmt homologues across 
the prokaryotic and eukaryotic kingdoms.  The active sites of Pmt family enzymes are mostly 
composed of extracellular residues and it is these regions that show the greatest sequence 
conservation.  
Three of the substituted residues are predicted to be located on the cytoplasmic side of Pmt, 
with R82 in the N-terminal region and residues R201 and R338 located in loops 3 and 5 
respectively. Finally, only two mutated residues are predicted to occupy the transmembrane 
spanning portion of Pmt, with residues P503 and F564 individually located on helices 9 and 11 
respectively.  
The N-terminal 82 residues preceding the first transmembrane helix of S. coelicolor Pmt 
encompass roughly 55 amino acids that are predicted to be highly disordered according to 
IUPred2A (≥0.5) (Figure 5.3). Subsequent moderate peaks in disorder tendency (< 0.5) are seen 
in the following regions: 135-156 (N-terminus), 259-282 (loop 1), 374-390 and 412-456 (loop 
7) and 541-548 (loop 10).  
ArnT is a GT-C fold glycosyl transferase from the bacterium Cupriavidus metallidurans, which 
catalyses aminoarabinose transfer to lipid A. This enzyme also has 11 transmembrane helices 
and the sequence of the extracellular loop domains (which constitute the globular domain in the 
GT-C family of enzymes) are strongly conserved between S. coelicolor Pmt and C. metallidurans 
ArnT (Figure 5.4). Alignment of the full S. coelicolor Pmt primary structure with C. metallidurans 







































Figure 5.3: S. coelicolor Pmt has 11 predicted transmembrane helices and a disordered N-
terminus. (A) TMHMM plot for S. coelicolor Pmt with regions predicted to be transmembrane 
helices, cytoplasmic portions and extracellular portions highlighted. H and L annotations refer 
to helix and loop respectively. (B) TMHMM results superimposed on to the S. coelicolor Pmt 
primary structure with conserved residues targeted for mutation highlighted in green. (C) 
IUPred2A plot shows the score of each residue in the protein from 0 to 1 (low to disorder 
respectively). A residue with a score of ≥0.5 is considered to have more disordered character.    
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Figure 5.4: S. coelicolor Pmt and C. metallidurans  ArnT have a sequence identity 
and similarity of 16.3 and 24.9 % respectively. The full length S. coelicolor Pmt 
primary structure was aligned with 432/600 to keep the lengths of the aligned 
sequences consistent.  
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5.2.2 Homology model analysis 
The ArnT structure from C. metallidurans (PDB ID: 5ezmA) was used to generate a Phyre2 
homology model of Pmt. 485 residues (82 %) were modelled at >90 % confidence using ArnT 
exclusively (figure 5.5).  The excluded regions include residues 1-84 and 563-591, representing 
the N and C-termini respectively. These excluded regions included two mutated residues R82 
and F564, which are consequently absent from the model.  
Of the 11 predicted transmembrane helices, 8 appear to be modelled very well, with helix length 
in full agreement with the TMHMM plot (Figures 5.3 and 5.5). However, the modelling of helices 
3, 7 and 10 partially agrees with the TMHMM plot and therefore may be unreliable. In the 
model, helix 3 is separated into 2 smaller helices, while for helices 7 and 10, roughly ½ and ⅔ of 
the residues were not modelled respectively. The helices: 1, 2, 4, 5, 6, 8, 9 and 11 did correspond 
well to the TMHMM plot and enabled membrane bilayer boundaries to be predicted.  
The largest loops are 1 and 7, these can be easily seen between transmembrane helices 1 and 2 
and 7 and 8 respectively. Both loops are comfortably above the defined membrane boundaries 
and sit on the periplasmic side of the membrane, as expected. The majority of residues targeted 
for substitution are predicted to occupy these loops (Figure 5.7). In the model, the residues: 
D113, E114, V158, H159, P161, K164 and R182 occupy a periplasmic facing loop that links 
transmembrane helices 1 and 2, as expected based on TMHMM. This region represents the 
hallmark loop 1 domain of GT-C fold glycosyl transferases. 5 residues are predicted to occupy 
the periplasmic loop domain 7: P393, W400, H410, S421 and W426. This is the second largest 
loop domain in the model and is clearly represented as being between transmembrane helices 7 
and 8. While W400, H410 and S421 sit comfortably in the periplasmic loop as expected, P393 
and W426 are shown to be just below the membrane boundaries. As expected, the smaller loop 
3 is found between helices 3 and 4, with the residues: R228, L231, L232 and D233 shown above 
the membrane boundaries. The final periplasmic residues: K302 and R510 are also shown 
above the membrane boundaries and located in loops 5 and 9 respectively. 
To summarise, of the 18 residues targeted for mutation that are predicted to occupy the 
periplasmic region, 16 (D113, E114, V158, H159, P161, K164, R182, R228, L231, L232, D233, 
K302, W400, H410, S421 and R510) are above the defined membrane boundaries, with each 
located in its expected loop domain. The TMHMM plot and model are therefore in agreement for 
these residues. Residues P393 and W426 were not identified in the periplasmic loop domain 7, 
it is however noteworthy that these residues occupy the periplasmic poles of the connecting 
transmembrane spanning helices 7 and 8 respectively.  
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For the cytoplasmic residues. R82 is not shown since the first 83 residues were not included in 
this model. The residue R338 is shown on the cytoplasmic pole of helix 5, while R201 is on the 
membrane boundary separating the cytoplasmic pole of helix 2 and loop 3. Considering the 
transmembrane helices, P503 is shown on helix 10 as expected. F564 is not included in this 
model due to exclusion of the final 27 residues.  
To summarise, 18 of the 23 residues substituted in this study have a position in the model that 
is in full agreement with the TMHMM profile. 3 residues (R201, P393 and W426) are close to 

























































Figure 5.5: Phyre2 homology model of S. coelicolor Pmt has typical facets of GT-C fold 
glycosyl transferases. The model is based on the template ArnT (5F15) from C. metallidurans 
.485 residues (82 %) were modelled at >90 % confidence. (A) Ribbon model coloured according 
to secondary structure. (B) Worm and tube model coloured according to rainbow format, going 
from blue (N-terminus) to red (C-terminus) with numbered transmembrane helices. Predicted 
















































































































































































































































































































































































































































































































































































































































5.3 In vivo pmt mutant characterisation 
 
5.3.1 Identification of pmt mutants unable to alleviate the antibiotic susceptible 
phenotype of DT1025 
Using the integrative vector pIJ10257, S. coelicolor pmt mutant alleles were stably introduced 
into the chromosome of the pmt – strain (DT1025) and the parent strain (J1929) and antibiotic 
disc diffusion assays carried out as described previously (Howlett et al., 2018a). Six of the pmt 
mutant alleles tested failed to complement the pmt mutation in DT1025: These alleles encoded 
PmtR82A, PmtD113A, PmtH159A, PmtD233A, PmtK302A, PmtR510A (Figures 5.7 and 5.8). 
These strains showed significantly increased susceptibility to all cell wall and/or membrane 
targeting antibiotics tested, in addition to rifampicin and nitrofurantoin, when compared to the 
J1929 parent strain (p < 0.05).  
DT1025 containing each of the six non-complementing pmt alleles had increased carbapenem 
(imipenem and meropenem) and vancomycin susceptibilities compared to J1929. The WT and 
17 remaining mutant alleles were able to complement DT1025, alleviating the antibiotic 
susceptible phenotype (Figures 5.8 and 5.9). The antibiotic susceptibility for the complemented 
strains was consequently not significantly different to J1929 for any antibiotic tested (p < 0.05). 
DT1025, the negative control strain (containing the plasmid only) and the non-complemented 
mutant strains interestingly did not exhibit significantly increased susceptibility to antibiotics 
inhibiting DNA replication and translation when compared to the J1929 parent strain (p < 0.05) 
(Figure 5.10), representing a clear contrast with the ppm1 non-complemented mutants 
discussed in chapter 4. All 23 strains therefore exhibited comparable susceptibility, with the 
ability to complement therefore having no effect (Figures 5.10 and 5.11). In summary, the 
absence of active Pmt is only noted when antibiotics targeting the cell wall/membrane or 
transcription are used, indicating a clear mechanistic bias.  
All mutant pmt alleles were additionally introduced into the J1929 parent strain. In these 
experiments, there was no significant difference in susceptibility to any antibiotic tested 
(Figures A8.3, A8.4, A8.5 and A8.6). This demonstrates that the expression of the non-
complementing and complementing pmt mutants in the parent strain, failed to reduce or 






























DT1025 + L231A DT1025 + R228A DT1025 + R201A DT1025 + R182A 
DT1025 + V158A DT1025 + K164A DT1025 + P161A DT1025 + E114A 
DT1025 + R510A DT1025 + K302A DT1025 + D233A DT1025 + H159A 



























DT1025 + H410A 
DT1025 + F564A 
DT1025 + P503A 
DT1025 + L232A 
DT1025 + W426A DT1025 + S421A 
DT1025 + W400A DT1025 + P393A DT1025 + R338A 
Figure 5.7: DT1025 strains that are not complemented with an active pmt allele 
exhibit increased susceptibility to antibiotic insult.  S. coelicolor DT1025 spores were 
plated out on DN agar and 4 µg of meropenem (top left), 40 µg vancomycin (top right), 80 µg 
ampicillin (bottom left) and 4 µg imipenem (bottom right) were added to each disc. The 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.3.2 Complemented DT1025 are vulnerable to ΦC31 cΔ25 phage infection and exhibit 
increased growth rates 
To further test the aforementioned strains, ΦC31 cΔ25 phage infection assays were performed 
(Figure 5.12 and Table 5.1).  If integrity of the glycosylation cascade has been restored, the 
complemented strains should be vulnerable to infection by phage. As expected, the no gene 
negative control and the mutants that failed to alleviate the DT1025 antibiotic susceptible 
phenotype (R82A, D113, H159A, D233A, K302A and R510A) showed no evidence of infection 
within the phage dilution range tested. The WT positive control and the 17 complemented 
DT1025 strains that showed restored antibiotic susceptibility to that observed in the J1929 
parent strain were vulnerable to phage infection, with countable plaques obtainable at a 10-6 
phage stock dilution. The plaques obtained for the complemented strains were phenotypically 
comparable to the J1929 parent strain, typically large and clear. Clear plaques are a hallmark of 
infection by a lytic phage such as ΦC31 cΔ25 (Lomovskaya et al., 1972). Introduction of the 
alleles in the J1929 parent strain had no effect on phage susceptibility (Table A8.3). 
DT1025 possesses a small colony phenotype when grown on DN agar and SM agar, the strains 
complemented with WT and 17 complementing mutant alleles grew faster yielding large 
colonies consistent with J1929 (Figure 5.13). R82A, D113, H159A, D233A, K302A and R510A 



































































Figure 5.12: Complemented DT1025 strains are vulnerable to ΦC31 cΔ25 phage infection. 
Phage were plated out on a portion of DN agar and then spores streaked from the phage absent 
region to the phage present region. Plates were incubated at 30 °C for 48 hours. Images are 
representative of 4 biological replicates. 


















































Strain Titre (PFU/ml) 
DT1025 
DT1025 + WT 
DT1025 + R82A 
DT1025 + D113A 
DT1025 + H159A 
DT1025 + D233A 
DT1025 + K302A 
DT1025 + R510A 
DT1025 + E114A 
< 1 x 102 
(2.63 ± 0.14) x 108 
< 1 x 102 
< 1 x 102 
< 1 x 102 
< 1 x 102 
< 1 x 102 
< 1 x 102 
(3.21 ± 0.29) x 108 
DT1025 + V158A (2.12 ± 0.09) x 108 
DT1025 + P161A 
DT1025 + K164A 
DT1025 + R182A 
(3.13 ± 0.14) x 108 
(2.37 ± 0.12) x 108 
(2.56 ± 0.36)  x 108 
DT1025 + R201A 
DT1025 + R228A 
(1.74 ± 0.07) x 108 
(4.12 ± 0.42) x 108 
DT1025 + L231A (2.28 ± 0.23) x 108 
DT1025 + L232A (3.48 ± 0.37) x 108 
DT1025 + R338A (2.32 ± 0.18) x 108 
DT1025 + P393A (1.94 ± 0.27) x 108 
DT1025 + W400A 
DT1025 + H410A 
(1.82 ± 0.08) x 108 
(2.67 ± 0.13) x 108 
DT1025 + S421A 
DT1025 + W426A 
DT1025 + P503A 
DT1025 + F564A 
(4.34 ± 0.34) x 108 
(2.59 ± 0.25) x 108 
(3.56 ± 0.27)  x 108 
(2.71 ± 0.07) x 108 
  
Table 5.1: Complemented DT1025 strains are vulnerable to ΦC31 cΔ25 phage infection. 
Phage were plated out on DN agar and then SN agar containing spores was added to the top with 
the plates incubated at 30 °C for 18 hours. The average titre is shown ± SEM from 4 biological 
replicates. 0.1 ml of a 10-6 phage stock dilution was used to obtain countable plaques for phage 
sensitive strains.  Strains that showed no plaques at the lowest phage stock dilution tested (10-1) 



































DT1025 + E114A DT1025 + V158A DT1025 + P161A DT1025 + K164A 
DT1025 + R182A DT1025 + R201A DT1025 + R228A DT1025 + L231A 
DT1025 + L232A DT1025 + R338A DT1025 + P393A DT1025 + W400A 
DT1025 + WT DT1025  DT1025 + R82A DT1025 + D113A 


































DT1025 + H410A DT1025 + S421A DT1025 + W426A DT1025 + P503A 
DT1025 + F564A 
Figure 5.13: Non-complemented DT1025 strains show a small colony phenotype. Strains 




5.3.3 Introduction of pmt mutants into DT2008 
Only six of 23 mutant alleles complemented DT1025. Interestingly, alleles encoding PmtE114A 
and R182A were able to complement the pmt – mutation in DT1025. Residues homologous to 
these were noted to be important for activity in S. cerevisiae and M. tuberculosis Pmts (Lommel 
et al., 2011; VanderVen et al., 2005; Girrbach et al., 2000). Based on this and the absence of 
intermediate antibiotic susceptibility profiles, the mutant alleles were introduced into another 
pmt – strain DT2008 and antibiotic disc diffusion assays carried out as described previously 
(Howlett et al., 2018a). The antibiotic sensitivity profiles for the pmt – alleles in DT2008 strains 
were comparable with DT1025. The six mutant alleles that failed to complement DT1025, 
encoding Pmt: R82A, D113A, H159A, D233A, K302A and R510A, were also unable to 
complement DT2008. As observed previously, these strains showed significantly increased 
susceptibility to all cell wall and/or membrane targeting antibiotics tested, in addition to 
rifampicin and nitrofurantoin, when compared to the J1929 parent strain (p < 0.05) (Figure 
5.14).  
DT2008 strain containing the mutant pmt alleles were notably more susceptible to the cell wall 
and membrane inhibitors compared to J1929. The greatest susceptibility was to the 
carbapenems: imipenem and meropenem. As with DT1025, rifampicin also yielded the smallest 
increase in zone of inhibition for all six non-complemented strains compared to J1929. 
Rifampicin was therefore the least effective antibiotic for exploiting the antibiotic susceptibility 
phenotype. The WT and 17 remaining mutant alleles were able to complement DT2008, 
alleviating the antibiotic susceptible phenotype (figure 5.15), again all consistent with previous 
observations for DT1025. The antibiotic susceptibility of all complemented DT2008 strains was 
not significantly different to J1929 for any antibiotic tested (p < 0.05).  
Neither the complemented or non-complemented DT2008 strains exhibited significantly 
increased susceptibility to antibiotics inhibiting DNA replication and translation when 
compared to the J1929 parent strain (p < 0.05), again mirroring the data previously obtained for 
DT1025 (Figures 5.16 and 5.17). The antibiotic susceptibility profiles of all 23 complemented 
and non-complemented strains in DT1025 and DT2008, was therefore comparable for all 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.3.4 Complemented DT2008 are vulnerable to ΦC31 cΔ25 phage infection and exhibit 
increased growth rates 
To further test the aforementioned strains, ΦC31 cΔ25 phage infection assays were performed 
(Figure 5.18 and table 5.2). If integrity of the glycosylation cascade has been restored, the 
complemented strains should be vulnerable to infection by phage. 
As previously observed for DT1025, DT2008 containing the plasmid only (negative control) and 
the mutants that failed to complement the antibiotic susceptible phenotype (encoding Pmt 
R82A, D113, H159A, D233A, K302A and R510A) showed no evidence of infection within the 
phage dilution range tested. The DT1025 strains complemented with the WT positive control 
and the 17 mutants that restored the antibiotic susceptibility observed in the J1929 parent 
strain were vulnerable to phage infection, with countable plaques obtainable at a 10-6 phage 
stock dilution. The phage titres obtained for the complemented strains were in the same order 
of magnitude as those previously obtained for DT1025, with the plaques again large and clear.  
The DT1025 strains complemented with WT and 17 complementing mutant alleles grew faster 
yielding large colonies consistent with J1929. Pmt alleles encoding R82A, D113, H159A, D233A, 
K302A and R510A that failed to complement DT2008 grew with the small colony phenotype 





















































































Figure 5.18: Complemented DT2008 strains are vulnerable to ΦC31 cΔ25 phage infection. 
Phage were plated out on a portion of DN agar and then spores streaked from the phage absent 


































Strain Titre (PFU/ml) 
DT2008  
DT2008 + WT 
DT2008 + R82A 
DT2008 + D113A 
DT2008 + H159A 
DT2008 + D233A 
DT2008 + K302A 
DT2008 + R510A 
DT2008 + E114A 
< 1 x 102 
(1.81 ± 0.23) x 108 
< 1 x 102 
< 1 x 102 
< 1 x 102 
< 1 x 102 
< 1 x 102 
< 1 x 102 
(2.13 ± 0.12) x 108 
DT2008 + V158A (2.83 ± 0.24) x 108 
DT2008 + P161A 
DT2008 + K164A 
DT2008 + R182A 
(2.84 ± 0.29) x 108 
(2.94 ± 0.07) x 108 
(2.73 ± 0.16) x 108 
DT2008 + R201A 
DT2008 + R228A 
(1.73 ± 0.34) x 108 
(3.02 ± 0.12) x 108 
DT2008 + L231A (1.78 ± 0.64) x 108 
DT2008 + L232A (2.56 ± 0.11) x 108 
DT2008 + R338A (1.84 ± 0.38) x 108 
DT2008 + P393A (2.62 ± 0.43) x 108 
DT2008 + W400A 
DT2008 + H410A 
(2.69 ± 0.09) x 108 
(1.95 ± 0.34) x 108 
DT2008 + S421A 
DT2008 + W426A 
DT2008 + P503A 
DT2008 + F564A 
(2.23 ± 0.08) x 108 
(2.66 ± 0.20) x 108 
(2.31 ± 0.39)  x 108 
(3.21 ± 0.42) x 108 
  
Table 5.2: Complemented DT2008 strains are vulnerable to ΦC31 cΔ25 phage infection. 
Phage were plated out on DN agar and then SN agar containing spores was added to the top with 
the plates incubated at 30 °C for 18 hours. The average titre is shown ± SEM from 4 biological 
replicates. 0.1 ml of a 10-6 phage stock dilution was used to obtain countable plaques for phage 
sensitive strains.  Strains that showed no plaques at the lowest phage stock dilution tested (10-1) 




5.4 Pmt mechanistic model  
 
Five of the six alleles that failed to complement the pmt - strains DT1025 and DT2008 encoded 
changes in residues that are putatively located in the periplasmic loop domains and are in close 
proximity to each other in the in silico model of Pmt (Figure 5.19) The side chains of D113, 
D233, K302 and H159 are predicted to point towards each other, in what is likely to be the 
active site, since D113 is part of the catalytic DE motif of GT-C fold glycosyl transferases. 
Interestingly, the R510 side chain is predicted to be pointing away from this region. When the 
undecaprenyl phosphate substrate derived from the C. metallidurans ArnT template is docked 
into the S. coelicolor Pmt model, the phosphate head group sits comfortably between D113, 
D233, K302 and H159 (Figure 5.19).  
It is necessary to assign direct roles to these residues (Figure 5.20). In the S. coelicolor Pmt 
model K302 is pointing towards D233, K302 may therefore form a salt bridge interaction to 
help position D233. Divalent cations have been shown to be important for function in multiple 
GT-C fold enzymes. D233 will be positioned to coordinate the divalent cation, a likely role for 
the cation is to help orientate the glycosidic bond linking polyprenol phosphate to mannose. 
Assuming the negative charge of D223 is involved in a salt bridge interaction with K302, only 
the negative charge on D113 would be available to act as the nucleophile. This nucleophile will 
deprotonate a hydroxyl on the acceptor serine or threonine, yielding a more powerful 
nucleophile that will attack the anomeric carbon on the mannose. Since the corresponding 
residue of H159 in C. metallidurans is involved in positioning the donor phosphate, it is possible 
it has the same function in S. coelicolor. This is further supported by the close proximity of H159 
to the undecaprenyl phosphate docked into the model. The side chain of R510 is orientated 
away from the predicted active site in the model, making it difficult to assign a role. It could be 
involved in forming a salt bridge interaction with another critical acidic residue, an alternate 



























































































































































































































































































































































































Figure 5.20: Proposed mechanism for Pmt, an inverting glycosyl transferase that utilises a 
single step SN2 mechanism. Nucleophilic attack by an acceptor serine or threonine yields 
mannosylated protein and liberated polyprenol phosphate. D233 both coordinate the phosphate 
group of the donor via a divalent metal cation. D113 activates a serine or threonine hydroxyl for 
nucleophillic attack of the C1 mannose, while D233 is fixed in position with K302 through a salt 
bridge. H116 helps position the phosphate while R510 interacts with the main chain of the serine 
or threonine residue. Amino acids/divalent cation, polyprenol phosphate, mannose and protein 





5.5.1 Overview of key findings 
In the study conducted by Howlett et al., (2018a) both the S. coelicolor pmt –  strains DT1025 and 
DT2008 had mildly increased susceptibilities to β-lactams and vancomycin. These increases in 
susceptibility were not as extreme as those obtained for ppm1 –, manB –  or manC –  strains, 
however the growth retarded phenotypes and ΦC31 cΔ25 phage resistance phenotypes were 
consistent across all strains (Howlett et al., 2018b; Wehmeier et al., 2009; Cowlishaw and Smith 
2001; Cowlishaw and Smith 2002). Based on the severity of the ppm1 - phenotype (for antibiotic 
susceptibility), it was considered a more appealing target for novel antimicrobials to be used in 
conjunction with the existing arsenal of antibiotics. Following the Ppm1 mutant analysis 
described in Chapter 4, the next logical step was to carry out a site directed mutagenesis study 
of Pmt. The majority of published mutagenesis data in the literature concerns the catalytically 
conserved DE motif, a hallmark of the GT-C family of glycosyl transferases (Lairson et al., 2008). 
In this study six critical residues for Pmt function were identified, the majority of these have not 
been previously mutagenised in a protein O-mannosyl transferase. Roles for these critical 
residues have been defined and several have been further supported by the recently published 
structures of GT-C fold glycosyl transferases including C. metallidurans ArnT (PDB: 5F15) and 
the S. cerevisiae Pmt1-Pmt2 complex (PDB: 6P25) (Petrou et al., 2016; Bai et al., 2019). The 
structure of the S. cerevisiae Pmt1-Pmt2 complex represents a significant breakthrough in our 
understanding of glycosyl transferases. Its structure was published following the conclusion of 
the work described in this Chapter.  
Using literature searches and sequence alignments, 23 residues of interest were identified and 
substituted to alanine. The alleles were introduced into the pmt – S. coelicolor strains DT1025 
and DT2008. Antibiotic susceptibility testing showed that alleles encoding PmtR82A, 
PmtD113A, PmtH159A, PmtD233A, PmtK302A and PmtR510A failed to complement both pmt – 
strains. The strains therefore had increased antibiotic susceptibility to β-lactams and 
vancomycin, in addition to growth retarded phenotypes and resistance to ΦC31 cΔ25 infection. 
These observations for the non-complemented DT1025 and DT2008 strains were consistent 
with the published literature (Howlett et al., 2018a; Wehmeier et al., 2009; Cowlishaw and 
Smith 2001; Cowlishaw and Smith 2002). Furthermore, the Ppm1 mutants (D57A and G143V) 
exhibited intermediate antibiotic hyper susceptibility, indicative of partial complementation, 
more recently this phenomenon was documented in a recent glycoproteomics study (Keenan et 
al., 2019). No such partial complementation phenotypes were obtained in this Pmt studies 
presented here; DT1025 and DT2008 strains were either fully complemented and had 
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antibiotic/phage susceptibilities, in addition to colony phenotypes that resembled the J1929 
strain, or were not complemented and retained the null mutant phenotypes.  
Many of the antibiotics tested in this study were previously used by Howlett et al., (2018a) to 
characterise ppm1 – and pmt – strains. The reported mildly increased susceptibilities of pmt – 
strains to β-lactam antibiotics and vancomycin (in comparison to greatly increased 
susceptibility in ppm1 – strains) was also observed in this study for the six mutants that failed to 
complement. Where the amount of antibiotic used in this study was consistent with that used  
by Howlett et al., (2018a), the magnitude of increase in sensitivity was comparable.  The 
consistency in antibiotic sensitivities of non-complemented and complemented pmt – strains in 
this study to the values reported in previous studies (Howlett et al., 2018a; Keenan et al., 2019) 
gives greater confidence in the robustness of the antibiotic hyper susceptibility assay, and 
indicates that the phenotypes are unlikely to be either under or overestimated. As expected, the 
mildly increased susceptibilities to antibiotics for the non-complemented pmt – strains was also 
lower than those reported for ppm1 – manB – and manC – strains (Howlett et al., 2018a; Howlett 
et al., 2018b). Statistically significant increases in sensitivity to cell wall inhibitors was routinely 
observed for the non-complemented strains (relative to J1929), this combined with minimal 
variation (shown by consistently small SEM error bars) gave greater confidence in the data 
obtained.  
Interestingly, the non-complemented DT1025 and DT2008 strains did not exhibit significantly 
increased susceptibility to antibiotics targeting DNA replication or translation (relative to 
J1929). This contrasts with the mildly increased susceptibilities of non-complemented DT3017 
strains to these antibiotics, as discussed in Chapter 4. Nevertheless, significant increases in 
sensitivity to cell wall targeting antibiotics has been routinely observed for ppm1 – and pmt –  
strains and this requires further discussion. A possible explanation for the elevated 
susceptibility to antibiotics targeting the cell wall, is provided by the recent in-depth 
characterisation of the S. coelicolor membrane glycoproteome (Keenan et al., 2019). Using 
glycoproteome enrichment by lectin affinity chromatography followed by mass spectrometry, 
95 glycopeptides were characterised from 38 glycoproteins (37 of which were newly 
identified). At least seven of the 38 glycoproteins have predicted roles in cell wall biosynthesis. 
SCO4847 (D-Ala-D-Ala carboxypeptidase) and SCO4934 (L,D transpeptidase) were each 
characterised in detail and S. coelicolor knock out mutants for both genes (S. coelicolor TK006 
and TK008 respectively) were made. There was no change in colony morphology or phage 
susceptibility, the latter observation is interesting as it indicated that neither SCO4847 or 
SCO4934 acts as the ϕC31 receptor. Of greater relevance to this work, the strains show 
increased susceptibility to β-lactams. It is therefore reasonable to assume that increased 
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susceptibility to antibiotics that exploit the cell wall, is due to impaired mannosylation of crucial 
proteins involved in cell wall synthesis and integrity. The likely result of this would be increased 
susceptibility to antibiotics that exploit the cell wall as their target. As expected the six non-
complemented DT1025 strains had higher susceptibilities to imipenem, meropenem and 
ampicillin than the TK006 and TK008 strains reported in the Keenan et al., study (2019), while 
having comparable zones of clearance to the control DT1025 strain.  The disc diffusion assays 
also showed that TK006 and TK008 could be partially complemented by the reintroduction of 
WT copies of SCO4847 and SCO4934 respectively.  
Another interesting phenomenon is that unlike for the Ppm1 mutant study presented here, no 
evidence of reversion was obtained for DT1025 and DT2008 strains carrying the six non-
functional alleles. This contrasts with the Ppm1 study where the S. coelicolor spore growth 
protocol had to be shortened, in order to minimise the emergence of revertent colonies which 
eventually outgrew the non-revertent colonies that retained the critical substitution. Reversion 
of ppm1 and pmt alleles to the WT gene has been discussed in a study of vancomycin resistance 
in S. coelicolor (Read et al., 2019). In the case of DT2008, the mutation that confers the null 
mutant phenotype remains unknown and sequencing attempts to elucidate the source of the 
phenotype during this study were ultimately unsuccessful. Consequently, it is difficult to 
speculate on the presence or absence of a template based DNA repair mechanism. The mutation 
that confers the null mutant phenotype of DT1025 is however known and is due to a premature 
stop codon insertion at residue position 390. In the case of the ppm1 - strain DT3017, it was 
understood that the native locus allele could act as a template to repair the introduced 
mutation, resulting in reversion back to the J1929 parent strain phenotype. The only instance of 
this not being observed was when the introduced allele had the same mutation as the allele at 
the native site (E218V). Assuming a similar repair mechanism is in operation for DT1025, it 
would be expected that five of the six non complementing pmt alleles introduced into DT1025 
(R82A, D113A, H159A, D233A and K302A) would revert back to the WT gene, since all WT 
codons preceding codon 390 exist in the native locus pmt allele. Consequently, only R510A 
would be expected to not be susceptible to reversion by this mechanism. The same integrase 
containing plasmid pIJ10257 was used to introduce the ppm1 and pmt mutant alleles therefore 
the location of the integrated allele is also the same. Sequencing of the PCR amplified integrated 
alleles was routinely carried out to verify the presence of the expected substitution and ensure 







5.5.2 Defining the roles of the DE motif and the divalent metal  
The structure of C. metallidurans aminoarabinose transferase (ArnT) published half way 
through the work presented here was used to help define roles for the six critical residues 
identified (PmtR82, PmtD113, PmtH159, PmtD233 and PmtK302). Even though ArnT uses a 
lipid (lipid A) rather than protein as the glycosyl acceptor, it was used as the template to 
develop a homology model of S. coelicolor Pmt due to its high sequence identity and similarity 
with Pmt.  
An obvious mutagenesis target was the DE motif, a hallmark of the GT-C fold glycosyl 
transferases (Lairson et al., 2008). In this study, both DE residues were individually substituted 
to alanine in S. coelicolor Pmt. The E114A mutant fully complemented the pmt- strains DT1025 
and DT2008 but the D113A mutant did not. As previously mentioned, the majority of residue 
substitutions reported in the literature concern this motif and therefore requires a thorough 
discussion. In a recent paper, the DE motif in S. cerevisiae was targeted for mutation and 
interestingly, when D77 and E78 were substituted to alanine individually there were negligible 
differences in in vivo glycosylation, indicating that other Pmt complexes could be compensating 
(Lommel et al., 2011). Indeed, the existence of eukaryotic Pmt complexes in the literature is well 
documented (Lommel et al., 2011). In vitro glycosylation was hampered when E78 was 
substituted to alanine with more modest effects observed for D77 however, when both residues 
were substituted together, in vivo glycosylation was notably reduced (though not eliminated) 
and in vitro there was no detectable mannosyl transferase activity (Lommel et al., 2011). It was 
also noted that DE motif substitutions did not prevent or reduce Pmt1p-Pmt2p heteromeric 
complex formation. These results can be compared with data on single residue substitution 
mutants in the DE motif of M. tuberculosis Pmt (VanderVen et al., 2005). Here, the DE-AE 
substitution decreased activity to a  much greater extent than DE-DA and interestingly, the DE-
AA substitution failed to completely abolish catalytic activity in contrast to the findings for S. 
cerevisiae pmt1p (Lommel et al., 2011; VanderVen et al., 2005). Nevertheless, both studies point 
to the importance of the DE motif in catalysis.  In another important paper, E78 in S. cerevisiae 
Pmt1p was substituted with alanine and catalytic activity was dramatically reduced in vitro, 
indicating an essential role in transferase activity (Girrbach et al., 2000). The results obtained 
here support the idea that the aspartate in the DE motif likely has a critical role in catalysis, 
while the glutamate is not critical (VanderVen et al., 2005). It is not clear why the DE motif 
glutamate appears to have a more critical role than the aspartate for S. cerevisiae Pmt activity. 
Another possible explanation for the ability of E114A to complement both DT1025 and DT2008, 
is simply a consequence of the antibiotic susceptibility phenotype being less severe than that 
obtained for ppm1 –, manB –, and manC – (Howlett et al., 2018a; Howlett et al., 2018b). Due to 
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this less severe increase, it may be that the antibiotic sensitivity assay is not sensitive enough to 
detect a partial complementation phenotype, which would presumably arise from a partially 
active mutant as described in vitro by VanderVen et al., (2005) and in vivo by Keenan et al., 
(2019). C. metallidurans D57 (S. coelicolor D113) was mutated in the study and a polymyxin B 
growth assay was used to monitor the in vivo consequences of mutation, a lack of lipid A 
glycosylation due to substitution of a critical residue would correlate with susceptibility to 
polymyxin. While the glutamate in the DE motif was not targeted for substitution, activity was 
eliminated following substitution of the aspartate by alanine (or even the conservative 
substitution to glutamate), indicating that strict conservation is necessary to maintain function. 
In the ArnT structure the aspartate is involved in coordinating the acceptor phosphate of lipid A. 
Based on this observation, we have hypothesised that D113 interacts with and activates the 
nucleophilic hydroxyl group of a serine or threonine on the acceptor protein, for attack on the 
C1 carbon of the mannose of the polyprenol phosphate mannose donor.  
Since a divalent metal cation is known to be important for activity in Pmt family enzymes from 
yeast and the prokaryotes, we propose that the divalent cation also has an important role in S. 
coelicolor Pmt catalysis, where it will be retained within the active site. This contrasts with C. 
metallidurans where the divalent metal cation is released from the active site to make the lipid A 
cavity accessible for donor substrate binding. Clues to the role of the divalent cation in S. 
coelicolor Pmt are provided by other structures. In the recently published structure of the 
Campylobacter lari oligosaccharyltransferase PglB (Napiorkowska et al., 2018) which carries 
out N-glycosylation, it was suggested that the divalent metal ion is stabilises the pyrophosphate 
leaving group of the donor substrate. The divalent metal cation in Pmt could perform the same 
function and stabilise the phosphate head group of polyprenol phosphate before and after 
mannose transfer. D113 may therefore have an additional role in coordinating the metal ion so 
it remains in position to interact with the donor phosphate, though we have not defined this 
role in our mechanistic model. 
Interestingly, in ArnT H267 (S. coelicolor H410), H265 (H408) and E85 (not conserved in S. 
coelicolor) are each critical for activity and important for coordinating a divalent cation (Zn2+), 
which fixes a loop in position and consequently opens up the binding cavity for the donor 
substrate (Petrou et al., 2016). H410 was mutated in our study but fully complemented both 
DT1025 and DT2008 without issue. The position of H410 in the S. coelicolor Pmt model is 
consistent with a role in divalent cation binding. The failure of this substitution to adversely 
impact Pmt activity could simply be due to one or more nearby residues compensating for the 
loss of H410. 
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S. coelicolor D113 (as part of the DE motif) was previously considered to constitute the acceptor 
binding site and would specifically activate the hydroxyl of a serine or threonine. The 
homologous residue in S. cerevisiae Pmt1 (D77) is proposed to function in the same way, based 
on its close proximity to the nucleophilic threonine on the peptide acceptor. Interestingly, in the 
Pmt1-Pmt2 structure, E78 (in the DE motif) forms a salt bridge with R138, this interaction is 
thought to direct D77 towards the acceptor residue. R138 is not conserved in S. coelicolor Pmt 
suggesting either that another nearby arginine forms a salt bridge with E114, or based on the 
activity of E114A mutants in vivo, there is an alternate mechanism by which D113 is orientated 
towards the acceptor serine/threonine in S. coelicolor Pmt that does not involve the DE motif 
glutamate. While the structure of S. cerevisiae Pmt1-Pmt2 has not clarified the role of the 
glutamate in the DE motif, it has supported the hypothesis that the aspartate plays a critical role 
in activating a serine/threonine nucleophile in the S. coelicolor Pmt catalysed reaction.  
5.5.3 Defining the roles of H159, D233, K302 and R510 
As well as D55 (D113), another aspartate (D158) in the C. metallidurans ArnT was critical for 
coordinating the phosphate head group of lipid A. This aspartate is not however conserved in S. 
coelicolor Pmt. In this study D233 in S. coelicolor Pmt residue was shown to play an important 
role. According to the homology model, D233 may well perform in S. coelicolor Pmt, the same 
role as D158 in C. metallidurans Pmt. Therefore, D233 may directly (or indirectly via the 
divalent cation) fix the phosphate in place so the bond between mannose and the phosphate in 
appropriate position for attack by a nucleophilic serine or threonine on the acceptor protein.  
The C. metallidurans ArnT structure was also used to help define a role for K302. The 
corresponding residue in ArnT forms a salt bridge with D158 and likely has a role in helping to 
delocalise the charge on the aspartate (Petrou et al., 2016). In our mechanistic model we 
suggest S. coelicolor K302 forms a salt bridge with D233, based on it’s position in the homology 
model. 
It has proved difficult to propose a role for R510 in S. coelicolor Pmt based on the homology 
model, since it points away from the active site.  Arginine (R58) in ArnT plays a similar role to 
K203 in C. metallidurans ArnT in charge delocalisation, however this residue is not conserved 
(Petrou et al., 2016). Alternatively, the homology model of S. coelicolor Pmt may be misleading 
and instead of pointing away from active site, R510 may point inwards to contribute to the 
reaction chemistry. 
The critical S. coelicolor Pmt residue H159 corresponds to K85 in C. metallidurans ArnT. When 
this residue is substituted to alanine, activity is completely eliminated (Petrou et al., 2016). K85 
is well positioned in ArnT to interact with the phosphate group of undecaprenyl phosphate. 
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Based on this observation, we propose a role for H116 in binding the phosphate of polyprenol 
phosphate in S. coelicolor Pmt.  
Finally, R82 was identified as a critical residue in this study. There is no data concerning 
mutation of homologous residues in GT-C family enzymes. Out the six critical residues identified 
in this study, R82 alone is not located in the periplasmic globular domain. Instead it is located 
on the cytosolic face of the membrane. It may be involved in binding polyprenol phosphate 
mannose or flipping the donor substrate across the membrane, although this is purely 
speculative.  
For C. metallidurans ArnT, a number of mutations were made to explore the role of hydrophobic 
residues that line the undecaprenyl amino arabinose binding pocket. None of these 
substitutions affected ArnT activity and the residues are not conserved in bacterial Pmts. In our 
study we substituted multiple hydrophobic residues conserved across Pmts in the 
prokaryotic/eukaryotic kingdoms including W400, L231, P393 to alanine. Based on the docking 
of the template derived undecaprenyl phosphate onto the S. coelicolor Pmt model, these 
residues are suitably positioned to engage in hydrophobic contacts with the donor. None of the 
substitutions yielded a non-complementing allele. This is not necessarily surprising, since 
multiple residues would be expected to form hydrophobic contacts with the isoprenoid chain of 
polyprenol phosphate. Consequently, multiple mutations would presumably have to be made 
simultaneously for deleterious effects on donor binding to be observed.  
In the Girrbach study (2000) several additional S. cerevisiae Pmt1p residues were substituted to 
alanine including R64, R138 and L408. All three residues were shown to be essential for activity. 
Furthermore, R138 was also shown to be essential for Pmt1p-Pmt2p dimerisation. S. coelicolor 
Pmt R182 (S. cerevisiae Pmt1p R138) was substituted to alanine in the present study and the 
mutant was active and complemented both DT1025 and DT2008. In the S. coelicolor Pmt 
homology model, R182 forms a putative salt bridge to E114 indicating that as in S. cerevisiae 
Pmt1 (REF), an ionic interaction may play a critical role in orientating the DE motif in S. 
coelicolor Pmt. However, the activity of the R182A mutant indicates that either this interaction 
does not take place, or is not important for activity of the enzyme.  
5.5.4 Building an improved homology model for S. coelicolor Pmt 
Recently and following the completion of this work, the first structure of a Pmt complex was 
published (Bai et al., 2019). The S. cerevisiae Pmt1-Pmt2 complex was therefore used as a 
template to build a new model of S. coelicolor Pmt (Figure 5.21). It was hoped that by using a 
new template a more reliable model could be built allowing a more complete interpretation of 
the mutagenesis data.  The new homology model consisted of 547 residues (92 %) modelled at 
144 
 
>90% confidence, compared with 477 residues (80 %) modelled at >90 % confidence for the 
previous model.  
In the previous model, 8 of 11 predicted transmembrane helices corresponded to the TMHMM 
predictions, helices 3, 7 and 10 however deviated from the plot. The modelling of helix 3 is 
separated into two smaller helices, while for helices 7 and 10, roughly ½ and ⅔ of the residues 
were not modelled respectively. Interestingly, in the new model, helix 3 is again split into two 
smaller helices (3a and 3b), this helix 3 topology is seen in the structures of both C. 
metallidurans ArnT and S. cerevisiae Pmt1-Pmt2 and could be a hallmark of GT-C fold glycosyl 
transferases. Importantly, in the new model all residues predicted to constitute helices 7 and 10 
are fully modelled. The resulting longer helices cover a greater portion of the predicted 
transmembrane space. Furthermore, helix 8 is orientated parallel to the other membrane 
spanning helices.     
When considering the positions of residues substituted in the present work, the previous 
homology model had a number of shortfalls. In total 18 out of 23 residues were modelled, with 
positions that were in full agreement with the TMHMM plot. Of the remaining five residues, 
three (R201, P393 and W426) were modelled but their positions deviated from the TMHMM 
plot, while large stretches of the N and C termini, which included the residues R82 and F564 
respectively, were not modelled at all. In the new model R82 and F564 have been modelled and 
their positions are in agreement with the TMHMM profile. In the new model, the positions of 
residues R201, P393 and W426 are consistent with the TMHMM profile. In the previous model 
P393 and W426 occupied the periplasmic poles of the connecting transmembrane spanning 
helices 7 and 8 respectively, while in the new model both residues occupy periplasmic loop 
domain 7. Finally, in the previous model, R201 was located on the membrane boundary 
separating the cytoplasmic pole of helix 2 and loop 3. R201 in the later model is in loop 3. 
A clear difference between the old and new models is that in the latter, R510 is clearly 
orientated towards critical residues in the predicted active site. When considering the Pmt1-
Pmt2 complex, R649 (S. coelicolor R510), it is orientated towards the phosphate of the donor 
substrate and can therefore be assumed to be a dolichol phosphate mannose binding residue. 
Based on the orientation of R510 in the new homology model and the known interaction of the 
homologous R649 with the donor substrate, we can revise the role of R510, the biochemical 
model has now been amended (Figures 5.22, 5.23) to reflect the more likely interaction of R510 














































































Figure 5.21: Phyre2 homology models of S. coelicolor Pmt have typical facets of GT-C fold 
glycosyl transferases. (A) Homology model of S. coelicolor Pmt based on the template ArnT 
(5F15) from C. metallidurans. 477 residues (80 %) were modelled at >90 % confidence (B) 
Homology model of S. coelicolor Pmt based on the template Pmt1-Pmt2 (6P25) from S. 
cerevisiae. 547 residues  (92 %) were modelled at >90 % confidence. Worm and tube model 
coloured according to rainbow format, going from blue (N-terminus) to red (C-terminus) with 










































Figure 5.22: S. coelicolor Pmt homology model exhibits typical facets of GT-C fold glycosyl 
transferase. (A) Homology model of S. coelicolor Pmt based on the template ArnT (5F15) from 
C. metallidurans. (B) Homology model of S. coelicolor Pmt based on the template Pmt1-Pmt2 
(6P25) from S. cerevisiae. All residues targeted for mutation are represented as cylinders and 
coloured according to their type: amide (light blue), basic (dark blue) and acidic (red). The 
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Figure 5.23: Proposed mechanism of Pmt action, an inverting glycosyl transferase that 
utilises a single step SN2 mechanism. (A) Initial model: R510 binds the mannose acceptor 





Chapter 6 – Pmt localisation studies and mutant library expansion 
 
In the previous chapter, six pmt alleles were identified encoding PmtR82A, PmtD113A, 
PmtH159A, PmtD233A, PmtK302A and PmtR510A that failed to complement the pmt – strains 
DT1025 and DT2008. To better understand the role of these critical residues, further 
characterisation was necessary. Since Pmt is an integral membrane protein, it was thought that 
some of the critical residues identified could have a role in targeting the protein to the 
membrane. Tagging the six mutants would therefore provide the opportunity to do western 
blotting to check for the presence of Pmt in purified membrane fractions. 
In addition, making conservative and semi-conservative mutations in the aforementioned six 
residues would enable an understanding of whether strict conservation was necessary to 
preserve function. These six residues are very tightly conserved across the prokaryotic and 
eukaryotic kingdoms, strongly indicating that even subtle changes in physicochemical 
properties would not be well accommodated. 
 
The aim of this chapter was to probe Pmt mutant localisation and expand the mutant library, 
with the following objectives: 
1. Add Strep II tags to either the N or C-termini of mutant Pmt and use Western blotting to 
determine the presence and abundance of Pmt variants in purified membrane fractions 
2. Make a small library of conservative and semi-conservative Pmt substitutions to 















6.1 Western blotting to probe enzyme localisation  
Six mutant alleles encoding PmtR82A, PmtD113A, PmtH159A, PmtD233A, PmtK302A and 
PmtR510A were identified in Chapter 5 that failed to complement the pmt – strains DT1025 and 
DT2008. With the exception of D113 (which has been substituted in multiple Pmt homologues), 
the roles of these critical residues were not well understood. Western blotting presented an 
opportunity to determine whether the mutant enzymes encoded by these non-complementing 
alleles, were present or absent from the membrane. Absence would suggest the targeted residue 
was directly involved in membrane localisation, or was critical for the maintenance of stability 
or correct protein folding.  
PCR was used to add the eight residue Strep II tag (WSHPQFEK) to either the N or C-terminus of 
the six non-complementing pmt mutant alleles. Upon addition of the tag, the alleles were cloned 
into the integrative plasmid pIJ10257 using Infusion. Following conjugal transfer of 
recombinant plasmids via E. coli ET12567 (pUZ8002), mutant alleles were introduced into the 
chromosomes of the pmt – strains DT1025 and DT2008 by conjugation and spores of 
exconjugants were harvested. Phage susceptibility testing was first carried out and as expected, 
ΦC31 cΔ25 was unable to plaque on DT1025 (Table 6.1) and DT2008 (Table A8.5) strains 
containing each of the six non-complementing alleles. Strains that had received the wild type 
(WT) allele with either an N or C-terminal Strep II tag were susceptible to infection, with the 
phage titres within the same order of magnitude as their non-tagged counterparts. This 
confirmed that the presence and position of the Strep II tag does not interfere with the ability of 
a pmt allele to complement either minus strain. 
The strains were then grown in liquid culture, the cells were lysed and membrane fractions 
obtained. Following separation of proteins by SDS-PAGE, transfer to a PVDF membrane and 
subsequent wash steps, an anti-Strep II tag antibody was used to probe for the presence of Pmt 
in the membrane fractions by Western blotting. No signal corresponding to the six inactive Pmt 
variants was obtained in soluble or membrane fractions in DT1025 (Figure 6.1) and DT2008 
(Figure A8.6). The WT positive control alone yielded a signal at (~55 kDa), this compares with 
the theoretical molecular weight (MW) of (~66 kDa) for Strep II tagged Pmt. This discrepancy 
while unexpected, was reproducible. The empty plasmid (pIJ10257) negative control possessed 
no signal, strongly indicating that the signal obtained from the positive control was the Strep II 































 C-terminal Strep Tag II N-terminal Strep Tag II 
Strain Titre (PFU/ml) Titre (PFU/ml) 
DT1025 
DT1025 + WT 
DT1025 + R82A 
DT1025 + D113A 
DT1025 + H159A  
DT1025 + D233A 
DT1025 + K302A 
DT1025 + R510A 
< 1 x 102 
(3.47 ± 0.37) x 108 
< 1 x 102 
< 1 x 102 
< 1 x 102 
< 1 x 102 
< 1 x 102 
 < 1 x 102 
< 1 x 102 
(2.03 ± 0.19) x 108 
< 1 x 102 
< 1 x 102 
< 1 x 102 
< 1 x 102 
< 1 x 102 
 < 1 x 102 
   
Table 6.1: Presence of the Strep Tag II on either termini does not affect the ability of pmt 
alleles to complement DT1025. ΦC31 cΔ25 phage were plated out on DN agar and then SN 
agar containing spores was added to the top with the plates incubated at 30 °C for 18 hours. 
The average titre is shown ± SEM from 4 biological replicates. 0.1 ml of a 10-6 phage stock 
dilution was used to obtain countable plaques for phage sensitive strains.  Strains that showed 
no plaques at the lowest phage stock dilution tested (10-1) are represented as having a PFU/ml 
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Figure 6.1: C-terminal Strep II tagged non-complementing Pmt variants are absent in 
DT1025 membrane fractions. Membrane and soluble fraction samples were first loaded onto a 
12 % SDS-PAGE gel which was run and stained to ensure protein concentrations of samples were 
consistent.  After transfer of proteins from an SDS-PAGE gel to a PVDF membrane and 
subsequent wash steps, the membrane was incubated with Strep Tag II Antibody HRP Conjugate, 
substrate added and X-ray film developed. pIJ refers to the empty pIJ10257control and WT to the 
pmt WT complemented strain control. 
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Fractions taken at the three steps preceding the final 100,000 x g spin in the differential 
centrifugation protocol (i. Sonication, ii. 5,000 x g spin and iii. 15,000 x g spin) failed to yield any 
detectable signal by Western blotting (data not shown). To investigate further, genomic DNA 
from the DT1025 strains was purified and pmt at the integration and native loci (including 100 
bp up and downstream) were amplified by PCR. Sequencing the PCR products showed no 
unexpected changes in the DNA sequence that could explain the lack of signal for the six 
mutants (data not shown). The absence of detectable signal in the membrane fractions for the 
non-complementing alleles indicates an activity localisation relationship, whereby only 
functional Pmt will correctly localise to the membrane.  
The absence of signal corresponding to any of the six Pmt variants in purified membrane 
fractions was unexpected, however the positive and negative controls consistently yielded 
signal presence and absence respectively. The decision was subsequently made to add Strep II 
tags to mutant alleles that were previously shown to complement DT1025 and DT2008. In this 
case, it would be expected that signal comparable in both intensity and position to the WT, 
would be observed in purified membrane fractions isolated from strains expressing a functional 
Strep II tagged Pmt. Of the 17 candidates available, six alleles were chosen encoding: PmtP160A, 
PmtK164A, PmtR228A, PmtL231A, PmtR335A and PmtS421A. As with the non-complementing 
alleles, Strep II tags were added using PCR and Infusion cloning. In the interest of time, the Strep 
II tag was only added to the C-terminus, since it was already known that the position of the tag 
had no effect on in vivo activity of the WT. The C-terminus was chosen since this is predicted to 
face the periplasm, while the N-terminus is predicted to be intracellular. The recombinant 
plasmids were introduced into DT1025 (Table 6.2) and DT2008 (Table A8.5) via pIJ10257. 
Phage susceptibility testing showed that all strains were vulnerable to phage infection. The 
titres were in the same order of magnitude as their non-tagged counterparts as in chapter 5, in 
addition to the positive control. Again, the position of the tag was of no consequence.  
Membrane fractions were purified as described above.  Signal corresponding to active Pmt 
variants (tagged at either termini) were indeed present in the membrane fractions and absent 
from the soluble fractions in DT1025 (Figure 6.2) and DT2008 (Figure A8.7). The signal 
obtained in the western blot is at the same MW as the WT positive control, roughly half way 
between the 50 and 60 kDa reference bands. It is noteworthy that for the WT positive control 
and active variants, a protein band corresponding to this signal could not be clearly identified in 
the SDS-PAGE, indicating that the ermE* promoter, while constitutive, does not drive clearly 
visible, over expression of the integrated pmt gene, which is expected.  
A selection of strains individually expressing 4 active and 4 inactive Pmt variants were chosen 
to demonstrate that mutant Pmt localisation (or lack of) could be identified on the same blot 
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(figure 6.3). As before, active mutants could be detected in membrane fractions while inactive 
mutants could not. 
From the data obtained, there is clearly a strict activity localisation relationship. It was hoped 
that at least a few of the variants encoded by these non-complementing alleles would be present 
in the membrane fractions. This would have then allowed biochemical characterisation by, for 
example, incubating the membranes with peptide glycosylation substrates and monitoring the 
outcome of glycosylation using mass spectrometry or thin layer chromatography. The absence 
of all six inactive variants in membrane fractions however prevented sensible progression to 
biochemical characterisation. While active Pmt variants were indeed present in purified 
membrane fractions, there would be little merit in the biochemical characterisation of these 
active enzymes, since their activity would not be expected to significantly deviate from that of 



































 C-terminal Strep Tag II N-terminal Strep Tag II 
Strain Titre (PFU/ml) Titre (PFU/ml) 
DT1025  
DT1025 + WT 
DT1025 + P160A 
DT1025 + K164A 
DT1025 + R228A 
DT1025 + L231A 
DT1025 + R335A 
DT1025 + S421A 
< 1 x 102 
(3.47 ± 0.37) x 108 
(2.52 ± 0.32) x 108 
(2.79 ± 0.19) x 108 
(2.18 ± 0.13) x 108 
(3.20 ± 0.23) x 108 
(4.10 ± 0.23) x 108 
(2.68 ±0.18) x 108 
< 1 x 102 
(2.03 ± 0.19) x 108 
(2.50 ± 0.26) x 108 
(4.05 ± 0.23) x 108 
(3.10 ± 0.25) x 108 
(2.43 ± 0.17) x 108 
(2.71 ± 0.76) x 108 
(2.35 ± 0.31) x 108 
   
Table 6.2: Presence of the Strep Tag II on either termini does not affect the ability of 
pmt alleles to complement DT1025. ΦC31 cΔ25 phage were plated out on DN agar and 
then SN agar containing spores was added to the top with the plates incubated at 30 °C for 
18 hours. The average titre is shown ± SEM from 4 biological replicates. 0.1 ml of a 10-6 
phage stock dilution was used to obtain countable plaques for phage sensitive strains.  
Strains that showed no plaques at the lowest phage stock dilution tested (10-1) are 



































70 kDa - 
60 kDa - 
40 kDa - 
30 kDa - 
50 kDa - 
70 kDa - 
60 kDa - 
40 kDa - 
50 kDa - 
30 kDa - 
Figure 6.2: C-terminal Strep II tagged complementing Pmt variants are present in DT1025 
membrane fractions. Membrane and soluble fraction samples were first loaded onto a 12 % 
SDS-PAGE gel which was run and stained to ensure protein concentrations of samples were 
consistent.  After transfer of proteins from an SDS-PAGE gel to a PVDF membrane and 
subsequent wash steps, the membrane was incubated with Strep Tag II Antibody HRP Conjugate, 
substrate added and X-ray film developed. pIJ refers to the empty pIJ10257 control and WT to 

































Figure 6.3: C-terminal Strep II tagged complementing and non-complementing variants 
were present and absent respectively in DT1025 membrane fractions. Membrane fraction 
samples were first loaded onto a 12 % SDS-PAGE gel which was run and stained to ensure 
protein concentrations of samples were consistent.  After transfer of proteins from an SDS-PAGE 
gel to a PVDF membrane and subsequent wash steps, the membrane was incubated with Strep 
Tag II Antibody HRP Conjugate, substrate added and X-ray film developed. pIJ refers to the 
empty pIJ10257control and WT to the pmt WT complemented strain control. 
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6.2 Expansion of the pmt mutant library   
All mutations hitherto described were simple substitutions to alanine. The previous western 
blotting data showed that for these alanine substitutions, variants encoded by complementing 
and non-complementing alleles were present and absent from the membrane respectively.  The 
next step was to create a smaller library of conservative and semi-conservative mutations. With 
this library, the goal was to identify a strain with an intermediate phenotype. With such a 
phenotype, the variant would still localise to the membrane fractions, however the activity 
would be diminished compared to the WT, which would then justify further biochemical 
characterisation.  
All six critical residues were subject to both conservative and semi-conservative substitutions. 
In addition D113 (due to it being well characterised in the literature) was subject to additional 
non-conservative mutations for comparison. To summarise, R82 was mutated to lysine and 
histidine, H159 to lysine and asparagine, D233 to glutamate and asparagine, K332 to histidine 
and arginine, R510 to histidine and lysine and finally D113 was mutated to glutamate, leucine, 
asparagine, proline, arginine serine and tyrosine. As previously described, these mutant alleles 
were all cloned into pIJ10257.  
In the interest of time, the alleles were introduced into one pmt – strain (DT1025). Since there 
had previously not been any difference in phenotypes obtained between complemented and 
non-complemented DT1025 and DT2008 strains. DT1025 was chosen since the mutation that 
confers the minus phenotype is known, enabling sequencing of the native locus as necessary. 
The mutant alleles were introduced into DT1025 as described previously. Since these mutations 
were novel, they were first tested by phage infection assays (Table 6.3). For the phage assays, 
three out of the 17 strains had received complementing alleles encoding PmtR82K, PmtD113N 
and D233E and were therefore susceptible to infection by phage, with a comparable order of 
magnitude to the WT. The remaining 14 alleles failed to complement DT1025. Regarding the 
three active mutants, D233E and R82K were conservative substitutions while D113N was semi-
conservative. Admittedly, the failure of the conservative D113E substitution to complement, in 


































Strain Titre (PFU/ml) 
DT1025 
DT1025 + WT 
DT1025 + R82H 
DT1025 + R82K 
DT1025 + D113E 
DT1025 + D113L 
DT1025 + D113N 
DT1025 + D113P 
DT1025 + D113R 
DT1025 + D113S 
DT1025 + D113Y 
DT1025 + H159K 
DT1025 + H159N 
DT1025 + D233E 
DT1025 + D233N 
DT1025 + K332H 
DT1025 + K332R 
DT1025 + R510H 
DT1025 + R510K 
< 1 x 102 
(2.20 ± 0.69) x 108 
< 1 x 102 
(2.46 ± 0.77) x 108  
< 1 x 102 
< 1 x 102 
(1.47 ± 0.82) x 108  
< 1 x 102 
< 1 x 102 
< 1 x 102 
< 1 x 102 
< 1 x 102 
< 1 x 102 
(1.94 ± 1.14) x 108  
< 1 x 102 
< 1 x 102 
< 1 x 102 
< 1 x 102 
< 1 x 102 
  
Table 6.3:  The majority of conservative and semi conservative substitutions yielded pmt 
alleles that were unable to complement DT1025.  ΦC31 cΔ25 phage were plated out on DN 
agar and then SN agar containing spores was added to the top with the plates incubated at 30 
°C for 18 hours. The average titre is shown ± SEM from 4 biological replicates. 0.1 ml of a 10-6 
phage stock dilution was used to obtain countable plaques for phage sensitive strains.  Strains 
that showed no plaques at the lowest phage stock dilution tested (10-1) are represented as 
having a PFU/ml < 1x 102. 
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Antibiotic susceptibility tests were then carried out to see if an intermediate phenotype could 
be obtained (Figure 6.4). A limited selection of antibiotics was chosen: ampicillin, vancomycin, 
imipenem and meropenem. The selection was based on these antibiotics giving the biggest 
difference in zone of clearance diameter between complemented and non-complemented 
strains. In previous assays, DT1025 expressing one of three previously identified active mutants 
(R82K, D113N, D233E) showed no increased sensitivity to the antibiotics (at the concentrations 
tested) compared to the WT complemented strain. The remaining 14 non-complemented strains 
had notably increased susceptibility, comparable to the empty plasmid negative control, with 
zone of inhibition diameters ≥15 mm. The most effective antibiotic for exploiting the antibiotic 
susceptibility phenotype was imipenem, with zones of clearance diameters ≥20 mm. Similarly to 
the data obtained in chapter 5 for the alanine mutants, there were no intermediate phenotypes, 
all strains resembled either the positive or negative control.  
While no evidence of an intermediate phenotype was obtained in the antibiotic and phage 
assays, it was necessary to confirm this with western blotting. As before, the strains were grown 
in liquid culture, the cells lysed and membrane fractions purified. When Strep II tag recognising 
antibodies were added to the membrane fractions, signal at the expected MW was observed 
only for membrane fractions from strains complemented with alleles encoding PmtR82K, 
PmtD113N and PmtD233E (Figure 6.5). This is consistent with previous data which showed a 
positive correlation between active mutants and presence in the membrane. The membrane 
fractions from remaining non-complemented strains showed no comparable signal. Not one 
conservative or semi-conservative substitution gave the desired intermediate phenotype. As 
with the alanine mutants descried previously, Western blotting of samples from stages 
preceding the 100,000 x g spin (i. sonication, ii. 5,000 x g spin and iii. 15,000 x g spin) , gave 
comparable western blotting results. Furthermore, sequencing analysis confirmed no 
unexpected changes in pmt alleles at the integration or native loci. Expansion of the mutant 
library to include conservative and semi-conservative substitutions therefore failed to break the 
strict activity localisation relationship. This strengthened the hypothesis that activity and 
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Figure 6.5a:  C-terminal Strep II tagged non-complementing Pmt variants are absent in 
DT1025 membrane fractions. Membrane and soluble fraction samples were first loaded onto 
a 12 % SDS-PAGE gel which was run and stained to ensure protein concentrations of samples 
were consistent.  After transfer of proteins from an SDS-PAGE gel to a PVDF membrane and 
subsequent wash steps, the membrane was incubated with Strep Tag II Antibody HRP 
Conjugate, substrate added and X-ray film developed. pIJ refers to the empty pIJ10257control 
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Figure 6.5b: C-terminal Strep II tagged non-complementing Pmt variants are absent in 
DT1025 membrane fractions. Membrane and soluble fraction samples were first loaded onto 
a 12 % SDS-PAGE gel which was run and stained to ensure protein concentrations of samples 
were consistent.  After transfer of proteins from an SDS-PAGE gel to a PVDF membrane and 
subsequent wash steps, the membrane was incubated with Strep Tag II Antibody HRP 
Conjugate, substrate added and X-ray film developed. pIJ refers to the empty pIJ10257control 
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Figure 6.5c: C-terminal Strep II tagged non-complementing Pmt variants are absent in 
DT1025 membrane fractions. Membrane and soluble fraction samples were first loaded 
onto a 12 % SDS-PAGE gel which was run and stained to ensure protein concentrations of 
samples were consistent.  After transfer of proteins from an SDS-PAGE gel to a PVDF 
membrane and subsequent wash steps, the membrane was incubated with Strep Tag II 
Antibody HRP Conjugate, substrate added and X-ray film developed. pIJ refers to the empty 




In chapter 5, six critical residues for Pmt function were identified: PmtR82, PmtD113, PmtH159, 
PmtD233, PmtK302 and PmtR510. Substitution of these residues to alanine yielded mutant 
alleles that failed to complement the S. coelicolor pmt – strains (DT1025 and DT2008). The 
strains therefore had increased antibiotic susceptibility to β-lactams and vancomycin, in 
addition to growth retarded phenotypes and resistance to ΦC31 cΔ25 infection. These 
observations for the non-complemented DT1025 and DT2008 were consistent with previously 
published literature (Howlett et al., 2018a; Wehmeier et al., 2009; Cowlishaw and Smith 2001; 
Cowlishaw and Smith 2002). 
The next step was to ascertain why these six residues were critical for function. Strep II tags 
were added to these non-complementing mutants and they were introduced into DT1025 and 
DT2008. Following purification of membrane fractions from these strains, western blotting 
analysis showed a lack of signal at the expected MW, in contrast the WT positive control alone 
yielded a clear signal at ~55 kDa, admittedly lower than the theoretical MW of (~66 kDa) for 
Strep II tagged Pmt. Encouragingly, no signal was detected for the empty plasmid (pIJ10257) 
negative control. Strep II tags were later added to a set of active variants: PmtP160A, 
PmtK164A, PmtR228A, PmtL231A, PmtR335A and PmtS421A. Signal was detected in the 
membrane fractions for all six of these variants and as before, the signal was again lower (55 
kDa). It should be stressed that when preparing the protein samples for SDS PAGE, instead of a 
standard 10 minute boiling step at 80 °C following β-mercaptoethanol addition, the protein 
samples were left in a 30 °C water bath for one hour (H). A boiling step was avoided to stop the 
proteins aggregating and consequently failing to enter the gel correctly (Sagne et al., 1996; Lee 
et al., 2005). It is possible that the 30 °C incubation, combined with the addition of SDS and β-
mercaptoethanol was not sufficient to fully denature the protein. In this case mobility would 
likely not be proportional to the MW.  
A possible explanation for the lack of signal in the membrane fractions of the non-
complementing mutants is that substitution of these critical residues yielded aggregation prone, 
aberrantly folded proteins. These proteins may be subject to clearance by the cell. Prokaryotes 
possess cellular molecular machinery to combat misfolding and aggregation termed the 
proteostasis network (Becker et al., 2016). Aggregation prone Pmt that cannot be refolded by 
chaperones, would be degraded by intracellular proteases. In eukaryotes and archaea 
proteasomes mediate intracellular protein degradation. While only certain orders of bacteria 
have proteasomes, a greater dependency on proteases is therefore observed in prokaryotes, 
FtsH is a particularly interesting protease as it has substrates which are misfolded membrane 
proteins (Becker et al., 2016). Bacterial proteasomes were first studied in actinobacteria such as 
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M. tuberculosis and S. coelicolor (Nagy et al., 1998; Lin et al., 2016). Aggregation can be driven by 
non-physiologically relevant levels of protein expression. We used integrase containing 
plasmids (pIJ10257) in this study to stably introduce the Strep II tagged alleles into the host 
genome with expression of the pmt genes under the control of the constitutive ermE* promoter. 
If a variant protein has a propensity for aggregation due to changes to its 3D conformation 
arising from a single residue substitution, this could be exacerbated by high levels of expression 
which could overwhelm the proteostasis network. Rather than the chaperones refolding the 
aggregation prone proteins, the latter are instead degraded by proteases to prevent a 
potentially toxic build-up of aggregates. 
It should be pointed out that no evidence of overexpression of the pmt alleles was seen in SDS-
PAGE. Other constitutive promoters drive higher levels of expression in S. coelicolor such as 
Psco5768, which increases the expression of GFP threefold compared to ermE*(Li et al., 2015). 
In contrast Psco4508 yields two-fold lower levels of expression. It is unlikely that the ermE* 
promoter is driving non-physiologically relevant levels of expression since this would 
presumably lead to an observable fitness cost in the complemented strains. The phenotype 
therefore would be expected to have deviated from that of the S. coelicolor J1929 parent strain. 
Results in Chapter 5 however showed full consistency between the phenotypes of the 
complemented strains and the J1929 parent strain. Furthermore, reproducible signal at the 
same MW was consistently obtained for all complemented strains. Based on these observations, 
it is unlikely that placing the gene under the control of a different promoter would have yielded 
a different result.  
Assuming these proteins are stable but not targeted to the membrane, their presence in either 
the soluble fraction or one of the earlier steps in the differential centrifugation protocol would 
be expected. No such signals were observed. The lack of signal immediately post sonication is 
particularly important, as it indicates that the factors contributing to the lack of Pmt signal are 
acting pre lysis, the most plausible explanation likely being protease mediated degradation.  
Genomic DNA from the non-complemented DT1025 strains was purified and pmt at the 
integration and native loci (including 100 bp up and downstream) were amplified by PCR. Of 
specific interest was the ermE* promoter region, since mutations in the region that prevent 
expression would explain the absence of signal however, no such mutations were observed. 
There were also no deviations in the DNA sequences of the ORF and termination region. 
More conservative substitutions of PmtR82, PmtD113, PmtH159, PmtD233, PmtK302 and 
PmtR510 were introduced in an effort to obtain mutants that had diminished in vivo activity, as 
shown by a partial complementation phenotype, but that would still be localised to the 
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membrane (Keenan et al., 2019). The majority of conservative and semi-conservative 
substitutions yielded non-complementing alleles. For three critical residues (H159, K332 and 
R510) strict conservation was crucial and no substitutions were tolerated. 
Three substitutions yielded active mutants D233E and R510K and D113N. Interestingly when 
D113 was substituted to glutamate the mutant failed to complement. In chapter 5, we 
hypothesised that D113 activates the serine or threonine to attack the mannose C1 carbon. It is 
therefore possible that the addition of an extra CH2 group is sufficient to cause an unfavourable 
steric clash with the acceptor serine or threonine. Asparagine however is isosteric with 
aspartate but it is a much weaker nucleophile. Asparagine’s ability to compensate for the loss of 
aspartate indicates that the asparagine would need to first be activated to act as a nucleophile. 
Known mechanisms of asparagine activation (that have been documented in N-linked 
glycosylation) include acid base catalysed activation and twisted amide activation (Lizak et al., 
2013). Interestingly, the same conservative and semi-conservative substitutions to glutamate 
and asparagine respectively were introduced into C. metallidurans ArnT and in both cases 
resulted in non-functional enzyme (Petrou et al., 2016). It is important here to highlight that in 
C. metallidurans ArnT, the DE motif aspartate is coordinating the nucleophilic phosphate head 
group of the lipid A acceptor substrate, rather than activating a serine or threonine hydroxyl in 
the case of S. coelicolor Pmt. 
Since D233E in our model is proposed to bind the phosphate of polyprenol phosphate mannose 
via a divalent metal cation, it would appear that the slight lengthening of the side chain has not 
interfered with its ability to do so. Another explanation is that the aspartate directly binds the 
phosphate and lengthening the side chain does not result in unfavourable steric clashes.  
The R510K substitution being tolerated is not so surprising since R510 is predicted to be on a 
cytoplasmic loop, rather than within the periplasmic active site. However, this conservative 
substitution being accommodated does not help us understand why this residue is critical for in 
vivo activity.  
The majority of the conservative and semi-conservation substitutions introduced into the 
expanded mutant library failed to complement DT1025 and none uncoupled the strict activity 
localisation relationship. The hypothesis that activity and localisation are linked has been 
strengthened and further supported by extensive troubleshooting. The molecular basis of this 





Chapter 7 – Overall conclusions and future perspectives 
In this work a combination of complementation assays and structural bioinformatics has been 
used to identify residues critical for the in vivo activity two S. coelicolor enzymes Ppm1 and Pmt. 
Furthermore, the in vivo data obtained for the Ppm1 mutants is supported by biochemical data 
provided by a collaborator. 
Analysis of these results in the context of the wider literature, has allowed roles to be 
defined/proposed for (i) eight of the nine critical Ppm1 residues identified, and (ii) five of the 
six critical Pmt residues identified. For both enzymes, the positions of these critical residues in 
the homology models indicates the majority have a role in either 1) participating directly in the 
catalytic reaction and/or binding either the donor or acceptor substrate. In this way, we have 
defined multiple critical active site residues. Identifying and/or developing inhibitors to target 
these enzymes, especially Ppm1 is an important future priority. To exploit an enzyme as an anti-
microbial-target requires knowledge of both structure and function. Research described in this 
thesis has focussed heavily on functional studies and while we have identified multiple critical 
amino acids, the structures of these enzymes unfortunately remain elusive.  
Since expression and purification conditions have already been established for Ppm1, future 
efforts should focus on obtaining a high resolution 3D structure to corroborate the inferences 
drawn from the mechanistic studies which underpin our biochemical model. Critically, the 
availability of a 3D structure will enable screening of fragment libraries and the identification of 
promising fragments, which could later be combined to generate a tight binding inhibitor.  In 
theory fragment screening could be carried out in the absence of a structure.  However 
assembling the fragments into the tighter binding inhibitor and then improving the affinity and 
efficacy of any resulting lead is  much more likely to be successful if guided by structure (Murray 
and Rees 2009). As a result, future efforts should continue to focus on obtaining suitably 
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Strain Titre (PFU/ml) 
J1929 + WT (1.75 ± 0.09) x 108 
J1929 (1.30 ± 0.09) x 108 
J1929 + Δ42 (1.47 ± 0.13) x 108 
J1929 + D57A (2.05 ± 0.10) x 108 
J1929 + R82A (2.53 ± 0.19) x 108 
J1929 + D111A (2.65 ± 0.06) x 108 
J1929 + D113A (2.77 ± 0.13) x 108 
J1929 + H116D (1.50 ± 0.04) x 108 
J1929 + R138A (1.10 ± 0.13) x 108 
J1929 + G143V (1.41 ± 0.41) x 108 
J1929 + S163L (2.08 ± 0.08) x 108 
J1929 + R226A (2.05 ± 0.19) x 108 
Table A8.1: Introduction of mutant alleles into J1929 had no effect on ΦC31 phage 
infection titres. Phage were plated out on DN agar and then SN agar containing spores was 
added to the top with the plates incubated at 30 °C for 18 hours. The average titre is shown ± 
SEM from 4 biological replicates. 0.1 ml of a 10-6 phage stock dilution was used to obtain 
countable plaques for phage sensitive strains.  Strains that showed no plaques at the lowest 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure A8.7: All J1929 strains are vulnerable to ΦC31 cΔ25 phage infection. Phage were 
plated out on a portion of DN agar and then spores streaked from the phage absent region to the 



































Strain Titre (PFU/ml) 
J1929 
J1929 + WT 
J1929 + R82A 
J1929 + D113A 
J1929 + H159A 
J1929 + D233A 
J1929 + K302A 
J1929 + R510A 
J1929 + E114A 
(3.17 ± 0.23) x 108 
(3.47 ± 0.37) x 108 
(3.40 ± 0.36) x 108 
(2.43 ± 0.22) x 108 
(3.90 ± 0.30 ) x 108 
(3.15 ± 0.34) x 108 
(2.92 ± 0.49) x 108 
(2.30 ± 0.20) x 108 
(1.85 ± 0.17) x 108 
J1929 + V158A 
J1929 + P161A 
J1929 + K164A 
J1929 + R182A 
J1929 + R201A 
J1929 + R228A 
J1929 + L231A 
J1929 + L232A 
J1929 + R335A 
J1929 + P393A 
J1929 + W400A 
J1929 + H410A 
J1929 + S421A 
J1929 + W426A 
J1929 + P503A 
J1929 + F564A 
(3.25 ± 0.27) x 108 
(2.42 ± 0.18) x 108 
(3.50 ± 0.25) x 108 
(3.00 ± 0.37) x 108 
(4.45 ± 0.28) x 108 
(3.10 ± 0.29) x 108 
(3.25 ± 0.41) x 108 
(4.05 ± 0.21) x 108 
(2.40 ± 0.19) x 108 
(3.70 ± 0.25) x 108 
(3.65 ± 0.13) x 108 
(0.22 ±  0.12) x 108 
(3.95 ± 0.26) x 108 
(2.98 ± 0.22 ) x 108 
(4.56 ±  0.24) x 108 
(2.60 ± 0.19) x 108 
  
Table A8.2: Introduced pmt alleles have no effect on the phage sensitivity J1929 parent 
strain. ΦC31 cΔ25 Phage were plated out on DN agar and then SN agar containing spores was 
added to the top with the plates incubated at 30 °C for 18 hours. The average titre is shown ± SEM 
from 4 biological replicates. 0.1 ml of a 10-6 phage stock dilution was used to obtain countable 






































 C-terminal Strep Tag II N-terminal Strep Tag II 
Strain Titre (PFU/ml) Titre (PFU/ml) 
DT2008  
DT2008 + WT 
DT2008 + R82A 
DT2008 + D113A 
DT2008 + H159A 
DT2008 + D233A 
DT2008 + K302A 
DT2008 + R510A 
DT2008 + P160A 
DT2008 + K164A 
DT2008 + R228A 
DT2008 + L231A 
DT2008 + R335A 
DT2008 + S421A 
< 1 x 102 
(2.68 ± 0.18) x 108 
< 1 x 102 
< 1 x 102 
< 1 x 102 
< 1 x 102 
< 1 x 102 
 < 1 x 102 
(2.70 ± 0.25) x 108 
(2.16 ± 0.17) x 108 
(3.05 ± 0.20) x 108 
(2.58 ± 0.23 ) x 108 
(3.35 ± 0.37) x 108 
(3.64 ± 0.32) x 108 
< 1 x 102 
( 2.20 ± 0.69) x 108 
< 1 x 102 
< 1 x 102 
< 1 x 102 
< 1 x 102 
< 1 x 102 
 < 1 x 102 
(2.53 ± 0.27) x 108 
(2.16 ± 0.14) x 108 
(3.10 ± 0.25) x 108 
(3.40 ± 0.21) x 108 
(2.70 ± 0.23) x 108 
(3.20 ± 0.18) x 108 
   
Table A8.3:  Presence of the Strep Tag II on either termini does not affect the ability of 
pmt alleles to complement DT2008. ΦC31 cΔ25 phage were plated out on DN agar and then 
SN agar containing spores was added to the top with the plates incubated at 30 °C for 18 hours. 
The average titre is shown ± SEM from 4 biological replicates. 0.1 ml of a 10-6 phage stock 
dilution was used to obtain countable plaques for phage sensitive strains.  Strains that showed 
no plaques at the lowest phage stock dilution tested (10-1) are represented as having a PFU/ml 









































Figure A8.8: C-terminal Strep II tagged non-complementing Pmt mutants are absent in 
DT2008 membrane fractions.  Membrane and soluble fraction samples were first loaded onto 
a 12 % SDS-PAGE gel which was run and stained to ensure protein concentrations of samples 
were consistent.  After transfer of proteins from an SDS-PAGE gel to a PVDF membrane and 
subsequent wash steps, the membrane was incubated with Strep Tag II Antibody HRP 
Conjugate, substrate added and X-ray film developed. pIJ refers to the empty pIJ10257control 
and WT to the Pmt WT  complemented strain control. 
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Figure A8.9: C-terminal Strep II tagged complementing Pmt mutants are present in 
DT2008 membrane fractions. Membrane and soluble fraction samples were first loaded 
onto a 12 % SDS-PAGE gel which was run and stained to ensure protein concentrations of 
samples were consistent.  After transfer of proteins from an SDS-PAGE gel to a PVDF 
membrane and subsequent wash steps, the membrane was incubated with Strep Tag II 
Antibody HRP Conjugate, substrate added and X-ray film developed. pIJ refers to the empty 
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Abbreviations and acronyms  
 
AI: Autoinduction 
CGD: Congenital disorder glycosylation 
DDM: n-Dodecyl β-D-maltoside 
Dp: Dolichol phosphate 
Dpm: Dolichol phosphate mannose 
DN: Difco nutrient 
DNB: Difco nutrient broth 
DNA: Difco nutrient agar 
ER: Endoplasmic reticulum  
FPLC: Fast Protein Liquid Chromatography 
FT: Flow through  
GDP: Guanosine diphosphate 
GT: Glycosyl transferase 
HPLC: High Performance Liquid Chromatography 




LB: Luria Burtani 
MSA: Mannitol soya flour agar  
Man: Mannose 
mAU: Milli-absorbance units) 
Min: Minute 
MSA: Mannitol soya flour agar 
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MW: Molecular weight  
ORF: Open reading frame  
PCR: Polymerase chain reaction 
PDB: Protein data bank 
PFU: Plaque forming units 
Pi: Inorganic phosphate 
PMT: Protein mannosyl transferase 
POMT: Protein O-mannosyl transferase 
Pp: Polyprenol phosphate 
Ppm: Polyprenol phosphate mannose 
PVDF: Polyvinylidene difluoride 
S: Second 
SDS PAGE: Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEC-MALLS: Size exclusion chromatography multiple angle laser light scattering 
SEM: Standard error of the mean  
SN: Soft nutrient 
TMHMM: Transmembrane Helices; Hidden Markov Model 
Und-P: Undecaprenyl phosphate 
WT: Wild type 
 
